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EDITORIAL 
PROGRESS IN CARDIOVASCULAR 
MEDICINE 
D e pi te recent declines in mortality, the toll of cardiova cular disea e (CVD) in pre ent ociety is till taggering. CVD accounted for 38% of all 
death in Canada in 1994, more than any other cau e of 
death, including cancer (28%). Twenty-three thou and 
individuals die each year as a result of a myocardial 
infarction. Cardiovascular disea e cost the Canadian 
economy approximately 19 billion every year in medical 
ervice , hospitalization expen e , lo s of income and lo s 
of productivity. With the increa e in the proportion of the 
population that is elderly, the total burden of CVD is 
expected to rise, at least for the next 15 year .1 
The term "cardiovascular di ea e" is a broad one and 
refers to many different entities, depending on the 
speciali t you peak to, the organ sy tern affected, the age 
of the patient, whether the di ea e wa acquired or 
congenital, and o forth. To many, CVD refer to 
atherosclerosis, which is a spectrum encompa sing 
ischemic heart di ea e (angina, myocardial infarction, 
ischemic cardiomyopathy, udden cardiac death), 
cerebrovascular di ea e (stroke, transient cerebral 
i chemia, va cular dementia), peripheral va cular di ea e, 
and arterial aneury mal di ea e. Mo t, but not all, article 
in this issue of the journal deal with athero dero i . 
Medical cience has made va t trides in the past half-
century toward understanding the underlying 
mechani ms of cardiova cular di ease and innovating new 
treatment . Epidemiologi ts, including tho e invol ed in 
the cia ic Framingham study, have given us an 
appreciation of the inherent risk factors that contribute to 
CVD: moking, hypertension, hyperlipidemia, diabetes 
mellitu , and age. With the exception of age, the e ri k 
factor are largely modifiable: it i likely that public health 
efforts, focu ing on improvement in diet and exercise, are 
re pon ible for the dramatic declines in CVD incidence 
and mortality een in the pa t everaJ decade . 
In term of the secondary prevention of va cular 
disea e (that is, the prevention of event occuring in 
patient with pre-existing disea e), clinical inve tigator 
have hown us that a multitude of effective 
pharmacological therapeutics are available, and thi has 
led to much excitement in recent year . Example include 
beta-blocker and ace inhibitor for the prevention of 
death in heart failure patients, tatins for the prevention of 
heart attack and troke , warfarin for the prevention of 
troke in atrial fibrillation, ju t to name a few. 
Unfortunately, this body of evidence i va tly 
underutilized in much of clinical practice in orth 
America: for instance, one recent tudy howed that only 
By Dan Hackam, BSc., Editor-in-Chief 
27% of hypertensive patients are adequately treated. Here 
too, then, there is room for improvement. 
Diagno is and therapy of acute cardiovascular event 
( troke, myocardial infarction, unstable angina) have also 
made great leap in the modern era, giving further 
credence to the u e of the term "progress" in the title of 
this editorial. The u e of radionuclide imaging tudie a 
well as more accurate cardiac enzyme have 
revolutionized the detection of coronary artery di ea e 
and myocardial infarction, re pectively. Thrombolytic 
agents, such as recombinant tis ue-type pla minogen 
activator and treptokina e, have roughly halved the 
mortality of heart attack patients presenting to hospital. 
And more revolutionary treatment are on the way: 
neuroprotective agents for acute troke, angiogene i 
promoter in coronary artery disease, as well as a 
multitude of other experimental approaches to the 
problem of myocardial revasculariza tion, technique 
which may one day replace coronary artery bypas 
grafting and angiopla ty. 
The epidemic of cardiova cular disease in the western 
world i a real one, with staggering economic and human 
consequences. One can only hope that scientific advance 
in the coming century, in combination wi th better 
implementation of measures devi ed in the pa t century, 
will u her in the beginning of the end of this modem-day 
courge. 
REFER£ CES 
1. lAboratory Centre for Disease Control, 1996. Q 
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PROFILES 
EDITORS: NAJI TOUMA AND HELEN L EWANDOWSKI 
AN 
DR. 
INTERVIEW 
DOUGLAS 
WITH 
BOYD 
D r. Dougla Boyd is a cardiac urgeon at the London Health Science Centre- University Campus (LHSC-UC) who ha a pecial intere t in robotics-
a i ted urgery. On September 24 1999, Dr. Boyd and hi 
team performed the fir t ucce ful clo ed-che t, robotic 
a i ted beating heart ingle bypa on John Penner, 60, of 
Seaforth. Thi new procedure could revolutionize the 
world ?f cardiac urgery and i propelling London' 
reputation as a world class facility for cardiac re earch and 
innovation. 
. I?r. Boyd re~eived hi MD and cardiac surgery 
trauung at the Uruver ity of Ottawa and the Ottawa Heart 
In titute, respectively. His primary po t-cardiac training 
wa in_ ~~art tran plant urgery and the development of 
the artlfioal heart. He_wa later attracted to London by it 
world cia reputation as a transplant centre . He is 
currently a i tant profe or of urgery at the Univer ity 
By Naji Touma and Helen Lewandowski 
of We tern Ontario and director of the Minimally Inva ive 
Cardiac Surgery Program at LHSC-UC. 
Do you consider yourself a researcher or a clinical 
surgeon? 
Honestly, I really don't think of myself as a re earcher 
per e. I am are earcher but a clinical re earcher. My be t 
work i really done in the operating room. My kill and 
experti e are in urgery and urgical techniques. Some of 
the e technique have to be innovated and in order for 
that to happen, work has to be done in the lab; but the lab 
work alway involve practical model uch a tudie on 
~al . I gue s I am a re earcher but most of my work is 
clinical. In fact, ince I have been here, I would spend four 
days in the operating room and one day on re earch. 
~tely, with _this new technology, it is more like two days 
m the operating room and three days in the lab. 
Could you discuss the technology behind the robotics 
assisted heart bypass that you recently performed at 
LHSC-UC? 
. w_e have been concentrating our efforts in minimally 
mva 1ve urgery lately on beating heart techniques. We 
know that the mailer the incision is, the more difficult it is 
to maneuver conventional endo copic instruments to be 
able to do the job. B fore we knew we were going to be 
a~le to use a robot, I went to the lab and u ed about fifty 
ptg heart in a training model in order to learn the 
dexter~ty . r~quired to perform coronary bypass with very 
mall rna 10n . We learned very quickly that there are a 
number of problems that have to be overcome before that 
job can be done. One problem i visualization. The two 
dime~sional c~era available at the time did not give us 
the kmd of visual dexterity required. That is when we 
tarted experimenting with three dimensional 
vi ualization sy terns. Three dimensional cameras gave us 
a better perception of depth and improved the vi ual 
dexterity. Another problem wa tabilization. To operate 
on the beating heart, one ha to be able to locally tabilize 
the area so that ana tomosi could be performed 
afterward . Yet another problem wa in trumentation. 
Conventional endo copic in truments did not allow 
sufficient degrees of freedom to operate freely wi thin 
mall ~ci ions a in the open heart ituation. For example, 
th~ ability to _move one's hands left and right and look at 
thing fre~Iy_ 1~ reduced greatly. One i also limited by the 
angle of mc1 ton and the di tance from the heart to the 
~h~ ~ wal_I. We found that the operation through small 
mci JOn IS doable but not practical. For example, to do 
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P r o fil es 
one single graft, it took u 90 minutes while in the open 
heart situation, it took us only 10-12 minute . In addition 
to the time, the accuracy left something to be desired in 
that we were not able to obtain the same kind of quality 
grafts as in the open heart procedure. So there were a 
number of factors that made us realize it is not qui te so 
easy to perform heart surgeries through small incisions. 
All of a sudden, this new robotic technology comes 
along that would allow the surgeon the arne dexterity 
enjoyed outside the chest with absolute preci ion . 
Movements of the surgeon outside are digitiz d by 
computer control and translated to a robotic manipulator 
attached through pin sized holes within the chest wall. 
The surgeon sits down in front of a control console and 
manipulates surgical instruments by looking at a 
magnified TV screen. This view comes from a little 3D 
camera that is attached to a robotic arm that is in turn 
hooked up to a computer controller and a head et. The 
robot supporting the camera is activated by a 
sophisticated voice activation software that only 
recognizes the surgeon's voice. The robot only responds to 
the commands of the surgeon and allows for different 
camera movements. Hence, the visualization inside the 
chest is controlled by voice command . The surgeon is 
sitting at the console, holding instruments very similar to 
the ones used in open heart surgery. The movemen ts of 
these instruments are digitized by computer control and 
transmitted to the instruments inserted within the chest. A 
surgeon could scale very gross movements on the console 
to very fine movements in the chest. For example a 6 em 
movement outside can be translated to a 6mm movement 
inside. A surgeon could also move his / her hand from a 
certain position to a more comfortable position by 
stepping off a clutch. The computer control also has built-
in filters so that very fine tremors are screened out. 
Another feature is the ability to scale a 180° rota tion 
outside to a 360° rotation inside. Hence, the robot has the 
effect of increasing a surgeon's dexterity. This is a very 
interactive system or a robot in the loop that enhances the 
urgeon's skills but doe not take over the operation. 
Could you discuss the benefits of minimally invasive 
surgery as opposed to open heart surgery? 
There are two factors that make a heart u rgery 
invasive and in turn force patients to stay an average of 
one week in the hospital after the operation. The first is the 
incision which is large enough to strip the breast bone and 
necessitate time for healing. The second is the use of the 
heart-lung machine. When one takes a patient's blood 
supply, reroute it into the heart-lung machine (which 
takes over the functions of both the heart and the lung) 
and recirculates his blood volume about 20,000 to 30,000 
times in this artificial surface, something has got to 
happen. You never get something for nothing. Thing that 
happen, and they have been very well documented years 
ago, include: a total body inflammatory response: blood 
coagulation due to exposure to an artificial surfac . The 
incidence of strokes after heart surgery increases 
dramatically with age. Our studies have shown that this is 
largely due to the use of the heart-lung machine; 
manipulating the blood vessels or having to insert tubes 
into the aorta. Any manipulation of the aorta causes 
microemboli that could go to the brain. Microemboli from 
the pump itself could also go to the brain. Dr. Merken, a 
professor of anesthesiology, has demonstrated that the use 
of the heart-lung machine causes a 20-30% increa e in 
neuro-cognitive dysfunction. That being said, there is 
merit in avoiding the heart-lung machine and invasive 
surgery. 
In minimally invasive surgery, we have not only 
avoided the use of the heart-lung machine, we have also 
done small incisions so we don ' t need to spread an 
incision about eight inche as in open heart surgery. In 
fact, one small working port of 2-3 em long is enough to 
get the heart stabilized. This enable us to not break any 
bone and have only a small amount of tissue trauma and 
ultimately make the surgery a lot more comfortable. This 
is likely to reduce the need for transfusions and the overall 
morbidity and complication of the surgery. 
When do you think this new technology will move from 
the experimental or research s tage to become m ore 
routine surgery? 
In my own practice now, it is almost routine because I 
am doing a robotic surgery every week. However, before 
it is widely adopted, I think it is very important that this 
new procedure undergoe rigorou scientific evaluation 
and we have to be very careful before we proceed any 
further. For example, we do not yet know if these devices 
are safe. We have been using simple robotics for years and 
have had no complications associated with the robot 
whatsoever. We anticipate that this will be the same but 
until we have an appropriate number of cases, we can't 
cientifically say it is safe. Once safety is shown, we will be 
able to demonstrate very clearly the benefits of this 
technology. After that, we will adopt the robot in routine 
urgery. I believe that within the next two years, the u e of 
robotics will become mainstream. 
What do you think the limitations of this technology 
are? 
I think cost is a major i ue. This is a very expensive 
technology. Although, ultimately I believe this technology 
will pay for it elf. We compared low risk patients who 
underwent robotic beating heart urgery and conventional 
surgery. Of tho e 30 patients we looked at, we saved 
$45,000 by adopting the robotics technology. At this rate, 
we fore ee that our robot will pay for itself within one 
year. We anticipate that if we can get 24-48 hour stays and 
patients up and out of the hospital and back to work 
quickly, this technology will pay for itself; but right now, 
the cost is the greatest limiting factor. This technology is in 
a rapid state of evolution. I don' t think the unit we have 
now will be the same unit used two years from now. We 
currently have contracts with a pri ate company that we 
will be involved in helping them develop their 
instruments. In return, we will get upgrades in the 
equipment in order to stay up to date. 
Other than th e b ypass, do you fo re see u s ing th is 
technology for other types of surgery? 
Absolutely, there is no question about that. I believe 
very strongly that in the next two years, we will be doing 
beating heart robotic valve replacements, robotic 
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arrhythmia operations and even pediatric surgery. 
Could you discuss the genesis of this technology and 
how it developed? 
Robotic research really started in the early 90's. There 
were two major groups in California working on it 
independently. One was the S military with the Stanford 
Re earch Institute and the other was ASA and the Jet 
Propul ion Lab . The e two groups had different 
objectives. 
The goal of the military group that contracted out to 
the Stanford Research Group was to have a robotic 
manipulator on a bunker like tractor trailer. The idea was 
to have the ability to move wounded oldiers quickly into 
this portable hospital with robot and have surgeons on 
their command console performing urgery from mile 
away. With the advent of fiber optics technology, data 
transmi sion could be done almo t at the speed of light. 
The objective of the group at the Jet Propulsion Lab of 
ASA was to have a robot on a mission to Mars where 
astronauts could go for two years without a hospital. The 
idea was to have a technician deploying the robot on 
board of the spacecraft and have a surgeon on earth 
perform any potential surgeries. This idea is not o far 
fetched and there is no question in my mind that this will 
be something available within seven years. 
Could you talk about how important private funding 
such as the Ivey Foundation gift is for maintaining and 
developing this research technology? 
Right now, I think we have established our elve as a 
major robotic surgery centre in the world. One of the 
obligations we have is to further robotic surgery and if we 
are going to do that in a scientific way, we have to have 
the foundations. The additional money from Ivey will not 
only support our research effort but also our clinical 
efforts. Just having a robot will not make us a world class 
facility; we need research, teaching and clinical 
applications. This generous Ivey gift will help in laying 
down the e foundations. It will not only fund the robotic 
program but also the imagery program. It will enhance 
our ability to link robotic urgery and interventional 
cardiology. This will make London a leader in the world 
in this minimally invasive approach to heart disease. 
Could you discuss other important current issues in 
cardiology and cardiac surgery? 
There is no question that angiogene is and the whole 
i ue of genetic research plays an important role. Also, 
stem transfer technology or the ability to transfer heart 
muscle cells into dead areas and regrowing it. Other 
important research areas include: myocardial 
revascularization, cardio-la er reva cularization in 
a ociation with genetic manipulation, robotics, catheter-
ba ed interventions, and endocardioly or ethocardioly. 
What would you tell medical students who may be 
interested in pursuing cardiac surgery as a career? 
Cardiac surgery is an extremely demanding but al o 
an extremely rewarding career. This is really an exciting 
time to be a cardiac surgeon. Heart surgery has been 
Prof il es 
practiced the same way for almost 30 years. In the last few 
years, even while I was undergoing my cardiac surgery 
training, it is being completely changed. Right now, we 
are about to redefine the way cardiac surgery is practiced 
and that is really incredible. The advent of things like 
computers, genetics and robotics have greatly impacted on 
cardiac surgery and that i very exciting. Q 
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THINKING ON YouR FEE T 
EDITORS: ALLAN VESCAN AND ]OHN L EE 
AN UNUSUAL CASE OF CHEST PAIN 
A 45-year old gentleman (A.B.) pre ent to hi family phy ician with a 24-hour hi tory of evere chest pain. The pain is localized to his left anterior che t, 
i harp and tabbing in quality, and wa fairly sudden in 
on et and has not remitted ince yesterday. The pain i 
worse with recumbency, cough, and deep inspiration, and 
better with itting up and taking hallow breath . A.B. 
took a pirin with only moderate relief. 
PLEASE STOP A 0 A SWER THE FOLLOW! G 
QUESTIO S: 
1) What is your differential diagno i for che t pain 
in thi gentleman? 
2) What other que tions on hi tory would clarify the 
differential diagnosis? 
3) Given the mo t likely diagnosi , what particular 
finding on phy ical examination would you be 
diligent to eek out? 
Examination of the head and neck, abdominal, 
re piratory and mu culo keletal sy tern i unremarkable. 
Turning your attention to the cardiova cular ystem, you 
obtain the following parameter : HR 100 and regular, BP 
140 /70, JVP 3 em above the ternal angle. Carotid are 
bri k bilaterally with no evidence of bruit. On insp cting 
the precordium, you note no abnormal lift , heave , or 
pul ations. On palpation, there i no parasternal lift and 
the apex beat i located in the fifth inter pace, 
midclavicular line (i t is normal in timing, duration and 
intensity). On au cultation, you note normal h art ounds, 
a Grade IT / VI y tolic ejection murmur at the base with no 
radiation to the carotid , no extra heart ounds, and no 
rub. 
PLEASE STOP A 0 A SWER THE FOLLOW! G 
QUESTIO S: 
4) If a carotid bruit were pre ent, what would thi 
indica te, and what clinical entity on the 
differential diagnosi would thi make more 
likely? 
5) What is the significance of a para ternallift? What 
would a di placed apex beat tell you? 
6) What is the ignificance (if any) of the murmur? 
7) What initial investigations would you order? 
By Dan Hackam, BSc., Editor-in-Chief 
CBC reveals a left- hift with mild leukocytosi (WBC 
11.3) and a neutrophilic predominance. Cardiac enzyme 
(myoglobin, troponin-1, CK-MB) and ESR are mildly 
elevated. A re ting electrocardiogram (ECG) reveals the 
following: normal sinus rhythm, rate 98, ST elevation in 
multiple contiguous leads. Che t X-ray reveal a normal 
heart ize with no evidence of pleural effusion or 
pulmonary infiltrate . 
PLEASE STOP A 0 A SWER THE FOLLOW! G 
QUESTIO S: 
8) Given the abnormality on ECG, what diagno i 
mo t likely? 
The patient i referred to a cardiologi t for further 
a e ment. Echocardiography (ECHO) reveals evidence 
of a mild pericardia! effu ion, with no evidence of 
pericardia! thickening, valvular abnormality, or dyskinetic 
myocardial segment . Ejection fraction is 55%. 
PLEASE STOP A 0 A SWER THE FOLLOW! G 
QUESTIO S: 
9) What are the etiologie of thi condition? 
10) What i the progno i of thi condition? 
11) Outline, in general and p cific term , the 
management of thi condition? 
ANSWERS: 
1) One can never be faulted for placing at the top of 
the differential tho e entitie that might endanger 
the life of the patient, and therefore mu t be ruled 
out. Given the udden on et of evere che t pain, 
myocardial infarction or i chemia, aortic 
di ection, or pulmonary embolus are all po ible. 
However, pericarditis is more likely, given that 
the pain of acute pericarditi i often pleuritic, 
relieved by sitting up and aggravated by 
recumbency and deep breathing. 
2) The four cardinal cardiac ymptom are: che t 
pain, dy pnea, palpitations and y ncope. In 
addition to the e, one would a k about symptom 
of heart failure: orthopnea, paroxy mal nocturnal 
dy pnea, and ankle welling. Che t pain related to 
exertion, emotion, cold weather or meal , or in the 
pre ence of diaphore is, nau ea, or vomiting, or 
against a background of coronary risk factors 
( making, hyperten ion, diabetes, family hi tory, 
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and hyperlipidemia) make infarction / ischemia 
more likely. One would al o a k about habits such 
a tobacco and ethanol con umption, as well as 
medications, and other medical conditions (for 
in tance, lupus [SLE] and other connective tissue 
disorder are associated with pericarditis). 
3) The sine qua non finding of pericarditis is the 
pericardia! friction rub. It may have up to three 
components per cardiac cycle and i high-pitched, 
scratching, and grating; it can ometime be 
elicited only when firm pre ure with the 
diaphragm of the tetho cope is applied to the 
che t wall at the left lower ternal border. It is 
heard mo t frequently during e piration with the 
patient in the sitting po ition. The rub i often 
incon tant and the loud to-and-fro leathery ound 
may disappear within a few hours, possibly to 
reappear the following day. 
4) A carotid bruit indicate turbulent flow in the 
carotid artery and i diagnostic of cerebral 
va cular disease. Becau e athero clerosi is a 
generalized disease, the finding of a carotid bruit 
would make coronary i chemia or infarction 
omewhat more likely. 
5) A para temal lift is palpated in right ventricular 
hypertrophy. A di placed apex can be found in left 
ventricular dilatation. 
6) The murmur de cribed has all the characteristics 
of a benign ("functional") flow murmur, which i 
often een in healthy, young adult and in high-
flow sta tes uch pregnancy, exerd e, and anemia. 
The e characteri tic are : mid y tolic timing, 
Grade II or le , non-radiating, be t heard in the 
pulmonic area, non-mu ical in character. 
7) The following investigation are appropriate : 
complete blood count (CBC), erythrocy te 
edimentation rate (ESR; a non- pedfic marker of 
inflammation), cardiac enzymes, electro-
cardiogram, and che t x-ray. 
8) Pericarditis. 
9) Differential : infectiou (viral, bacterial, 
tuberculous, fungal, protozoal), a ociated with 
myocardial infarction (actuely, or days to weeks 
later; the latter is known a Ore ler's syndrome), 
collagen vasc u lar di ea e (SLE, periarteritis 
nodo a, rheumatoid arthriti ), uremia, neoplasm 
(brea t, lung, renal, melanoma), infiltrative 
di ea e, drug , trauma, radiation, and idiopathic. 
10) The progno i i dependant on the underlying 
etiology. Acute idiopathic (or viral) pericarditis i 
u ually elf-limited and abate wi thin 1 month. 
One or more episodes of recurrent pericarditis 
occur in up to one-fourth of patients. Constrictive 
pericarditis is a rare complication. 
11) The treatment of pericarditi is virtually always 
ymptomatic and directed toward optimizing the 
comfort of the patient . Bed res t and anti-
inflammatory treatment with a pirin, if nece ary 
up to 900 mg qid, may be given . If thi s i 
ineffecti ve, one of the nonsteroidal anti -
inflammatory agents, such as indomethacin (25 to 
75 mg qid) or a glucocorticoid (e.g., predni one, 20 
to 80 mg daily ) u ually suppresses the clinical 
manifestation of the acute illness and may be 
u eful in p atient in whom the purulent and 
tuberculou form of pericarditi have been 
excluded. Anticoagulant hould be avoided. After 
the patient ha been a ymptomatic and afebrile for 
about a week, the do e of the anti-inflammatory 
agent is gradually tapered. When recurrences are 
multiple, frequent, disabling, and continue beyond 
2 year , pericardiectomy may be effective in 
terminating the illness. Q 
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MEDICINE AND THE LAW 
EDITORS: MAHMOUD SHARAF, NAJIB SAFIEDDINE, AzADEH MOAVENI 
DEFECTIVE PACEMAKERS 
LEGAL LIABILITY 
AND 
W ith the development of pacemakers and implanted defibrillators, patients pron e to cardiac arrhythmia by reason of ischemic di ease 
or congenital abnormality have seen dra m atic 
improvement in quality of life and life expectancy. The 
pacemaker consists of an external unit, either single or 
dual-chambered, with a lead embedded in the right 
atrium, or two leads implanted in atrium and ventricle1• 
The pacemaker sets the heart rate and can ad just 
dynamically to suit systemic activity levels1• 
The combination of intense patient reliance on these 
devices to sustain an active lifestyle and the inevitable 
tendency of mechanical parts to malfunction can result in 
cardiac events, and even death. The courts are a frequent 
recourse for settlement of claims of manufacturer liability 
for the complications of pacemaker malfunction. There are 
several actual and potential claims that plaintiffs can use. 
This paper will serve to discuss a few of them using 
illustrative examples. 
In the case of Tracy v. Telectronics Pacing Systems, Inc., 
Ronald Tracy of St. Clair County, Michigan brought forth a 
lawsuit against the manufacturer after his pacemaker 
failed, forcing him to replace it at the Cleveland Clinic at 
substantial personal risk and expense •. The J-lead 
pacemaker has a thin, flat intracardiac lead that is 
abnormally prone to metal fatigue, thereby incapacitating 
the pacemaker. The proceedings in the U.S. District Court 
indicated the manufacturer was aware of the fault as early 
as 1992, but did not recall the unit until1994, a year before 
this trial 1• The court decided in favour of the plaintiffl. 
The Food and Drug Administration ascertained from 
Telectronics, Inc. that 22 000 persons have received the J-
lead model which the company estimates has a 17% 
failure rate1• It is estimated that 2 individuals have died as 
a result of this malfunction•. There are currently 60 
pending cases against Telectronics Pacing Systems, Inc. in 
U.S. courts1. 
In Ontario there are 2 cases pending aga inst 
Medtronics, Inc.'s Canadian subsidiary, out of 
Mississauga1. In 1998, Sudbury residents brought a class 
action suit against the company because of fa ulty 
polyurethane insulation on the leads. Any of the thou and 
Ontarians having received the 4004 model (between 1989-
1995) is eligible to participate in the suit1• 
Susan and Jeff Blanchard of London, Ontario brought 
forth a suit in ovember, 1998 in the Ontario Court of 
Justice against the same manufacturer of the 4004 model 
alleging negligence in the design, development, testing, 
manufacture, licensing and distribution of their product. 
They seek $275 000 in assorted damages•. 
By Mahmoud Sharaf, MEDS 2002 
The risk of serious atrial thrombus formation pursuant 
to pacemaker lead implantation is rare (only about 2%t 
However, the possibility of claims being drafted based on 
thrombogenic lead configuration can not be discounted. 
Another interesting potential cause for future claims is 
the proposed link between cellular phone use and 
interference in pacemaker signaling. The ew England 
Journal of Medicine study (May 29, 1997) indicated that if 
cellular phones were operated directly over the 
precordium, interference could be noted in 20% of 
individuals. Serious interference wa noted in one third of 
this twenty percent. Normal operation of cellular phones 
at ear level had no role in producing interference•. There 
have been no cases to date brought to general attention 
that have been argued along these lines, but this may not 
dissuade enterprising lawyers from trying. 
The last, and perhaps most interesting, potential cause 
of lawsuits in the future is the Y2K non-compliance issue. 
This cause celebre of Ann Couffou, Managing Director of 
the Giga Year 2000 Relevance Service, was serious enough 
to warrant her testimony before the House Subcommittee 
on Science and Technology in 19971• 
The Veterans Adminis tration asked 5 pacemaker 
companies about Y2K readiness. One company refused 
outright to cooperate while the other four indicated 
readiness would be achieved before the end of 19991• 
In actuality, most pacemakers (including those made 
by Medtronic, Inc. and PaceArt, Inc.) have no date-
computing chips, and are thus Y2K-proofl . Some 
pacemakers contain chips that serve to record cardiac 
traces for physicians to study. These date-computing chips 
would cease to record information on New Year's Day, 
and thus will sacrifice the close monitoring required in 
some patients•. Implanted defibrillators, which assess 
arrhythmia and rectify it, do use date-computing chips. If 
these monitors have recorded no event in 6 months time, 
then the defibrillators will not subsequently function, 
assuming the long inactivity means that the device should 
be replaced because it may be defective. If no event has 
been recorded since 1900 (which is the case on 01.01.2000), 
then th e defibrillators will s top, not in line with 
replacement schedules•. 
Some manufacturers of date-computing chips have 
switched to an 8-digit date format to avoid Y2K problems, 
like the British manufacturer of CriSPR. Others are still 
considering the problem 1• 
In conclusion, the grounds for successful liability suits 
for pacemaker malfunction will primarily rest on 
demonstration of mechanical defect present at production 
or abnormal tendency to wear out. It is important to show 
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multiple cases of malfunction for the model in question. 
The technology of pacemakers ha greatly improved over 
the decades and lawsuits, despite their unsavoury 
conno tations, ha ve played an integral part in the 
con tinuous dri ve towards product quality and 
standardization. 
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THE ZEBRA FILES 
EDITORS: ]OHN D. STEIN AND ]ASO ASHLEY 
A BRIEF REVIEW OF TRUNCUS ARTERIOSUS 
INTRODUCTION 
Truncu Arteriosu , fir t de cribed in detail in 179 , i 
a congenital defect of the great ve el invol v ing 
incomplete eparation of the pulmonary artery and the 
aorta during embryogene is. The condition affect 1 in 
12,500 births 1 and patient pre ent with cyan i , 
tachypnea (very rapid ventilation), murmur , sweatinp 
during feeding, a failure to thrive and hepatomegaly . 
Other anomalie a ociated with TA include ventricular 
eptal defect , truncal valve regurgitation and incr a ed 
pulmonary va cular re i tance1• Untreated, thi condition 
has a 65% mortality rate in the fir t 6 months of life 
increasing to 75% within the fir t year 1• Cau e of 
mortality include excessive pulmonary blood flow, 
conge tive heart failure and progre ive cyanosis due to 
accelerated pulmonary va cular ob tructi e di a e . 
Palliative urgical intervention performed before the e 
conditions appear ha lowered the two-year mortality to 
approximately 20%.1 
Embryology and Etiology 
In the normal development of the great ve e ls, 
truncal ridge form in the truncus during the fifth and 
ixth week of embryogenesis. The left anterior ridge 
meet and fuse with the right po terior ridge (Fig. 1) 
during the eventh week of ge tation thu forming two 
lumen which give rise to the aorta and pulmonary artery. 
The fusion of the truncal ridges al o occur in the fetal 
heart contributing to ventricular eptum formation . The 
failure of the e ridge to fu e ha been u ed to explain 
Truncu Arteria u , and by exten ion, the ob rved 
ventricular eptum defect .1 Thi model of development 
ha been accu ed of being an oversimplification and not 
A B 
By John D. Stein and Jason Ashley 
fully accounting for the po ibility of Truncus Arteria u 
without a ventricular eptaJ defect. 1 Admittedly however, 
thi occurrence i exceedingly rare with only 2 
documented case . 
Truncu Arteria u i frequent ly as ociated with 
DiGeorge' Syndrome, a condition where the thymus and 
parathyroid gland fail to develop from the neural ere t. 
Ablation of the cardiac neural cr t in chick embryo has 
b en hown to re ult in per i tent Truncu Arteria u . A 
theory that the etio logy of Truncu Arteria u s may 
involve orne genetic defect or teratogenic insult affecting 
the neural ere t may explain the frequent a ociation of 
the e two congenital malformation .1 This i an attractive 
idea ince any damage to the neural ere t that would 
comprorni e truncal ridge fu ion could have the potential 
of al o interfering with the normal development of the 
thymu and parathyroid glands. 
Anatomical Classification of Truncus Arteriosus 
At pre ent there are two main y tern for cla sifying 
Truncu Arteria u . The first, introduced in a classic 
report by Collett and Edward in 19494 wa widely 
adopted. In general the defect wa cla ified according to 
the arre t in development which corre pond to the 
po ition of pulmonary branching from the truncu . (Fig. 2) 
Type I. Type I involve a hort pulmonary trunk 
which further divide into a left and right pulmonary 
artery. Thi type i further subdivided into 7 categories 
(Table 1). 
Type II. In Type II Truncu Arteria u the right and 
left pulmonary arterie have separa te but do e origins 
from th dor al wall of the Truncu Arteria u . This type 
is further subdivided into 4 categorie (Table 2). 
c D 
Figure 1. Embryogenesis of the Aorta and Pulmonary A rteries ari ing from the Tru ncus Arteriosus at the 5th (A ), 6th (B), 7th (C), and 8th (D) 
week of gestation. 
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Collett and Edwards 
I II 
Van Praagh 
Al A2 A3 A4 
Figure 2. A comparison of the Collett & Edwards and Van Praagh & Van Praagh Clas ifications ofTnmcus Arteriosus. 
Type ill. In type ill Truncus Arteria us the right and 
left pulmonary arterie have eparate origins from the 
right and left lateral walls of the truncu . This type is 
further subdivided into 4 categorie (Table 3). 
Type IV. Type IV Truncu Arteria us is characterized 
b an ab ence of pulmonary arterie a well as a lack of 
any 6th aortic arch derivatives. Perfu ion of the lungs 
occurs by way of the bronchial arteries. Type IV i further 
ubdivided into 4 categories (Table 4). 
Table 1 
Type I 
Subtype 1 
Subtype 2 
Subtype 3 
Subtype 4 
Subtype 5 
Subtype 6 
Subtype 7 
Table 2 
Type II 
Subtype 1 
Subtype 2 
Subtype 3 
Subtype 4 
Single pulmonary trunk arising from the Truncus Arteriosus 
(from the left side unless otherwise noted) 
Pulmonary trunk from left side. 
Pulmonary trunk from right side. 
Patent ductus arteriosus. 
Patent ductus arteriosus and coarctation of the aortic arch. 
Complete atresia of part of the aortic arch. 
Right aortic arch. 
Double aortic arch. 
Separate but close origins of the right and left 
pulmonary arteries 
Ductus arteriosus is absent. 
Patent ductus arteriosus. 
Patent ductus arteriosus with coarctation and atresia of 
the aortic arch. 
Right aortic arch 
An alternative cia ification sy tern was offered by 
Van Praagh and Van Praagh7 to include in tance of 
Truncus Arteria us without ventricular eptal defects 
(VSD) and further, to exclude Collett and Edward' Type 
IV category . It wa argued that Type IV hould be 
con idered a ca e of failed pulmonary artery formation 
rather than a failure of the aorta and pulmonary artery to 
eparate. 
Table 3 
Type Ill 
Subtype 1 
Subtype 2 
Subtype 3 
Subtype 4 
Table 4 
Type IV 
Subtype 1 
Subtype 2 
Subtype 3 
Subtype 4 
Separate origins of the right and left pulmonary arteries from 
the right and left lateral wall of the truncus. 
Ductus arteriosus is absent and both 6th aortic arches present. 
Patent ductus arteriosus with only one 6th aortic arch present 
and supplying one lung. The other lung perfused by the 
ductus arteriosus or bronchial arteries. 
Right aortic arch and both 6th aortic arches present. 
Right aortic arch with only one 6th aortic arch present and 
supplying one lung. The other lung perfused by the ductus 
arteriosus or bronchial arteries. 
Pulmonary arteries are absent 
Bronchial supply to lungs via descending aorta. 
Bronchial supply to lungs via descending aorta and aortic arch. 
Bronchial supply to lungs via aortic arch. 
Right aortic arch and bronchial supply to the lungs via 
descending aorta. 
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Table 5 
Type A 
Subtype 1 
Subtype 2 
Subtype 3 
Subtype 4 
Truncus Arteriosus with VSD 
Partial separation of a main pulmonary artery from the truncus. 
No main pulmonary artery, right and left branch off from 
the truncus separately. 
Absence of single pulmonary artery (left or right). 
Ipsilateral lung receives collateral perfusion. 
Atretic or absent aortic arch with large patent ductus arteriosus. 
A main pulmonary artery arises from the ascending aorta. 
Table 6 
Type B 
Subtype 1 
Subtype 2 
Subtype 3 
Subtype 4 
Truncus Arteriosus without VSD 
Partial separation of a main pulmonary artery from the truncus. 
No main pulmonary artery, right and left branch off from 
the truncus separately. 
Absence of single pulmonary artery (left or right). 
Ipsilateral lung receives collateral perfusion. 
Atretic or absent aortic arch with large patent ductus arteriosus. 
c 
Figure 3. A. Truncus Arteriosus with aortic cross-clamping, pulmonary artery constriction, and aorto-bicaval bypass in place. B. Transventricular 
closure of the ventricular-septal defect using a Dacron Patch has been performed. The pulmonary trunk has been excised from the truncus. The 
resulting neoaortal defect is closed with a homograft patch. The pulmonary trunk is sutured to a homograft conduit which is in turn sutured to the 
rim of the ventricular defect. C. In cases where the pulmonary artery graft cannot envelop the entire ventricular defect, an homograft hoot may be 
implemented. 3f4 of the hood circumference is sutured around the remaining rim of the ven tricular defect. The pulmonary artery is su tured to the 
remaining 1f4 of the hood's circumference to complete the continuation between the pulmonary artery and the right ven tricle.2 
In their scheme, Van Praagh and Van Praagh cla sify 
Truncus Arteriosus with ventricular septal defect as Type 
A. (Fig. 2) The exceedingly rare occurrence of Tuncus 
Arteriosus without ventricular septal defect occurs when 
the pulmonary infundibulum develops normally as do 
separate pulmonary and aortic valves. Within the trunk 
however, there is a defect in the septum which would 
normally separate the aorta and main pulmonary artery 
such that there is direct communication between th two 
and mixing of oxygenated and deoxygenated blood. Van 
Praagh and Van Praagh classify this type of Trun cus 
Arteriosus as Type B. These two broad categorie are 
further ubdivided as outlined in tables 5, 6. 
Given the variable morphology of this condition, a 
review of each procedure devised for each subtype is 
beyond the scope of this review. Instead, a de cription of 
the latest procedure for addressing the mo t common 
form of Truncus Arteriosus will be undertaken. 
Repair of Truncus Arteriosus Type 1-1 I Al 
The goal o f the procedure to repair Truncus 
Arteriosu s Ty pe 1-1 I A l is to restore, as nearly as 
possible, the regular course of blood flow from the heart to 
the lung and systemic circulation. To begin, the patient is 
put on pediatric cardiopulmonary bypass ( Fig 3-A) which 
may also include deep hypothermic circulatory arrest to 
extend the time the patient can be su tained on bypass. 1·2.3·4 
The pu lmona ry trunk is d ivide d fro m th e Truncu s 
Arteriosus and the resulting defect, in what i now the 
neoaorta, is closed. 
To co rrect any regurgitative flow diagnosed pre-
operatively, repair of the truncal valve would be indicated 
prior to closure of the neoaorta. This involves removing 
the smalle t valve lea£let (u ually one of four) and do ing 
th e inci ion to br ing se p a ra te d lea fl e ts into clo e 
a pproximation . 1 The ve ntricul ar septal d e fec t is 
approached through a right ventriculotomy, and do ed 
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with an albuminized Dacron or Gortex patch (Fig 3-B).5 
The exci ed pulmonary artery is fashioned into a tube 
with the aid of an allograft patch if nece ary (Fig 3-B). 
The pulmonary trunk is then sutured to the right ventricle 
at the site of the ventriculotomy (Fig 3-B). This final 
communication may implement a non-valved Dacron 
conduit1 or a valved homograft. If the graft is unable to 
completely surround the ventricular defect a homograft-
pericardia! hood may be implemented to channel blood 
flow from the ventricle and into the pulmonary artery (Fig 
3-C). 
Post-Operative Mortality 
The morbidity associated with the repair of Truncus 
A rteriosus has certainly been reduced with recent 
technological innovations that improve the surgeon's 
ability to maintain an infant on cardiopulmonary bypass. 
However, one of the most significant factor contributing 
to a reduction in mortality for repair of this condition is 
the indication that such repair be performed before the 
patient reaches ix months of age. 5•11•1 In this way, a 
s ignificant contributor to early death, pulmonary 
morbidity due to protracted pulmonary hypertension, can 
be preempted with early repair of the defect. 
While a patient age of le s than six months of age is 
de irable for reducing mortality, more stringent 
requirements may be necessary for minimizing morbidity. 
Hanley et al. reported that morbidity, a indicated by 
pulmonary hypertension, was increased by postponing 
surgery beyond 1 month of age.11 While not an immediate 
contributor to death, Hanley et al. sugge t that " ... an 
inten ive care unit team with less experience managing 
pulmonary va cular problems could theoreticallY. increa e 
the significance of this factor as a ri k for death." 1 
The age of the patient has been demon trated to 
greatl y improve intermediate urvival. For repairs 
performed on infants less than 30 days old, survival at 1 
month ha been reported at 87% and 81% at 3 months and 
beyond5. Hanley et al. reported 83% of patients urviving 
to 4 months post-operatively and a many as 76% 
urviving to a late as 22 months po t-operatively. 
Conclusion 
Truncus Arteriosus is a rare cardiac congenital defect. 
While the mortality rate of the condition is very high in 
the untreated infant there are procedures to repair ve sel 
architecture which have promi ing rate of succe . The 
opportunity for a favourable outcome is maximized with 
earl y intervention as the equelae of pulmonary 
hypertension and the associated pulmonary morbidity can 
be mitigated or eliminated. 
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TAOISM AND THE 
CHINESE ANCIENT 
ADVENT OF 
MEDICINE 
A retro pective view of civilization has shown that cientific advancement of a ociety can only take place if the social infra tructure allows for it. 
Ancient China was no exception in that the tructure of 
ociety and the conditions of the time were uch a to 
allow for advancement in medicine. More specifically, 
ancient Chine e society fostered the Taoist religion, 
thereby allowing Taoist follower to pur ue their ultimate 
goal of immortality, thus indirectly advancing medical 
knowledge, mainly in the field of pharmaceutic . 
Society wa capable of fo tering the ideas of Taoism 
ince the underlying belief that Chinese society 
pre cribed to paralleled the paradigms of Taoism. The e 
beliefs were centred around the doctrine of Yin and Yang, 
in which ature was a ingle, unified y tern with polar 
and complementary aspect . When they are in balance, life 
i harmonious. However, when the delicate balance i 
up et, di a ter looms 1• The fir t follower of Tsou Yen' 
philo ophy merged with the Taoi ts, who then adopted 
T ou Yen' ideas. Furthermore, the a pect of Taoism that 
dealt with the earch for immortality had originated from 
folk medicine3. Thus, since the Taoi t religion conformed 
to prevailing ideas held in the culture, uch as that of Yin 
and Yang, and was born of the magico-religiou part of 
ociety, Taoi m wa able to progre within the ociety 
generally unabated. 
Another parallel between social attitudes and Taoi m 
that allowed it to flourish wa that both were cone rned 
with the idea of prevention. In ancient times, China wa a 
bureaucratic feudalism where great importance wa 
attached to the prevention of trouble both in politics and 
in p r onal health3. As the term bur aucracy irnplie , th re 
would be little imagination on the part of government 
emplo ee to olve problems ince they would all be dealt 
with in a preordained mechani tic fashion. This then 
nece itated a need to prevent potential problems from 
ever ari ing. Prominent member of ociety, uch a 
Emp ror H ia Tzu-Liang, e tabli hed the first permanent 
ho pital in 491AD. Before uch time, ho pices had been 
formed only in time of locu t plague, evere drought or 
other type of epidemic 3. Thi action, on the part of the 
Emp ror was most probably due to the prevailing attitude 
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of prevention pre ent in ancient China. Taoism mirrored 
thi ba ic principle in their philo ophies of immortality4• 
By earching for immortality, the Taoi ts were concerned 
with keeping the health of the individual so as to prevent 
the occurrence of any di ease which could potentially lead 
to death. 
By being devout Taoist , many monks were able to 
advance their social standing by ri ing to positions in the 
Emperor' s court. Since their philo ophie were favored by 
the ruling class, the religion wa free to develop. Their 
e calation through the ocial hierarchy was facilitated by 
the de ire of Emporer to drink the formula of life. To 
fulfill this desire, they enli ted the knowledge and 
cientific kills of the Taoi t , and with it came the open 
upport of the religion. The fa cination Emperor had with 
Taoi t beliefs of immortality i reflected in a preface to one 
recipe for the elixir. It de cribe the Yellow Emporer' 
journey to the Taoist Chung Huang-chih to tell him that he 
i giving up his place on the throne to pursue Tao (the 
order of things) . The Taoi t philosophy was a trong 
current under a great number of rulers, especially from 
the Fir t Emperor onward through the Han dynasty. The 
Taoi t were favored by ruler to the point that their 
religion wa actively furthered. 
One uch ruler, Thopa Kuei, instituted a profe or hip 
of Taoi m and alchem with facilities for the tudy and 
preparation of elixir . The Mongol , like Thopa Kuei, 
were al o very receptive to various Taoist practice 6• For 
instance, in 1276, Khubilai i ued an edict in which he 
ummoned the head of the South Taoi t clergy to Shang-tu 
from whence they had a formal pokesman in the capital. 
From this point on and until the end of Mongol rule, 
Taoism held a major po ition in the religious Jive of the 
ruler and the Taoist influence wa there in the court and 
government. The influence Taoi m exerted upon the court 
was evidenced strongly between the years 1307 and 1322, 
when on many occa ion there were edict i ued that 
demanded the protection of the Taoist religion6. The 
Taoist were very capable of attaining influence in the 
ruling ection of society and with thi influence the Taoi t 
philo ophy was further fo tered . 
With this fo tering by th court and their political 
influence a een in Mongol time , it is obviou that the 
religion was anything but per ecuted. A long a the 
religion i not per ecuted by the ruler, it is allowed to 
flouri h and thereby attempt to achieve its goals. Alchemy 
was the main occupation of the Taoi ts and it flouri hed 
during the Mongol rule6• It was through these alchemical 
practices that the pharmaceutical knowledge of ancient 
China developed. 
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A con equence of the Taoi t earch for immortality 
wa that many recipe for the elixir of life were created, 
which amounted to a wealth of knowledge about "life-
prolonging drug ". Although many of the e elixir proved 
to be impotent, thi doe not detract from the fact that due 
to Taoist work in alchemy, the amount of experimentation 
increa ed, leading to the increa ed knowledge of drug in 
general. One of the thing that Taoists living in olitude 
occupied them elve with wa the writing of 
compendium of pharmaceutics. Thee b came known a 
the Pen-t ' ao 7. The de criptions of elixir were followed 
with Taoi t monk ' to in ight and experience on how to 
achieve long life without aging . The Taoi t Ma Chih 
compiled a collection of drug by adding another 133 
type to the repertory of the Pen-t ' ao, which were u ed 
then and now a ucce ful pre cription 7. In another of 
the Pen t ' ao , one of the many recip for immortality 
include ulfur, which found u later in civilization a an 
antidote to ar enic poi oning7. 
The u e of ulfur wa one of many ucce sful drug 
a nd recipe that came into u e through the 
e perimentation of Taoi t alchemist . There were many 
more, one of which wa ammonium chloride. Medically, it 
wa u ed to timulate exp ctoration. It wa introduced by 
Arab , who had picked it up from their Chine e 
alchemical colleague . Moreover, T'ao Hung-ching, 
another Taoi t alchemi t, wa quick to ob erve through hi 
alchemical experiment that mercury wa able to change 
gold and ilver into a pa te . It turned out that he had 
di covered the principle of amalgam and this wa to 
have an effect on health care ince the e amalgam were 
then u ed for filling teeth7. 
Taoists also dabbled in iatro-chemi try, leading to 
further advancement in m dicine. By preparing mixtures 
of androgens and e trogen in a relatively purified form, 
they were able to treat many hypo-gonadic condition . 
Thi advent of medicine had come about ince exual 
endocrinology and pecial e ual practice had always 
b en one Taoi t method of attaining immortality3 . 
Ev idently , Taoi m ha made a distinctive mark on 
medicine through con tant experimentation and 
development of new therapie . 
Mo t of Taoist ucce in medicine wa een in 
pharmacopoeias, where the Taoi t philo ophy led to more 
work and expan ion of work on drug literature. One 
author of the pharmaceutical , Tang Shen-wei, combined 
the Chia-yu pu-chu Shen-mung pen-t ' ao and the T' u-
ching pen-t 'ao into a ingle work that wa more practical 
for the practitioner. He al o in erted an additional 662 
treati e of drugs and e panded the complete work by 
approximately 29,000 instructions for drug application . 
He did not write into the books any of hi own view , but 
in tead quoted from other author and referenced other 
material. ine of tho e reference pertained to other Pen-
t 'ao , 9 were from other medical literature, one from a 
Buddhi t work, and 35 were from Taoi t work 7• 
The way in which the ancient Chine e ociety can be 
viewed then, i a a cyclical arrangement. One can tart by 
aying that Taoi t experiment in alchemy led to advances 
in drug knowledge and other general field of medicine. 
However, thi would not have been pos ible, were it not 
for the fact that ociety, on all levels, fostered the 
development of Taoism, thu allowing it to p ur ue its 
goal with the utmo t freedom. With this freedom, then, 
the Taoists were able to influence odety into ub cribing 
to their philo ophie , in piring them to make medical 
advancement with Taoi tic tendencie in mind . 
Therefore, just as the Taoi t believed that everything was 
circular and interconnected in their odety, o they proved 
it with their progre in medicine. 
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PSYCHOSOCIAL RECUPERATION 
FOLLOWING CARDIAC SURGERY 
Cardiac surgery and angioplasty have advanced to the point where fatality rates for these procedures, performed electively in patients under 70 years of 
age, are less than 2% in many medical centers 1• 
Unfortunately, there are patients who do not benefit to the 
extent that would be expected from successful surgery. 
For these patients, a poor social outcome is associated 
with lingering somatic complaints and a lack of 
confidence concerning physical exertion. These patients do 
not engage in activities of the type that their improved 
cardiac tatus might allow. Poor psychosocial adaptation 
is also linked with social isolation and low compliance 
with medical and exercise regimens 2• 
It is well known that psychological distress figures 
prominently in a patient's rehabilitation following surgery 
for cardiac disease. Timberlake et al (1997) provide the 
following benchmarks regarding the pattern of depre sian 
after such surgeri: Eight days following surgery, SO % are 
depressed due to discomfort, pain, and estrangement from 
the home setting. At eight weeks, 24 % and at twelve 
months, 22% are still depressed. Given, for example, that 
most coronary bypass patients at London Health Sciences 
Centre (LHSC) will be discharged post-operatively after 
five days or less, this means that many will have to cope 
with depressive symptoms at home. Depre sive 
symptoms increase the probability of visits to the 
emergency department and frantic calls to h ealth 
professionals on account of a cognitive state of 
helplessness and other symptoms involved in depre sian. 
Similarly, a sub-clinical level of pessimism involving 
negative self-perception has been found to be associated 
with a reluctance to return to work and a reduction in 
leisure activities4• 
Using a prospective sample of patients admitted for 
coronary angioplasty and coronary artery bypass, Levine 
et al (1996) found that both psychological depression and 
disease severity predicted the number of days of re-
hospitalization when patients were followed fo r six 
months after discharge5. Statistical analysis revealed the 
independent contribution of psychosocial variables (in 
particular, in predicting frequency of patient symptoms) 
after indicators of left ventricular function (e.g. angina, 
dyspnea and fatigue) had been controlled fo~. With this in 
mind, it should be possible to improve our abili ty to 
predict which patients will recover well and which will 
recover incompletely after heart surgery. 
A recent study has found that patients with less severe 
disease pre-operatively may be more prone to depre sion 
following surgerr. It is possible that those patients who 
were most incapacitated prior to surgery received the 
greatest relief from their operation. Alternatively, patients 
By Dan Mendonca 
who were under the impression that their disease severity 
was not very serious may have been ill-prepared for the 
subsequent incapacitation. Langosch et al (1992) reported 
that patients who perceived their operation as a purely 
technical event (avoiding emotional involvement) were 
more depressed post-operatively6 . It is important, 
therefore, to take into account patients' expectations and 
their understanding of the extent of their disease. 
During the early phase of recovery, there is heightened 
somatic concern and anxiety. Anxiety, in this case, results 
in activation of the sympathetic nervous system, a key 
modulator of cardiovascular function. Strategies aimed at 
inducing a relaxation response might be useful during this 
initial phase. Unfortunately, a h igh level of anxiety 
provides the motivation for relatively swift learning of 
maladaptive conduct. A perceived reduction in fear 
reinforce negative behaviours such as phobic responses, 
superstitious acts, and avoidance behaviour 7• 
With reference to social disability, it has been found 
that 50 % of marriages may deteriorate after a myocardial 
infarction . This might be due, in part, to changes in role 
imposed during the recovery process which often affect 
self-esteem. Patients and family could benefit from the 
opportunity to interact with well-adjusted former patients 
to develop positive expectations regarding the future. 
Patients report experiencing pecific problems of 
emotional adjustment following cardiac surgery. In a 
study involving focus groups of former patients, Border et 
al (1985) report the following 9: i) going through a 
"downer" (e.g. crying for no reason, memory problems, 
crying because one cannot return home), ii) feeling fearful 
on leaving the security of the hospital, iii) fearing they will 
appear less attractive to their partners on account of their 
scar. Patients may go through different phases in terms of 
accepting emotional support. Some patients may prefer to 
"crawl into a hole" and wait while they either "die or get 
better" . Others opt to have family milling about them, 
talking and doing all kinds of things. 
Chest pain is perhaps the major symptom that 
concerns patients, spouses, and personnel. Patients should 
be encouraged to mentally review the experience of chest 
pain and its implications6 • Medical staff can clarify 
misconceptions and provide new information to aid 
patients in appraising their physical condition. Patients 
can be taught to notice whether they change their rate of 
breathing, tense up specific muscles, change their posture, 
or focus on specific thoughts during the experience of 
chest pain. Techniques which can be used to counteract 
the anxiety associated with chest pain include breathing 
exercises, deep muscle relaxation techniques, imagery, 
and diversion (e.g. focusing on the idea that the pain will 
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One of the key ingredient of depre ion following 
urgery is " learned helplessne s"-ie, a belief that the 
patient cannot meaningfully alter their own recovery. 
With respect to counteracting this effect, two major foci 
have been identified: symptom reporting and activity 
progression6• Both strategies are directed at helping 
patients regain a sense of personal control. In the fir t case, 
patients can be taught specific vocabulary which allows 
them to accurately describe bothersome symptoms (eg, 
chest pain). Positive reinforcement is given to patients 
when de criptors give clear information about the pain 
experience. Pain in the chest wall, for instance, can be 
readily differentiated from anginal pain. In the second 
instance, patients can be taught to assess the body's 
respon e to exercise and thu participate in planning 
activity progression. This might involve taking the pulse 
before and after specific activitie . In this context, fatigue, 
shortness of breath and chest pain might be viewed as 
indicators of the body' s slowly improving response to 
exercise (rather than imminent threats) . The patient 
experiences a sense of control in helping to determine 
when their heart can successfully manage a particular load. 
In addition to monitoring physical symptom and 
activity progression, patients can be taught ways to better 
manage recurring worries regarding their future . These 
thoughts lead to changes in mood which can impact on a 
patient's ability to improve. The cognitive technique of 
" thought stoppinf is one which can be used to arrest 
such ruminations 0. Patients may also be disturbed by 
fluctuations in affect which are commonly experienced 
following heart attack. Counselor might be used to help 
patients articulate their troubling feelings and place them 
into perspective. 
Interventions designed to promote patients' 
perception of control are one approach to improving 
psycho ocial recovery following a cardiac event. Patients' 
perception of control (relating specifically to their cardiac 
disease) appears to be adaptable (amenable to change) 
and, indeed, predictive of later psychosocial recovery. In 
studies where patients were involved in planning a pects 
of their own rehabilitation programme, psychological 
distre s was found to decrease a perceived control among 
patients increased2• 
Artinian et al (1995) sought to determine whether 
phy icaJ, psychological or social recovery differ for men 
and women during the first six weeks following coronary 
artery by pass 11 . Women in the study reported a 
significantly higher number of physical symptoms. This 
wa especially true for activities involving ambulation. 
Women al o had more ymptom of depre sion than men. 
(It is worth noting that female patients were more likely to 
be without a spou e.) Importantly, female patients 
experienced lengthier recoverie and were less likely to 
have adequate spou al support (e.g . with home 
management activitie ). 
In recent year , controversy has ari en over the i sue 
of long-term psychological maladjustment in patients 
following open-heart surgery. While Timberlake et al 
(1997) confirm an increase in the prevalence of depre ion 
following surgery, they report an eventual decrease in 
Promotion & Prevention 
prevalence to a level below that een prior to surgery 3. 
Perhaps patients' improved cardiovascular function 
following surgery can account for the long-term decline in 
depressive symptoms. 
Beck et al (1995) report that the crucial component of 
depression may be the cognitive dimension 1 · Further 
investigation is needed to elucidate the course of 
depression and artXiety, particularly the cognitive core, 
following cardiac surgery. (The cognitive core refers to 
perceptions of diminished self-worth, helplessness and 
pe sirnism regarding the future). Providing interventional 
therapy for all patients receiving open-heart surgery would 
be both expensive and time-consuming. It may be possible, 
however, to identify those patients who may be at risk of 
showing poor postoperative psychological adjustment. 
SUMMARY 
Although most patients experience a successful 
psychosocial recovery following cardiac surgery, a 
significant proportion experience persistent distress which 
impacts negatively on physical well-being and 
reintegration into ordinary work, leisure, and domestic 
activities. The potential economic benefit of assisting the 
psychosocial recuperation of such patients is substantial. 
Fundamental information regarding the mechanisms of 
emotional maladjustment could prove indispensable to 
the cardiac care team. This should continue to be an area 
of focus for cardiac rehabilitation re earch. 
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A REVIEW OF NEW 
MARKERS 
CARDIAC 
INTRODUCTIO 
I n the emergency room etting, early diagno i i important in the initial treatment and management of patient presenting with acute on et of che t pain . 
Early monitoring in the coronary care unit and the u e of 
thrombolytic therapy greatly decrea e morbidity and 
mortality1• Diagno i ha traditionally been ba ed on 
clinical history, physical examination, and 
electrocardiographic (ECG) findings. When World H alth 
Organization (WHO) criteria (pre entation of che t pain 
over 20 minute , evolutionary chan§e on the ECG, and 
abnormal level of cardiac enzyme ) are used to da ify 
patients with uspected myocardial infarction, only 50% of 
all che t pain ufferer admitted to the CCU are confirmed 
a having thi condition. Although the ECG can be 
performed ea ily and rapidly, pecific change may be 
ab ent or inconclusive in the early hour in about half of 
the patient arriving at ho pita] with acute myocardial 
infarction (AMI)3. Furthermore, approximately 2% of 
patient with AMI are inadvertently ent home4• It i for 
this rea on that mea urement of biochemical marker of 
myocardial mu de cell damage play an important role in 
the diagno i of AMI. 
In the pa t, te t for lactate dehydrogena e, aspartate 
transaminase, and creatine kina e were developed and 
widely u ed . The e te ts were later replaced by newer 
technology uch a minicolumn and electrophoretic 
eparation methods for mea uring the erum CK-MB 
i oenzyme, a more cardiac- pecific marker5. But the e 
traditional cardiac marker (total CK and CK-MB activity) 
do not aid in the early diagno i of AMI becau e they peak 
too late and are not pecific for cardiac injury. In r cent 
years, the earch for more en itive and pecific marker 
of myocardial infarction ha brought about a new 
generation of biochemical cardiac markers such a the 
rna concentration assay of CK-MB, CK i oforms of the 
i oenzyme CK-MB (MB2 / MB1 ratio), myoglobin, and 
troponin I and T. In the following review article, the e 
new biochemical markers will be examined. 
MYOGLOBI 
Myoglobin, an oxygen-binding cyto olic protein of 
low molecular weight, is normally found in cardiac and 
keletal mu de. When necro i of the e mu des occur , 
myoglobin is relea ed into the erum and can be detected 
by radioimmunoa ay as early as 1-4 h after cell death 
with a peak between 4-12 hour and a return to norma118-
24 h later6•7 • Woo concluded that becau e myoglobin i an 
early and en itive marker of necro is, it i valuabl for 
early detection and exclusion of AMr. However, becau e 
myoglobin i al o found in keletal mu cle, it ha poor 
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pecificity, and can lead to many fal positive in patients 
pre enting with keletal mu de trauma. Some re earcher 
have sugge ted simultaneous mea urement of a keletal 
mu de pecific marker, carbonic anhydra e Ill to re olve 
thi limitation10. 
Myoglobin ha been compared with CK-MB (activity 
and rna ) in a number of tudies with inconsistent 
finding . One tudy howed that the te t for CK-MB mass 
was superior to that of myoglobin ''. However, Brogan 
reported that myoglobin wa a more ensitive marker of 
myocardial necro i than CK-MB (mass) during the first 
3h of pre entation in the emergency department12• Thi 
wa upported by Tucker, who howed that the en itivity 
within 4 h of the on et of ymptoms was 78% for 
myoglobin ver us 63% for CK-MB mass13• Finally, another 
study howed no significant difference in the performance 
of myoglobin compared to CK-MB rna 15• Bakker 
concluded that the be t predictor of AMI within 4 h after 
on et of che t pain u ing WHO criteria were the 
combination of ECG and myoglobin14 • 
Although myoglobin lacks p cificity, it early relea e 
sugg~ t that it may ? co~e an ~portant dia~o tic tool 
for triage of che t pam patients m the future 11 • 3•16• This is 
support d by the fact that orne ho pita! emergency 
department have already in tituted the rou tine u e 
myoglobin to aid in triaging patients presen ting wi th chest 
pain (Ed. Note - LHSC-UC routinely measures myoglobin in 
the emergency department). 
CREATINE KINASE 
Creatine kina e i a cardiac enzyme that is relea ed 
into the blood when myocardial necro i occur . It con i ts 
of three i oenzyme - CK-MM, CK-MB, and CK-BB, but it 
i the CK-MB i oenzyme which i most widely u ed a a 
biochemical marker for the diagno i of AMI 16• 17 • 
Specifically, erial mea urement of CK and CK-MB are 
u ed to diagnose myocardial cell damage and its 
characteri tic ri e and fail in serial measurement i nearly 
pathognomic for AMI. The a ay of CK-MB i oenzyme 
and the calculation of it percentage relative to total CK i 
the tandard of reference for the diagno i of AMI 1 • 
Although the en itivity of CK-MB activity for AMI 
diagnosis is very high, cardiac pecificity is comprorni ed 
in patient with keletal mu cle tra um a, myocarditis, 
chronic renal failure, cardiac urgery, a well a rare 
ectopic production in patient with tumor 19• 
Thi problem ha led to effort to find more specific 
marker for AMI. In earlier studie , electrophoretic or 
chromatographic procedure were u ed to mea ure levels 
of CK-MB. Thi led the way for the production of CK-MB 
monoclonal antibodie , which were e sential in the 
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development of rapid and co t-effective a ay procedure 
using fully automated analyzer 5. The development of 
automated rna a ay for CK-MB also led to 
improvement in clinical en itivity and specificity and 
turnaround time when com~ared to catalytical 
determinations done in the pa t11 • 7• However, CK-MB i 
not a perfect biochemical marker becau e -12 h may be 
required after the on t of ymptoms for the test to be 
elevated above normal and yield a high en itivity and 
specificity 19 (although CK-MB has been noted to rise 
earlier in orne patient with large infarcts). Another major 
drawback is that CK-MB mas concentration ha been 
hown to increase in the first 48-72 h with a return to 
normal within 72 h after the on et of chest pain in patient 
with known AMI. This leaves a relatively short diagnostic 
window of only 2-3 day 22.23. 
CK ISOFORMS OR SUBFORM 
In addition to the three i oenzymes of CK, both CK-
MM and CK-MB can be metabolized by enzymatic 
cleavage of the terminal ly ine amino acid from the "M" 
ubunit. High-voltage electrophoresis technique can be 
u ed to eparate and measure CK-MB and it two i oforms 
- CK-MB 2 and CK-MB 1 in an attempt to improve CK-MB 
ensitivity in the early tages of AMI. Bhayana found that 
time to po itivity of both the rna s monoclonal a ay of 
CK-MB and the i oform as ay were comparable, but noted 
greater difficulty in performing and interpreting the 
i oform assaf~. Hetland and Dickstein reported that the 
i oform ratio was the mo t en itive test in the early 0-3 h 
after the onset of chest pain and at adrnis ion to ho pital15• 
In the following 3-5 h, no ignificant difference among the 
ensitivitie of myoglobin, CK-MB i oform ratio and CK-
MB mass concentration wa found 15• Puleo performed a 
tudy comparing CK-MB activity with CK-MB i oform in 
diagno ing AMI and ha recommended widespread CK-
MB i oform testing after finding reliable detection of AMI 
within the first 6 hour after the onset of symptoms25. 
However, no study comparing CK-MB rna with CK-MB 
i oform has been done at the pre ent time. 
There are some disadvantages to u ing CK-MB 
i oform te ting. The time to perform isoform quantitation, 
difficulty of the procedure, lack of a practical 24-hour tat 
a ay, difficulty in interpretation, a well a high co t will 
restrict the wide- pread implementation of this te t until 
further development are made. 
TROPONIN 
The troponin complex play an important regulatory 
role in the contraction of triated muscle. Thi complex 
con i t of three protein ubunit -troponin C, which 
bind to calcium and regulate contraction, troponin I, 
which inhibits actomyo in A TPa e, and troponin T, which 
bind the troponin complex to the tropomyo in strand22• 
Troponin T and troponin I have amino acid sequences 
that differ in skeletal and cardiac muscle at various 
location 22 • Antibodie have been developed which 
recognize the e cardiac- pecific equence , and it i the e 
antibodies which form the ba i for cardiac troponin T 
(cTnT) and cardiac troponin I (cTnl) immunoa ays22 • 
Troponin C cannot be utilized a a cardiac-specific marker 
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b ecau e it amino acid es uence i identical in both 
keletal and cardiac mu cle . CTnT differ from cTnl in 
that the former i found in great amounts in the cyto olic 
pool and has a longer life pan in the bloodstream. Cardiac 
troponin T al o ha a lower ab olute cardiac pecificity 
than cardiac troponin I19• 
Quantitative as ay for both cTnT and cTni te t have 
been hown to be more en itive and pecific than CK-MB 
for the diagno i of AMI 19• The enhanced pecificity allow 
for more accurate diagno i of cardiac injury, especially 
when keletal mu cle trauma is pre ent. As well, troponin 
level remain elevated up to 7-14 days after an AMI 1 • 
Thu , troponins can be mea ured long after myoglobin 
and CK-MB have returned to normal levels. This broader 
diagno tic window i advantageous in the minority of 
p a tient who delay eeking medical care becau e of 
equivocal ymptoms or other rea ons. However, the fact 
that troponin can detect cardiac damage days after 
infarction limit it ability to detect reinfarction. 
A recent pro pecti ve tudy examined the use of a 
rapid, qualitative troponin T and troponin I te t in patients 
arriving to the emergency department with acute che t 
pain . The result indicated that no patient was 
inappropriately di charged when the troponin T bed ide 
te twas routinely u ed3. Furthermore, when patient were 
te ted 6 h after the on et of pain, 94% of patient with MI 
and without ST-segment elevation had a po itive troponin 
T te t, and 100% had a po itive troponin I te . Although 
the diagno tic pecificity of the e tests were omewhat 
low, the e figures are nonetheless significant. 
Cardiac troponin T has been recognized as a highly 
en itive and pecific a ay for AMI in a number of 
tudie 23.26. Wu demonstrated in their tudy that cTnT wa 
a ensitive marker of myocardial damage during the fir t 6 
h, and wa comparable with the "gold standard" CK-MB 
mas a ay. After thi time, the clinical sensitivity of cTnT 
urpa ed that of CK-MB because of the prolonged relea e 
of cTnT into the blood 23. The same study, however 
reported a diagno tic pecificity for cTnT of only 46%, a 
lower pecificity than in earlier papers. Another tudy 
found that cTnT to be more efficient than CK-MB in 
determining and excluding AMI17• Bakker found that the 
diagno tic ensitivity of troponin T wa much better than 
that of myoglobin, CK, and CK-MB activity14. 
Cardiac troponin I, unlike CK-MB, is highly specific 
for myocardial ti ue, and i not found in the blood of 
healthy individuals19• Troponin I ha been shown to have 
great progno tic value. Antman examined the prognostic 
value of cardiac troponin I in patients with either unstable 
angina or non-Q-wave myocardial infarction. He found 
that cTni i an independent ri k factor identifying patients 
with un table angina or non-Q wave MI who are at 
increa ed ri k of death27• The progno tic value of cTni wa 
found to be greater in tho patients presenting more than 
6 h after the onset of che t pain27. Antman a! o reported 
that there wa a direct relationship between the amount of 
cTni and mortality. That i , the hi:9her the level of cTni, 
the greater the ri k of mortality-. The e findings are 
ignificant in that cTni allow for the early identification of 
patient at increa ed risk of death. 
A di advantage for troponin use is that the assay for 
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troponin requires a dedicated instrument that i not 
widely available, as well as 90 minute for completion. 
Furthermore, the cost of the reagents is much higher than 
tho e for CK-MB. A relatively new rapid troponin test 
a ay, which allows the determination of troponin levels 
in whole blood at the patient's bedside shows some 
promise. It can be performed conveniently in the 
emergency room or in laboratories, and can potentially be 
used to aid in the triage of chest pain patients. 
CONCLUSIONS 
Early diagnosis of myocardial infarction is of great 
importance in decreasing morbidity and mortality, 
especially with recent advances in thrombolytic therapy. 
Although the ECG remains the standard test for 
diagnosing AMI and initiating thrombolytic therapy, often 
it is unable to guide the clinician to definitive 
management. Therefore, alternative diagnostic methods 
must be used, especially in those patients without ECG 
changes or with unstable angina3. ew biochemical 
markers have been shown to facilitate successful 
intervention by identifying individuals at risk of sudden 
death from an ischemic cardiac event. These markers are 
not only useful in aiding in the diagnosis of AMI, but they 
ma y also have valuable prognostic utility as w ell. 
Specifically, cardiac troponin I is an important prognostic 
marker of acute coronary syndromes or unstable angina. 
This allows some patients to be discharged home rather 
than being admitted to hospital resulting in enormous 
savings to the health care system. 
Myoglobin, CK-MB, and troponin have all been 
shown to be valuable diagnostic tools for reliable and 
rapid detection of patients with AMI Early recognition of 
myocardial cell death will allow appropriate triage of 
patients with chest pain and the selection of therapeutic 
strategie . 
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PREGNANCY: HYPERTENSION IN 
AN UNUSUAL ETIOLOGY-
REPORT A CASE 
Hypertension pre enting in, or being aggravated by pregnancy i a common occurrence. It is e timated that 6-10% of nulliparous women 1 will have a 
pregnancy complicated by hyperten ion. If a woman 
develop hypertension during her pregnancy, most 
clinicians initially a ume the diagno i of preclampsia or 
pregnancy induced hypertension . It is important to 
remember, however, that occasionally, the etiology of a 
condition characteri tic or pecific to pregnancy may be 
the re ult of some other pathology. A ca e is presented 
below in which the etiology of hypertension occurring in 
pregnancy was an aldo terone- ecreting adrenal adenoma. 
Primary hyperaldosteronism is a rare, but well-
documented disea e occurring during pregnancy. There 
have been less than twenty ca e reported, the majority of 
which were due to an adrenal adenoma. Since surgery is 
the treatment of choice for active adrenal tumour , it i 
important to document the presence of a neopla m o that 
it can be treated appropriately. 
CASE REPORT 
A 33 year old nulliparou woman pre ented to the 
emergency department at 17+4 weeks gestation 
complaining of acute onset of proximal leg weakness. This 
came on quite uddenly after a three week hi tory of 
migraine headache , vomiting, and migratory myalgias 
involving her lower limb bilaterally including her right 
hip, calf, left foot and calf. Significant past medical history 
includes a two year hi tory of hyperten ion and 
headache , for which she wa taking atenolol. 
On phy ical examination, abnormal finding included 
a blood pressure of 190 / 110, decreased power in the hip 
flexor and dor iflexor at the ankles bilaterally, and 
pitting edema bilaterally to the knees. The only abnormal 
laboratory value wa a erum potas ium of 1.8 mmol / L 
(ref. 3.3 -3.5 mmol / L}, and U wave present on the ECG. 
There wa no proteinuria. 
At this point, a tentative diagnosis of 
hyperaldosteronism was made, and the patient was 
admitted to ho pital. Her pota sium level was tabilized 
using pota ium boluses and supplements. Inve tigations 
in hospital included a renal ultrasound and serum 
aldo terone level . o adrenal masse were een, but the 
aldo terone level was found to be elevated at 2041pmol / L. 
The blood pres ure was stabilized using atenolol, and the 
patient was placed on potassium supplements. 
At 29 week ge tation the patient had an abdominal 
MR1 which demonstrated a 2.5 em adenoma on the left 
ide. This confirmed the diagno is of an adrenal tumour; it 
was concluded that the tumour was most likely secreting 
aldo terone. 
As she continued with her prenatal care, her blood 
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pre ure was found to be high, but stable at 170/100. Her 
urine was normal until 33+{; weeks ge tation when she had 
1 + protein on the urine dip tick. A 24 hour urine collection 
for protein wa done, and wa found to be within the 
normal range at 400mg / day. Subsequent urine dips were 
normal, until her antenatal vi it at 36+5 weeks, when he 
again had 1 + protein in her urine. Her blood pre sure was 
becoming more volatile at this time as well. Since the 
patient was non-compliant and refu ed admi sion to 
ho pital for fetal-maternal monitoring, she was induced at 
37 weeks gestation. She had a normal labour and vaginal 
delivery which produced a healthy infant. 
She has been sub equently referred to a surgeon for 
the removal of her tumour. 
DISCUSSION 
Primary hyperaldosteronism, due mo t commonly to 
adrenal adenoma or bilateral adrenal hyperplasia, is the 
cau e for approximately 1-2% of hypertension found in 
non-pregnant adult 2• It i more common in women (2:1}, 
and usually occurs between the age of 30 and 50 years. 
However, there are les than twenty case report of 
aldo terone ecreting adrenal adenoma presenting 
during pregnancy. 
The mo t common pre entation, in pregnancy as well 
a non-pregnancy is ymptoms of fatigue, muscle 
weakness, nocturia, lassitude and headaches. Blood 
pressure i mildly to severely elevated. In pregnancy, 
however, a complicating factor may be uperimpo ed 
preclamp ia; it may present quite a challenge to 
appropriately interpret all of the clinical findings. 
The laboratory value which are abnormal include a 
low erum pota ium, high serum aldo terone, low erum 
renin, and often a metabolic alkalosis . A definitive 
diagnosis can be made using CT scanning or MRI. Since 
CT scanning during pregnancy is not desirable, and MR1 
is an imaging modality which is becoming more 
acce ible, these tumour may be identified using MRI. A 
renal ultra ound i often the first radiologic procedure 
done; however, as this ca e demonstrated, renal / adrenal 
ultrasound may not be helpful in making the diagnosi . 
In a non-pregnant adult, the treatment of an 
aldo terone secreting adenoma is surgical re ection3 . 
However, medical treatment, in the form of 
pironolactone, an aldosterone antagonist, can be used to 
stabilize blood pressure and treat hypokalemia4 • Other 
anti-hypertensives, such a calcium channel blockers and 
ACE inhibitors have been tried with some success5• 
Problems specific to the pregnant state ari e in the 
treatment of hyperaldosteronism during pregnancy. 
Spironolactone i known to have antiandrogenic effects in 
humans; as well it can cause feminization of male rat 
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fetu e when adrnini tered to pregnant rats, it i therefore 
not recommended for u e during pregnancy6 . Since 
urgery i the definitive treatment, it i po ible that if the 
di ea e wa medically unmanageable, using anti-
h y perten ive and pota ium upplement , then 
adrenalectom could be performed during pregnancf. 
In conclu ion, hyperten ion during pregnancy i not 
an uncommon clinical finding. Although the va t majority 
of hypertensive, pregnant women will be diagno ed with 
preclamp ia, it i important to remind one elf that the 
differential diagno i of hyperten ion in pregnan y i 
quite diver e, and the ca e that one i dealing with may 
have a more unu ual etiology that expected. 
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FACTOR V 
VENOUS 
LEIDEN MUTATION AND 
THROMBOEMBOLISM 
Venou thrombo i i a multicau a] di ea e in which genetic and acquired ri k factor interact in an individual to determine whether or not a 
thrombotic event will occur at a pecific point in time. 1 
Recently, the Heart and E trogen Replacement Study 
(HERS), the fir t major placebo-controlled clinical trial of 
hormone replacement therapy (HRT) in the econdary 
prevention of coronary heart di ea wa published. Over 
an average of 4.1 years of follow-up, HRT failed to reduce 
the overall rate of coronary heart di ea e event , but 
increa ed thromboembolic events (a econdary outcome 
mea ure) by 2. 9 time .2 In the pa t five year , advance in 
the genetic of thrombo i have re ulted in the elucidation 
of novel coagulation abnormalitie that predi po e to 
venou thrombosi . In particular, a defect in the 
hemo tatic pathway, called activated protein C (APC) 
re i tance, and it underlying mutation, factor V Leiden, 
were found to be common in the population (3% to 
7%) .3. 1 0. 1 ~ . 15, 1 6 
They are a ociated with ubstantially higher ri k of 
venou thromboemboli m among patient with a co-
exi tent predi po ition for thrombo i , uch a advanced 
age, u e of oral contraceptive , hyperhomocy teinemia, 
and deficiencie of protein C and protein S.3 To date, the 
thromboembolic ri k in po tmenopausal women with the 
factor V Leiden mutation ha not been tudied. The intent 
of thi review is to e tabli h a rationale for research into 
the po ible a ociation of venou thromboemboli m in 
po tmenopau al e trogen u r and the APC re i tance 
phenotype, or the factor V Leiden mutation. 
Risk Factors for Venous Thrombosis 
Ri k factor for venou thrombo i are different from 
those for arterial thrombosi , and are cla ified into 
genetic and acquired ri k factor . Many acquired ri k 
factors for venous thrombosi have been identified, uch 
a pregnancy, the puerperium, immobilization, urgery, 
trauma, lupu anticoagulant, malignant di ea e, and 
female hormone .1 For example, oral contraceptive u e i 
a ociated with a four-fold ri k for venou thrombo i 
above ba eline.6 The ri k of venou thromboemboli m 
with hormone replacement therapy are also well-
e tabli hed. Prior to the HERS trial, re earcher in Britain 
and in the United State found relative ri k estimate for 
venou thromboemboli m in current u er of hormone 
replacement therapy of 3.5 and 3.6, re pectively, 
compared with non-u er or pa t-u ers.~.s 
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The genetic ri k factor for venous thrombo is include 
di order of the clotting y tern, uch a protein C and 
protein S deficiencies, antithrombin III deficiency, 
prothrombin 20210A, hyperhomocysteinemia and 
re i tance to activated protein C.1 Re i tance to APC wa 
fir t de cribed in 1993 by Dahlback et al, and it ha been 
ub equently hown that in the majority of ca e , it i 
caused b what is now known a the factor V Leiden 
mutation. 
Activated Protein C Resistance and the Factor V Leiden 
Mutation 
In the protein C / protein S pathway of coagulation 
inhibition, protein C i activa ted (ie becomes an active 
protea e) when it bind to thrombomodulin, an 
endothelial membrane protein.9 On a pho pholipid 
urface, activated protein C, in the pre ence it cofactor, 
protein S, and calcium ion , inhibits coagulation by 
proteolytic cleavage of activated factor V and VIII, thu 
mainly acting on the feed-back activation of the intrin ic 
pathway of coagulation.10·11 (Fig. I). The factor V Leiden 
mutation involve a single adenine-for-guanine point 
mutation in the gene encoding for coagulation factor V 
which lead to the replacement of arginine by glutamine at 
po ition 506. This po ition i one of the three cleavage ite 
on factor V for APC, and thu the mutation cau e the 
activated form of factor V (Va) to be degraded at a slower 
rate than normal factor Va.3 Thi results in the APC 
re i tance phenotype, which cau e increa ed thrombin 
forma tion and a lifelong hypercoagulable tate.12 The 
factor V Leiden mutation is inherited in an auto omal 
dominant fa hion. 10 In 1997, the pre ence of a factor V 
genetic component other than factor, the HR2 haplotype, 
was de cribed in patient who did not have the VRSOOQ 
mutation. This genetic component, i also able to 
contribute to the APC re i tance phenotype in patient 
with venous thromboemboli m. 13 The original factor V R506Q 
mutation will be the focu of thi review, however, 
becau e it has been tudied exten ively, and henceforth, 
u e of the term " factor V Leiden mutation" will refer to 
the VRSOOQ mutation. 
Unlike other inherited defect of hemo tasis, such as 
protein C and S deficiencie , and antithrombin III 
deficiency, factor V Leiden mutation is common. The 
carrier frequency of factor V Leiden mutation in healthy 
control populations ranges from 3% to 7% in Europe and 
the United States and may be as high a 15% in orne 
elected group . 1 0· 1 ~ · 1 5· 16 It is mo t prevalent in white 
per ons (5.27%) and i notably uncommon in Asian and 
African populations, a fact that may explain the decrea ed 
ri k for venou thromboembolism in these groups. 17·1 
Factor V Leiden Mutation and Risk of Venous 
Thromboembolism 
In referral populations of patient with venou 
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Figure I. The mechanism of action of the antithrombin III 
and protein C natural anticoagulant pathways. The "a" 
beside the roman numeral of a coagulation factor indicates 
activation, and " i " indicates degradation, or inactivation. 
PL = phospholipid.28 
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thromboemboli m, factor V Leiden mutation is the mo t 
common identifiable risk factor, with a prevalence of 11% 
to 37%. 10•14•19.20.21 Heterozygous carrier of factor V Lei den 
have a even-fold increa ed relative risk for venous 
thromboembolism versu non-carriers. Homozygous 
individuals have an alarming 80-fold increased relative 
risk of thrombo is. Still, mo t homozygou patient do not 
develop thrombosis until adulthood and may remain 
symptom-free until old age.21 Thi is likely becau e venous 
thrombo i a result of the interaction between concomitant 
risk factors in a given individual. ' Homozygous 
individuals al o experience their thrombo i at a much 
younger age than heterozygous individuals (31 v . 44 
year ) and non-carriers ( 46 year ). 
lntere tingly, studies have found that the majority of 
patient with venous thromboembolism who were 
identified as homozygous for the factor V Leiden mutation 
were women, and it was felt that these patients had 
become ymptomatic due to their u e of oral 
contraceptive .21.22 An earlier population-based ca e-
control tudy had in fact shown that women who carried 
the factor V Leiden mutation and who used oral 
contraceptive had a more than 30-fold increase risk of 
thrombo is compared to women who did not hav either 
ri k factor. 6 Clinical studies al o indicate that factor V 
Leiden mutation is associated with increased risk for 
venous thrombosis during pregnancy.23.24.25 Thus, there i 
ample evidence of an interaction between genetic and 
acquired risk factors for venous thrombosis, where in 
combination they can produce an effect that exceeds the 
sum of their separate effects. 
Thrombin 
Ca2+, PL 
Proteins 
Future Directions 
Activaled 
Protein c 
This year, the fir t report of an acquired activated 
protein C resistance ~ the ~o ~enopaus_al period, wa 
publi hed by MarcucCI et al. 1 Thi APC resistance wa not 
a ociated with the factor V Leiden mutation, but with 
high pia rna levels of factor VIII, which the author 
propo e would require more APC for a comparable 
anticoagulant effect. The author admit, however, that the 
factor V genetic component marked by the HR2 haplotype 
may be responsible . everthele s, thi finding in 
postmenopausal women rai es the question of risk of 
venou thromboembolism in users of hormone 
replacement therapy who have APC resi tance or who are 
carriers of either factor V genetic mutation. Given that the 
ri k of venous thrombosis increa e with age,26 and that 
HRT in it elf increases thromboembolic risks, it i po ible 
that po tmenopau al women with the factor V Leiden 
mutation who are taking hormone replacement therapy 
could be at a very high risk for venous thromboembolism. 
The e are question which need to be addressed if 
phy icians are to be informed abo ut the risks of 
pre cribing hormone replacement therapy. At a simpler 
level,even the effect of menopause on the incidence of 
venous thrombosis is yet to be determined. 
The study of APC resistance could become relevant in 
explaining the increa ed ri k for venous thrombosi 
associated with postmenopausal estrogens. Should we 
screen for the presence of APC resistance in women 
reque ting HRT? This que tion has been debated in the 
literature concerning oral contraceptive use. Let us 
consider the example of creening for factor V Leiden in 
28 
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women requesting oral contraception, assuming that all 
fatal thromboembolic event are attributable to the factor 
V Leiden mutation. Vandenbroucke et al estimated that 
almo t half a million women would require screening to 
identify the 20,000 to 25,000 women who carry the 
mutation and would be denied oral contraception, in 
order to avoid one death per year.27 The costs of such a 
program would be formidable. 
For now, physicians must be aware that a careful 
empha is on thromboembolic events in both the per onal 
and family histories of patient can often identify those 
who might need to avoid oral contraception and hormone 
replacement therapy, or who hould be anticoagulated if 
they choose such treatments. But perhaps in patients 
identified as being high risk, it is justified to investigate 
the coagulation statu . Thi would identify patients for 
w hom hormone replacement therapy need not be 
withheld, and would differentiate them from patients who 
hould only take hormone replacement therapy if they 
take concomitant anticoagulant therapy. Thus screening 
for APC re istance, particularly in high risk populations, 
should be considered. 
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HEART DISEASE IN WOMEN: 
RESOLVING MISCONCEPTIONS 
I n the past decade there has been a strong drive to discover the sex differences regarding heart disea e. 1 Many misconceptions have been corrected in the 
literature; however, men, women and their physicians 
alike are still not keeping abreast of new discoveries. From 
a physician's standpoint, educating one's patients can be 
one of the most effective means of preventive medicine. 
Unfortunately, misconceptions still prevail, allowing 
symptom recognition and lifestyle changes to become less 
effective as time passe . 
What are these misconceptions and what are the facts? 
Heart di ease is now the number one killer of both men 
and women in the United States and Canada.1•2.3 It had 
been believed for a long time that heart disea e only 
affects older women who are post-menopau al. While it is 
true that the effects of e trogen have a cardia-protective 
function, this only delays the on et of di ea e. Studies 
have shown that a woman's first pre entation to the health 
care sy tern is between three and ten years later than men 
on average, but the outcome for women are wor e after 
having a myocardial infarction.4 The e patterns reinforce 
the notion that women should be better educated about 
their risks of heart disease. 
Life tyle improvements and risk factor modifications 
have been implemented aggressively with men, in order 
to reduce their prevalence of heart di ea e. This same 
aggressive preventive medicine should be used in 
affecting the outcomes that women face. Although 41% of 
all deaths in women are related to heart di ease, women 
continue to believe that their major health ri k is breast 
cancer. In the 1990 Ontario Health Survey, 81% of women 
stated their most serious health concern to be br a t 
cancer,5 when in reality the number of women who die 
from heart disea e each year is almost a great as the 
number of deaths in women from all cancer combined.2 
These misconceptions not only give women fa ! e 
impressions about their general health, but their abili to 
modify their risk factors is severely hindered a well . 
As a member of the health care system, the phy ician's 
role is to diagnose, treat and educate patients. Education is 
an incredibly important factor in successfully 
implementing preventive medicine protocols. When 
people are empowered with knowledge they are more 
likely to respond to ri k factor modification . Wher do 
mo t women receive pertinent health information? Their 
physicians. Herein lies another problem. A 1997 study in 
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the Journal of Women's Health report that 59% of the 
subjects who responded believed that their primary care 
phy ician had inadequately coun eled them about heart 
di ease. Ma ny women also felt that they were never 
properly assessed for heart di ease risk factor .2 
The e bia es have been propagated, hi torically, by 
the exclusion and under-representation of women in 
cardiova cular clinical trials.6 As national regulations have 
changed in the pa t decade, study populations ha ve 
become more repre entative of the pa tient population 
that are een each day. The e change have led to many 
large scale re earch projects that will report their finding 
on women's health in the early part of the 21st century.7 
The goal of such projects is to correctly asse s the health 
ri ks of women, while correctly documenting the sign 
and ymptom with which they will pre ent. 
What is known already? Gender difference have been 
de cribed in clinical presentation and in ri k factor 
profile . For example, re earch has shown that women 
uffer from heart di ea e, with an average age of onset ten 
years greater than that of men. Women are more likely, 
however, to face a worse prognosi after a myocardial 
infarction than men, and their prognosi following 
urgical therapy for coronary artery di ease i al o wor e 
than that for men. In terms of clinical pre entation, che t 
pain in women is not as specific an indicator for heart 
di ea e a is the ca e with men. This does not allow one to 
di rni the po sibility of heart di ease. On the contrary, a 
very careful history hould be elicited to ensure that the 
number one killer of women i not overlooked, especially 
becau e 50% of women with heart di ea e first pre ent 
with angina. 
Men and women do share a lot of symptoms and risk 
factors, but in different ways and wi th a different 
emphasi . Smoking i a strong predictor of heart disease in 
both men and women, to the point that women who 
moke lo e their protective e trogen advantage and are 
ju t as likely to develop heart di ea e men of the same 
age.1 Diabete is a prominent ri k factor for men and ha 
been hown to be more o in women. In term of 
cholesterol status, hypertriglyceridemia and low level of 
HDL are more predictive than total chole terol status and 
elevated LDL level ; the oppo ite i true for men. Another 
modifiable risk factor which has been ignored to a large 
extent in women i edentary lifestyle. Men tend to lead 
more active lives than women, with an a tounding 83% of 
women in a elf-reporting database being rated a 
inactive. The e difference do exi t, but many of the 
strategie for modifying ri k are not different. 
Re earch protocols have come a long way in the Ia t 
ten year to actively report on women's health issue . 
With re pect to heart di ea e, women have been shown to 
have similar risk to men that should not only be 
recognized, but monitored and treated with pecial 
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empha is on the gender differences that do exist. Women 
have different needs than men, but the important thing to 
remember is that every patient who visits a doctor has 
their own pecial story, needs and risk factors. The most 
important tool that we have still remains a good, detailed 
hi tory. ever underestimate its usefulness. 
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GLYCOPROTEIN lib/lila RECEPTOR 
ANTAGONISTS: NOVEL ANTIPLATELET 
IN CARDIOVASCULAR AGENTS 
MEDICINE 
Coronary artery disease (CAD) is one of the leading causes of death in developed countries . The atherosclerotic plaques in CAD consist of two main 
components: a fibrous cap and a lipid core. Disruption of 
the fibrous cap leads to exposure of the underly ing 
components such as lipid, foam cells, and tissue factor, 
resulting in platelet aggregation and ultimately, thrombus 
formation . This process of atherosclerotic plaque 
disruption leading to platelet aggregation and formation 
of associated thrombus defines the acute coronary 
syndrome (ACS), a continuum of clinical manifestations 
ranging from unstable angina to non Q-wave myocardial 
infarction or Q-wave myocardial infarction.1 Platelets are, 
thus, key players in the triggering of the acute 
manifestations of CAD. 
Antiplatelet therapy, such as aspirin, has become 
mainstay in both the primary and secondary prevention of 
cardiovascular events. However, aspirin is a relatively 
weak antiplatelet agent since it is only able to prevent 
thromboxane A2-dependent platelet aggregation without 
any inhibition of thromboxane A2-independent 
aggregation. Circulating mediators for thromboxane A2-
independent platelet aggregation include adenos ine 
diphosphate (ADP), thrombin, serotonin, and shear rate.2 
In fact, more than a hundred different mechanism can 
result in platelet activation. Yet, regardless of the pathway 
chosen, all mechanisms lead eventually to a final common 
pathway involving the platelet surface glycoprotein 
llb l illa receptor. 
The glycoprotein llb I ma receptor, a member of the 
integrin family, is the most abundant receptor on the 
platelet surface. For platelet aggregation to occur, a 
conform a tiona! change in the glycoprotein lib /I lia 
receptor from the inactive to the active state must occur 
before the receptor will bind to its primary liga nd, 
fibrinogen . Fibrinogen causes platelet crosslinking 
necessary for aggregation by simultaneously binding to 
the glycoprotein lib I lila receptors of two adjacent 
platelets.3 Thus, since glycoprotein lib I Ilia receptors 
comprise the final common pathway leading to platelet 
aggregation, blocking these receptors via antagonists 
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would be an effective means of preventing platelet 
aggregat ion, thrombus formation, and ultimately, 
cardiovascular ischemic events. 
Abciximab is one such glycoprotein llb I ma receptor 
antagonist that is currently being investigated for clinical 
use. It is a chimeric monoclonal an tibody Fab fragment 
(c7E3) tha t binds w ith high avidity to the glycoprotein 
lib /lila receptor as well as to the " v$3 vi tronectin 
receptor, which is involved in smooth muscle cell 
migration and proliferation.4 The fir t large-scale double 
blind randomized control trial to investigate the potential 
benefits of using abciximab to prevent cardiovascular 
events was EPIC (Evaluation of 7E3 for the Prevention of 
Ischemic Complications). This trial involved 2099 patients 
undergoing high-risk atheroplasty or atherectomy. All 
patients received a pirin as well as heparin. The patients 
were then randomly assigned to one of three treatment 
arms: 1). abciximab bolus + abciximab infusion; 2). 
abciximab bolus + placebo infusion; or 3). placebo bolus + 
placebo infusion. The treatment arm of abciximab bolus + 
abciximab infusion demonstrated a significant 35% 
reduction in the composite primary end point of death, 
nonfatal myocardial infarction, refractory ischemia, or 
urgent revascularization within 30 days, when compared 
to the placebo group. Only a 10% reduction was noted in 
the abciximab bolus group compar d to placebo. There 
was, however, a two-fold increase in the risk of bleeding 
complications and need for transfusions in the abciximab 
bolus + abciximab infusion group compared to control. 
Yet, the reduction in ischemic events noted in the 
abciximab bolus + abciximab infu ion treatment arm 
persisted at both 6 months and 3 years followup.s-7 
The EPILOG (Evaluation in PTCA to Improve Long-
Term Outcome with Abciximab Glycoprotein lib I Ilia 
Blockage) trial was conducted next to determine whether 
low-risk patients could also benefit from abciximab. The 
trial wa prematurely terminated ince the abciximab 
treatment group had a 57% reduction in the composite 30 
day endpoint of death, myocardial infarction, or urgent 
revascularization as compared to control (standard 
heparin therapy). Interestingly, unlike the EPIC trial, there 
was no increased risk of bleeding in the abciximab 
treatment group. It was determined that the highe r 
bleeding rate in the EPIC trial were due to the use of high 
do e adjuvant heparin therapy. Thus, the EPILOG tri al 
demon trated two critical points: 1). The benefits o f 
reductions in ischemic complication from abciximab 
treatment could be extended to low-risk patients; and 2). 
The risk of bleeding complications could be decreased by 
using only low do es of adjuvant heparin therapy. 
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The ability of platelet glycoprotein Ilb I rna receptor 
antagonists to not only prevent progre sion to myocardial 
infarction in patients with unstable angina but al o avoid 
myocardial infarction at the time of coronary intervention 
wa fir t demonstrated in the CAPTURE (Chimeric 7E3 
Antiplatelet Therapy in Unstable Angina Refractory to 
Standard Therapy) trial. Patient were randomly assigned 
to receive either abcixirnab or placebo infu ion prior to 
angioplasty and continuing until 1 hour after the 
procedure. The trial was terminated prematurely ince 
there wa not only a 29% decrease in the compo ite 30 day 
e ndpoint of death, m yocardial infarction, or 
reva cularization but al o a ubstantial 71% reduction in 
the progression to myocardial infarction prior to 
percutaneous transluminal coronary angioplasty (PTCA). 
The re ult of this trial, thu , showed that abiciximab 
could a! o provide benefit for patients with unstable 
angina not undergoing angioplasty.9 
Ba ed on the results of the above trial , it eems 
rea onable to con ider the po ible application of 
abciximab to the management of acute myocardial 
infarction. Animal studie have demonstrated increa ed 
thromboly tic activity a well a prevention of early 
reocclusion after reperfu ion with the admini tration of 
glycoprotein Ilb / illa receptor antagoni ts.10•11 Pilot studie 
w ith humans have indeed reported improved patency 
rate of infarct-related artery v ia increa ed peed of 
reperfusion, although only a small number of patients 
were involved.12 Based on the e encouraging re ult , the 
potential for using glycoprotein lib I Ilia receptor 
antagoni t in the management of acute myocardial 
infarction does certainly exist. 
Abciximab i just one o f the many glycoprotein 
Ilb I Ilia receptor antagonists being currently studied. The 
ynthetic agents under inve tigation include lamifiban, 
eptifibatide (Integrilin), and tirofiban which, unlike 
abciximab, are all specific for the glycoprotein Ilb / llla 
receptor alone . All four agent can only be u ed 
parenterally.~ Oral glycoprotein lib/lila receptor 
antagoni t al o exi t, including ibrafiban, xemilofiban, 
and lefradafiban. Trial with oral agents are currently 
underway to determine efficacy and afety . Thu far, 
tudie have reported consistent blockade of receptors 
ranging from 50- 0% depending on the agent. However, 
the e studies have noted an increa e in mucocutaneous 
bleeding with the oral agent _1 3- ts Yet, the importance of 
the oral agent lies in their potential use in both acute 
ituations a well as in econdary prevention. Table 1 lists 
orne of the po sible indications for the oral glycoprotein 
Ilb I Ilia receptor antagonists. 
Since the glycoprotein lib / Ilia receptor antagoni t act 
a t the final common pathway required for platelet 
aggregation, the e antagoni t offer everal important 
advantages: 1) their effect on platelet aggregation will be 
considerably more potent than any of the other available 
antiplatelet agent ; 2) their efficacy can not be bypassed by 
redundant pathways of platelet activation; and 3) the 
on et of action of parenteral agent is nearly 
in tantaneous .16 These advantages together with the 
clinical trials supporting the u e of glycoprotein Ilb / illa 
receptor antagonist to reduce i chemic complications 
F eatu r e A rt c les 
Table 1 Potential Indications of Oral Inhibitors of Platelet 
GPIIb/llla Membrane Receptor 
Acute Indications 
Percutaneous coronary interventions 
Acute coronary syndromes 
Unstable angina 
Non Q-wave Ml 
Ml with ST elevation 
Secondary Prevention 
Percutaneous coronary interventions 
Acute coronary syndromes 
Stroke 
Prevention of acute events in patients with stable disease 
Primary prevention in high-risk individuals 
Control of atherothrombosis and progression of coronary 
artery disease 
explain the huge intere t currently in these antagonists as 
a novel means for combatting the acute manifestations of 
cardiova cular di ease, and in particular, as a possible 
addition to the current therapy for the acute coronary 
yndromes, including Q-wave myocardial infarction, non 
Q-wave myocardial infarction, and unstable angina. 
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RATIONALE AND EVIDENCE 
BLOCKERS 
THE 
FOR THE USE OF BETA 
THE MANAGEMENT OF 
HEART FAILURE 
IN CHRONIC 
Introduction 
H eart Failure i a major cau e of morbidity and mortality in orth America. The incidence of heart failure in the general population varies from 1 to 5 
per 1000 per annum and can be as high as 40 per IOOO per 
annum for people over the age of 75 year . The prevalence 
ranges from 3 to 20 per 1000 for the general population 
and can be a high a 130 p r 1000 in people over the age 
of 65 year . 1 De pite the heavy burden of di ease, there i 
no univer ally agreed upon definition of heart failure. The 
diagno i is made clinically and therefore, there i no one 
'gold standard' te t to confirm the diagno i .1 The primary 
igns and symptom include hortne of breath, 
orthopnea, paroxy mal nocturnal dy pnea, fatigue, 
peripheral edema and elevated jugular venous pressure. 
Thi article will briefly discus the medical management of 
chronic heart failure focu ing on the role of beta blocker . 
Medical Management of CHF 
The medical management of chronic heart failure 
(CHF) i a complex undertaking and typically involves the 
use of multiple da e of drugs. The goals of treatment are 
to reduce symptoms, decrea e the number of recurrent 
ho pitalizations, and to improve urvival.2 
Diuretic are often the firs t line treatment for acute 
exacerbations of heart failure . They work by reducing 
excessive salt and water ret ntion and therefore, decreas 
the preload which, in turn, re ults in a decrease in 
ymptom from pulmonary and ystemic conge tion. 
Although the impact of long-term diuretic u e on urvival 
is difficult to evaluate, their ability to reduce symptom 
ha made them one of the mainstays of heart failure 
!re~t~ent. 2 Angioten in Converting Enzyme (ACE) 
inhibttor have made a igrlificant impact on heart failure 
treatment and numerous Randomized Controlled Trial 
(RCTs) have been conducted to evaluate their impact on 
urvival. It ha been found that ACE inhibitor reduce 
mortality by about 23% when compared to placebo. This 
effect was hown to be con i tent aero all ew York 
Heart A ociation (NYHA) cla e and all ACE inhibitor .4 
Digoxin, a cardiac glyco ide which is commonly 
pre cribed in heart failure, has been shown to have no 
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impact on mortality but doe decrease the risk of 
hospitalization by approximately 30%.5 Additional drugs 
u ed to treat heart failure include organic nitrates, calcium 
channel blocker (e.g. Amlodipine), antiarrhythmics (e.g. 
Amiodarone), Angiotensin II receptor blockers (e .g. 
Lo artan), Spironolactone a well as Beta Blockers which 
will be di cus ed below. 
Rationale for Beta Blocker Use 
The sympathetic nervou system has long been known 
to play a sigrlificant role in the pathophy iology of heart 
failure. When ventricular dy function lead to a decrea e 
in cardiac output, there is a baroreceptor-mediated 
increa e in sympathetic tone, which has several 
con equence . ln the short term, it results in increa ed 
m yocardial contractility, tachycardia, arterial 
va ocon triction with a con equent increa e in afterload, 
and venoconstriction with a consequent increase in 
preload. Long-term activation of these compensatory 
mechanisms re ult in remodeling and hypertrophy of the 
myocardium and al o leads to myocyte toxicity, apopto is, 
and altered gene expression? orepinephrirle is known to 
be directly toxic to myocardial cell , an effect mediated 
through calcium overload and induction of apoptosis.6 
Since the failing heart is dependent on this constant 
ympathetic drive, beta blockade wa thought to be 
contraindicated in patients with heart failure.6•7 However, 
if beta blockers can be tolerated in the hort-term, then 
they have been shown to have beneficial effects on 
ventricular function likely due to reduced myocardial 
toxicity. An up-regulation of P-receptor expre sion, which 
occur in response to treatment with a beta blocker, is al o 
as ociated with improved ventricular function? 
Important Properties of Beta Blockers 
Beta Blocker have certain important characteri tics 
which can affect their efficacy and u efulness. They are 
briefly described below: 
• Cardioselec tive vs. nonselec tive-PI receptors are 
responsible for mo t of the cardiac effects of beta 
blocker wherea P2 receptor are prevalent in 
pulmonary ti sue. Therefore, cardioselectivity of beta 
blockers is imply a mea ure of the ability of the drug 
to more potently antagonize the PI receptor as 
opposed to the P2 receptor. This is al o thought to be 
the reason why cardioselective beta blockers are better 
tolerated in a thmatic patients . Bucindolol, 
propranolol, and carvedilol are examples of 
nonselective beta blockers whereas bi oprolol and 
metoprolol are example of cardioselective ones. 
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• Lipophilicity vs. hydrophilicity-The lipophilicity o f a 
beta blocker allows it to penetrate the central nervous 
system and therefore, potentially alter the vagal tone 
which is already altered in heart failure. 
• In ver e Agonism-Thi is a property by which an 
antagonist may inactivate an unoccupied active state 
receptor. An agent with a high degree of inv rse 
agonism may have a greater degree of negative 
inotropic and chronotropic effect. 
• !SA/Partial Agon ism-A beta blocker with this 
property partially timulates the receptor while 
blocking the effects of the ympathetic nervous sy tern 
on the receptor. 
• Ancillary properties-Carvedilol has a very prominent 
non-hemodynamic property i.e . antioxidant eff cts 
which may play a role in heart failure possibly by 
reducing apoptosi in myocardial tissue.9 
Evidence for Beta Blocker Use 
Although numerous RCTs have been conducted on 
heart failure patients to evaluate the effects of beta 
blockers on hemodynamic , exercise, and quality of life, 
relatively few RCTs have measured the impact of beta 
blockers on morbidity and mortality. The re ults of three 
of the major trials, which involved a large number of 
patients and used mortality as their primary endpoint, are 
discu sed below. 
In May 1996, The U.S. Carvedilol Heart Failure Study 
Group published the results of a trial that involved 1094 
patients and compared the effects of Carvedilol to plac bo. 
This trial was discontinued early due to the obvio us 
survival benefit in the Carvedilol group. The conclusions 
were that the relative ri k reduction (RRR) in mortality 
due to Carvedilol was 65% and there was also a relative 
risk reduction of ho pitalization due to cardiovascular 
cause of 27%. 10 
The Cardiac Insufficiency Bi oprolol Study II (CIBIS-
11), published in January 1999, studied the effect of 
bisoprolol (a cardioselective beta blocker) on patient wi th 
YHA cla s ill or class IV heart failure. This trial was also 
stopped early and demonstrated a reduction in risk of 
mortality of 32% as well as a significant decrease in the 
number of sudden deaths (RRR- 44%) in patient on 
bisoprolol vs. placebo. Although, the effect wa consi tent 
across both NYHA classes, the greatest effect was een in 
patients with NYHA class ill heart failure at ba eline.11 
The third major trial i the most recent and w as 
published in June 1999. Metoprolol CR / XL Randomized 
Intervention Trial in Congestive Heart Failure (MERIT-
HF) tudied 3991 patients with NYHA class II - IV heart 
failure and was also stopped early due to a 34% reduction 
in all-cause mortality. It also demonstrated a significant 
decrease in sudden deaths (RRR- 41%) as well as deaths 
from worsening heart failure (RRR - 49%), which w as 
consistent across all NYHA classes. 12 
In addition, a meta-analysis of double-blinded, 
placebo-controlled, randomized trials published in May 
1998 combined the results of 18 trials with a total of 3023 
patients . The authors concluded that beta-blockade 
increased ejection fraction by an average of 29% and 
reduced the risk of all-cause mortality by 32%. Another 
important finding wa that there was no difference in 
mortali ty risk reduction between cardioselective and 
nonselective agent .13 
Some Considerations 
It i important to note a few characteristics pertaining 
to the above trials, which help determine the criteria for 
beta blocker use. 
• In all three major trials above, beta blocker were 
added to standard optimal therapy, which included 
ACE inhibitor and diuretics. 1 0- 1~ In the Carvedilol 
trial, the patients were also on digoxin.10 
• All p atients included in these trials were s table in 
terms of heart failure symptoms, regardless of the 
NYHA class that they belonged to.10-12 
• The mean age of the patients included in these trials 
was between 58 and 63 with very few patients over 
the age of 75 years. 1a-12 A significant portion of patients 
in the general population presenting with symptoms 
of heart failure are over the age of 75 years. 
• Since ventricular fibrillation has been documented a 
the m ajor cause of sudden d eath in heart failure 
patient , the ignificant decrease in sudden death in 
th e beta-blocker group u ?zges ts a po s ibl e 
antiarrhythmic effect of the drug. 
Conclusion 
Beta blocker have been known for many year to 
have beneficial effects in patients with coronary artery 
disea e . Their role in the treatment of heart failure, 
however, has been unclear and they have traditionally 
been avo ided for fear of exacerbation of the di sea e 
process. Recent s tudies have clearly demons trated a 
survival benefit of long-term beta blocker u e in addition 
to treatm nt with ACE inhibitors and diuretics in patient 
with table symptoms of congestive heart failure . Thus, 
beta blockers should be given to all patients with mild to 
moderate heart fa ilure in the absence of a n y 
contraindications ( evere asthma, etc). The role of beta 
blockers in treating YHA class IV i till unclear, and 
caution should be exercised when treating elderly patient 
(age > 75) due to lack of clear evidence. Ongoing trials are 
currently underway to determine the effects in these high 
risk group a well a in patients with asymptomatic left 
ventricular dysfunction. 
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PULSUS ALTERNANS: MECHANISM 
SIGNIFICANCE AND CLINICAL 
Definition and History 
Put us alternan (mechanical alternans) i the phenomenon of alternating trong and weak beat in the pre ence of regular interval . It i not 
ynonymou with electrical alternans which indicate a 
beat to b at alternation in one or more component of the 
electrocardiogram. Pul us alternan wa fir t described 
under e perimental condition in a frog' heart over a 
century ago by Ga kell. 1 The clinical de cription of pul u 
alteman by Traube was made even earlier in 1872. Since 
then, alternan ha been tudied both in human and 
experim ntal animals and there ha been continuou 
debate about its underl ying mechani m and clinical 
igni£icance. 
Proposed Mechanisms 
The cia ic debate about the m echanism which 
precipitate put u s alternan i taged between the 
hemodynamic argument and the contractility argument. 
The former employ the concept of alternating ventricular 
filling and the latter, an intrin ic defect in the myocardium 
a a po ible factor contributing to the alternating b at . 
Recently, a cellular mechani m hypothe i ha emerged. 
The Hemodynamic Argument 
Thi argument i ba ed on the Frank-Starling 
mechani m that involve the alternation of ventricular 
filling (preload).3 A ventricular premature contraction 
(VPC) i one of the event that ha been ob erved to r ult 
in pul u altemans. It has been propo ed that although the 
VPC would have a relatively low ventricular filling, the 
beat following it would have an enhanc d troke volume 
and it y tole would la t longer. On the next beat, the 
dia tole would be horter and a a con equence, the 
re ulting lower ventricular end dia tolic volume would 
re ult in lower troke volume and aortic pre ure. This 
equence would continue, manife ting a alternating 
trong and weak pul e . Thi h y pothe is wa fi r t 
ugge ted by Wenckebach~ in 1902. Although there have 
been orne tudie in animals and humans that support 
thi hypothe i ,5 recent studie again t the hypothe i 
have ugge ted that the hemodynamic abnormality i not 
the primary mechani m underlying pul u altemans.6 
The Contractility Argument 
Thi argument is based on the h y pothesis of an 
intrin ic myocardial defect that inevitably re ult in an 
aberrant contractility of the heart. Although it is till not 
clear what the ba ic mechani m of the contractile 
disturbance due to the myocardial defect is, a few studie 
on pre ure-volume relationship in an intact hea rt 
demon trated alternation of contractility a the primary 
mechani m underlying alternans.7 In a tudy on i olated 
By Peter Kim 
canine heart preparation , the lope of the end- ystolic 
pre ure-volume relation hip wa ignificantly greater 
than tho e of weak beat , ugge ting that alternating 
contractile tate i the ource of alternans.9 Alternation of 
ventricular filling was ob erved in the e studies, but it wa 
econdary to the changes in contractility. 
The Cellular Argument 
Alternation of the action potential duration and 
alternation in intracellular Ca2+ cycling to and from the 
sarcoplasmic reticulum have been the ba i of thi 
argument. It was been uggested that alternation of action 
potential duration would re ult in mechanical alternans by 
altering sarcopla mic reticular Ca 2+ release. There are 
everal line of evidence against this theory 10 and 
mechanical alternan ha been a sociated with both 
prolonged and hortened action potentials.5 Although 
action potential duration doe not eem to play a major 
role in mechanical alternans, there i mounting evidence 
for the role of calcium in alteman . Recent studie have 
shown the phenomenon of " calcium alternans" 
~alternating large and mall calcium currents in regular 
mterval ) a odated with mechanical alternan in i olated 
animal ventricular mu cle.10•11 Thi ob ervation upport 
the role of Ca 2+ as the principal factor in mechanical 
alternan , and the favored view at present is that 
mechanical alternan repre ent a Ca2+ cycling 
phenomenon involving the arcopla mic reticulum. 
Clinical Relevance of Pulsus Altemans 
Phy ica/ Examination 
Pulsus alternan i more readily recognized by 
phygmomanometry than by palpa tion . As the blood 
pre sure cuff i lowly deflated, only alternate beats are 
heard for a number of millimetr of mercury below the 
sy tolic level and then all beat are heard. When the 
y tolic pre ure alternate by more than 20 mm Hg, it can 
b detected by palpation of peripheral pulse (e pedally 
the femoral) rather than the central pulse.12 To avoid the 
uperimpo ition of re piratory variation of the pul e, 
palpation hould be carried out while the patient hold 
hi / her breath in mid-expiration. Total alternan occurs 
when the left ventricular ystolic pre sure is less than the 
aortic pressure o that the aortic valve fai ls to open, 
re ulting in apparent halving of the pul e rate. Decrea e in 
venous return by maneuvers uch as tilting the patient in 
upright position and nitroglycerin administration may 
e aggerate pulsu altemans and a i tin it detection.12 
In the cour e of it detection, pulsus altemans should 
be differentiated from conditions with similar examination 
characteri tics. Pulsu bigeminu occurs when the cardiac 
rhythm i bigeminal with the premature beats decrea ing 
stroke volume and sy tolic peak pre sure. Put u 
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paradoxu i a decrease in pulse amplitude of greater than 
10 mm Hg during in piration and i cia ically een in 
pericardia! tamponade, po ibly in con tricti ve 
pericarditis (although le s commonly), and in obstructive 
airway di ea e13•15• In this condition, when the patient has 
a rapid re piratory rate which i equal to the heart rate, 
the phy ical findings may re emble pulsu alteman .13•14 
Clinical Significance of Pulsus Altemans 
Pul u alternan occurs mo t commonly in heart 
failure and implies left ventricular systolic dysfunction. It 
is also found in patient with evere myocardial di ea e 
due to aortic steno i , sy temic arterial hyperten ion, 
coronary athero clero i , and dilated cardiomyopathy. 12 
Thi i mo t likely due to the contribution of these 
conditions to ventricular dy function. Pul u alteman i 
often a ociated with the third heart ound (53) and 
disappears with treatment of heart failure .12 It has 
however, been de cribed in patient with normal hearts 
for brief periods during or after an epi ode of 
upraventricular tachycardia . Therefore, it should be 
emphasized that the ab ence of pulsus alternans doe not 
exclude left ventricular sys tolic d y function 3 and 
conver ely, its pre ence is not nece sarily indicative of 
di ea e. 12 everthele , pul u alternan i a helpful 
finding in diagno ing and confirming the left ventricular 
ys tolic dy function. Presence of pulsus alternans 
indicate a poor progno is.13 
Conclusion 
The mechanism underlying the pul u alternans i yet 
to be elucidated. However, it i generally accepted that 
pul u alternans reflects event occurring at the cellular 
level rather than the hemodynamic . The favored view at 
pre ent is that pulsus alternan is associated with Ca2+ 
cycling phenomenon involv ing the arcoplasmic 
reticulum. It i po sible that the initiation of the alternans 
is at the cellular level, but it i further augmented and 
perpetuated by al teration in the hemodynamic . In the 
clinical etting, pulsus altemans i as ociated with heart 
failure and severe myocardial di ea e. It may be helpful in 
diagnosis of left ventricular dy function. 
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HORMONE REPLACEMENT 
FOR CORONARY ARTERY 
THERAPY 
DISEASE 
IN THE DOMAIN OF EVIDENCE 
BASED MEDICINE 
INTRODUCTION 
The field of medicine is evolving such that clinical practice is being guided by the findings of Evidence Based Medicine. This allows physicians to provide 
the best po sible treatment for their patients based on 
valid outcomes. The use of Hormone Replacement 
Therapy (HRT) for the reduction of coronary artery 
di ea e (CAD) in postmenopausal women is no exception. 
With the abundant literature on the benefits of HRT, it is 
surprising to note the low rate of use of HRT in 
po tmenopausal women who are at high risk for CAD or 
have existing disea e. This article postulates reasons for 
current prescribing practices and patient compliance 
regarding HRT by examining the current information 
available to patients and their doctors. 
CORONARY ARTERY DISEASE IN WOMEN 
In Canada, coronary artery disease (CAD) is cited as 
being the leading cause of mortality. In women, deaths 
due to coronary artery disea e outweigh the number of 
deaths due to cancer and is econd only to bone and joint 
disea e in limiting daily activities and decreasing the 
autonomy of affected women.1 Overall CAD incidence is 
higher in men than in pre-menopausal women. However, 
after the menopause, the incidence in women increases to 
rate equivalent to men, sugge ting the protective role of 
e trogen in women. A SO year old woman has a 46% 
lifetime probability of developing CAD and a 31% chance 
of dying from heart disease.2 
THE BENE FIT S O F HORM O NE REPLA CEM ENT 
THERAPY 
Over the past 20 year more than 30 epidemiological 
tudie on hormone supplement and CAD have been 
carried out. The e studie provide evidence of the lower 
morbidity and mortality from coronary artery d i ea e 
amo ng u ers of HRT than among non-users. 3 
Observational studies comprise the majority of this 
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literature. These studies demonstrate the risk of coronary 
artery disease in HRT u ers as being 30-50% that of non-
users.4 The relative risk among users compared with non-
u ers of HRT is 0.55-0.65 from meta-analyses.4 In terms of 
secondary prevention of CAD, HRT users have been 
shown to have had 84% fewer cardiac events than non-
users of HRT.4 Mechanisms of action proposed by these 
studies include the improvement of endothelial function, 
alteration of lipid profiles with a reduction in LDL 
cholesterol and increase in HDL cholesterol, and reduced 
insulin resistance .1•5 Guidelines referring to the 
cardioprotective effects of HRT have been published by 
the American College of Physicians and the Society of 
Obstetricians and Gynaecologists of Canada . These 
guidelines recommend that "women who have coronary 
artery disease or who are at risk of coronary artery disease 
are likely to benefit from hormone therapy" .1• 2 
USE OF HORMONE REPLACEMENT THERAPY 
Regardless of the biological and epidemiological 
evidence, as well as published guidelines supporting the 
benefits of prescribing HRT to those at risk for or who 
already have CAD, HRT use remains low.4 An American 
longitudinal study of 2,500 women, showed that the 
overall rate of use was only 12.3%.6 Further, a recent study 
by Wise et al proposed that HRT u e would be higher in a 
population of postmenopausal women who presented 
wi th CAD to an academic cardiology clinic in Toronto 
between January 1996 and August 1997. These authors 
based their hypothesis on the current guidelines and 
literature that supported HRT use for CAD. It was further 
thought that women at higher risk for CAD would be 
more likely to use HRT if informed about its potential 
benefits.6 The results of thi tudy revealed that only 13% 
of women who had CAD were currently using HRT, while 
only 22% of those at high ri k for CAD were current 
users.6 
REAS O N S FOR LO W RATE OF HORMO E 
REPLACEMENT THERAPY USE 
In light of the evident cardioprotective benefit of 
HRT, why does use remain low? Firstly, the perceived 
threat of brea t cancer plays a significant role in 
determining whether a woman feels confident about 
starting therapy, regardle s of literature finding .2 
Secondly, women may al o worry about the side effects of 
HRT such as irregular bleeding, weight gain and 
symptoms of premenstrual syndrome? These factor not 
only deter the start of HRT but may also contribute to 
early ce ation of therapy. 
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Thirdly, due to the nature of CAD and its modifiable 
ri k factor , phy icians may not con ider the role of HRT 
in patient management. The main mechani m of HRT a a 
cardioprotective agent i it effect on erum lipid level . 
Phy ician may bias their treatment of abnormal lipid 
level towards the u e of lipid lowering af ents, proven 
effective by randomized control trials . A well the 
recommended guidelines are unclear as to do ing 
regimen , pretreatment inve tigations, follow up and 
duration of therapy. Thi may lead to phy ician confu ion 
regarding when to pre cribe, how long to pre cribe for, 
and whom to pre cribe HRT therapy to. La tly, in thi era 
of evidence based medicine, the greate t po ible reason 
for low pre cribing practice of HRT i that the evidence 
upporting the use of therapy i not robust.9 Tho e tudies 
advocating a reduction in mortality and morbidity of CAD 
in u er are ba ed on ob ervational data with inherent 
methodological flaws.9 
LIM ITATIONS OF OBSERVATIONAL STUDIES 
With the limitations of ob ervational tudies, the 
cardioprotective finding of HRT may be mi leading. 
Many participants taking part in the e tudie initiated 
hormone therapy to reduce menopausal ymptoms, and 
prevent o teoporotic fracture , rather than to reduce their 
ri k of CAD.7 The e participant tended to be leaner, more 
health conscious and from higher socio-economic 
backgrounds than non u er of HRT, thus indicating a 
election bia in these tudie .7 Due to the e factors, 
occurrence of CAD would be le s likely within the tudied 
population. 10 As such, the healthy u er effect may have 
bia ed the re ults in favour of a cardioprotective effect of 
HRT? Furthermore, women who were prone to adver e 
outcome , uch as a cardiac event de pite u e of HRT, 
were more likely to have di continued therapy. This could 
lead to an increa ed prevalence of urvivors participating 
in the ob ervational tudie 10• Due to the controver ial 
nature of the protective finding of HRT, and in the r aim 
of evidence-ba ed medicine, mo t phy ician may only 
feel confident in prescribing therapy in light of the 
outcome of Randomized Control Trials (RCT). 
HRT AND RANDOMIZED CONTROL TRIALS 
Currently, two orth American randomized trial are 
available for consideration. It is hoped that these 
e perimental tudie will help to re olve quest ions 
regarding the effect of HRT on cardiova cular ri k. The 
fir t, the Heart and Estrogen I Proge tin Replacement 
Study (HERS) examined econdary prevention of heart 
di ea e in postmenopau al women. 10 The HERS t rial 
randomized 2,763 po tmenopausal women with exi ting 
heart di ease to either an e trogen and proge tin 
intervention or to a placebo group. The e women were 
followed for an average of 4.1 year with main outcome 
mea ure including the occurrence of non-fatal MI or 
CHD death . Secondary outcome of un table angina, 
coronary revascularization, conge tive heart failure, 
re u citated cardiac arre t, troke or tran ient i chemic 
attack and peripheral arterial di ea e were a! o included. 
Re ult of the tudy were worrisome in that they howed 
no overall significant difference between the treatment 
and placebo groups for primary or econdary 
cardio a cular outcome .1° Further, the trial found a 
pattern of early increase in the risk of CAD event, 
although a slight improvement wa noted at the four year 
follow-up .10 This improvement uggests that follow-up 
over a longer period of time might reveal a more 
ignificant outcome. 10 Unfortunately the trial did not 
extend it follow-up period o evidence of this effect i not 
available. Based on the e finding , the trial doe not 
recommend HRT for the econdary prevention of CAD, 
although, it recommend that women already receiving 
treatment should continue on HRT, due to the potentially 
favorable long term effect .1° Finally, the trial did not 
evaluate the effects of unoppo ed estrogen therapy for 
women having undergone hy terectomies, nor did HERS 
evaluat the cardioprotective b nefit of hormone therapy 
for women at high ri k for CAD .10 Thus, the 
recommendations made by HERS cannot be extrapolated 
to the cohorts and should be u ed with caution. The 
econd tudy, the Women' Health Initiative (WHI) 
enrolled 27,500 women in March of 1993 and will not be 
completed until 2005.'-7 The tudy will evaluate the effect 
of HRT on women without exi ting CAD. The trial will 
include both women who have undergone a hysterectomy 
and are receiving unoppo ed estrogen therapy and 
women with an intact uteru receiving combined estrogen 
and proge tin therapy. 10 Re ult of this study will 
hopefully re olve some of the i ues rai ed by the HERS 
trial . 
CONCLUSIONS 
With the advent of evidence-based medicine, 
phy icians must wade through conflicting da ta regarding 
the prevention of CAD when considering prescribing 
hormone therapy for their patient . Although the gold 
tandard i the Randomized Control Trial, HERS remain 
elu ive in providing coherent prescribing practice for 
women at high ri k of CAD. Due to the limitation of 
HERS, publication of comprehen ive guideline will have 
to wait for the new millennium, when results of further 
RCTs are available. 
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HEART DISEASE 
Introduction 
H eart disease is the most common cause of mortality and morbidity in orth America. Due to the large numbers of people affected, there have b een 
substantial resources directed in finding the causes and 
possible cures for various heart conditions. Through out 
this research, many risk factors such as h ypertension, 
smoking, obesity and diabetes have been elucida ted . 
Family history of cardiac disease is also a very important 
factor used to identify patients who may be at r isk . 
However, until molecular techniques became available, 
the genetics of how heart disease is passed down within 
families has been poorly understood. Current technology 
has now allowed for a search of common varian ces 
(polymorphisms) and mutations of genes related to heart 
disease. So far, several mutations of candidate genes for 
different cardiac problems have been identified within 
certain families. More research is still needed to determine 
how these mutations may cause disease and how to 
determine the prognosis of severity for a specific 
mutation. Heart disease is a complex illness and it must be 
understood that there will never be one responsible gene. 
The purpose then is to have a bank of responsible genes 
that can be used to screen individuals early in life in order 
to implement good lifestyle habits and to monitor those 
with the genes carefully . The discovery of these genes 
along with the identification of other risk factors will help 
in gauging an individual's risk and play an important role 
in preventive medicine. 
Familial Hypertrophic Cardiomyopathy (FHC) 
FHC is an autosomal dominant disease that affects 
two out of one thousand individuals1• It causes an increase 
in myocardial mass and myofibrillar disarray resulting in 
fibrosis , abnormally small coronary vessels and 
arrhythrnias1• Those who suffer are at a higher risk for 
sudden and premature cardiac death . There have been 
several mutations found in contractile proteins, a 
tropomyosin, troponin T and cardiac myosin binding 
protein C within families who have FHC1• Over fifty 
mutations have already been identified most of which 
exhibited a defect in their organization within cells1• An 
example would be a mutation found in a tropomyosin, 
which is a component of muscle thin filaments and is 
encoded on chromosome15. The mutation involves a 
substitution of a negatively charged glutamic acid by a 
neutral glycine near the calcium binding domain2• The 
resulting protein is believed to disrupt assembly and 
function of the sarcomere structure2. Heterozygotes of 
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m y osin mutations are not protected because when 
mixtures of normal and mutant myosins were created an 
overall decrease in motility and activity occurred1• It is 
believed that the severity of FHC among families depends 
on the type of mutation. Mutations that alter the amino 
acid and occur at actin-myosin junctions or at the essential 
light chain binding domain have a poorer prognosis 1• 
Those with mutations where the charge of the amino acid 
remains the same have been shown to have a higher life 
expectan~. In studies of large unrelated families sharing 
the same mutation an association between a specific 
genotype and survival rate have been shown3. However, 
there is still a range on severity observed within related 
individuals which confirms that this disease has other 
factors involved. 
Coronary Heart Disease (CHD) 
Coronary heart disease is usually due to 
atheros clerosis in the ep icardial coronary arteries 
occluding the arterial lumen and limiting blood flow 
feeding the heart. When the supply of oxygen cannot meet 
the myocardial demand due to stenosis, ischemia occurs 
leading to angina pectoris or myocardial infarction. 
Family history is a serious risk factor for CHD and many 
genes are believed to be involved. Since CHD can be 
combated with drugs or lifestyle changes, screening may 
become important in both prevention and treatment. It is 
believed that the genotype may influence CHD risk by 
interacting with other risk factors such as cholesterol 
levels and blood pressure4• There are several candidate 
genes that encode proteins related to known risk factors; 
not all of these genes are mutations but instead are a 
common variant of a gene. Apolipoprotein E for example 
has three common polymorphisms, E2, E3 and E4, which 
influence plasma lipid concentrations4 • It is a structural 
component of circulating chylomicrons, VLDL and HDL 
and affects the fasting plasma lipid levels5• E4 produces 
cholesterol levels higher than average while E2 produced 
lower levels and may in fact protect individuals from 
coronary heart disease. 
Angiotensin converting enzyme (ACE) converts 
angiotensin I into the angiotensin IT, a vasoconstrictor that 
may promote vascular smooth muscle growth. It also 
degrades bradykinin, a vasodilator and inducer of 
endothelial factors5. This implies that concentration itself 
may contribute to vascular tone, which is critical for 
healthy coronary arteries. ACE concentrations are stable 
within an individual and appears to be unaffected by 
environmental factors suggesting that it must be 
genetically determined6• There are two known alleles: 
ACE I (insertion) and ACED (deletion). As Table 1 shows 
ACED has the highest ACE concentration; its frequen~ is 
found to be higher for patients with angina and MI . A 
meta-analysis of fifteen studies has also correlated ACED 
with an increased risk of MI4 • 
Gene products involved in endothelial functions such 
as fibrinogen, coagulation factors and PAl Bl have been 
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Table 1: ACE genotype versus ACE serum levels 
Genotype 
Homozygous ACE Ill 
Heterozygous ACE VD 
Homozygous ACE DID 
ACE serum levels 
299 +1- 49Jlg/L 
393 +1- 67Jlg/L 
494 +1- 88 Jlg/L 
implicated in CHD. They have been studied becau ether 
are all involved in plaque formation and plaque rupture . 
Candidate gene include tho e that determine adhe ion of 
monocytes, expression of va oactive peptide and 
va cular proliferation. However, few mutations have been 
found which cau e abnormal protein tructure and it i 
now believed that it i a mutation in the regulatory 
regions of the genes which i re ponsible. Such a case has 
been found in equence of the promoter of PAI-l that 
cau e an alteration in transcrirtion cau ing an increa e in 
athero clero i and thrombo is7. 
Homocysteine levels are al o involved in endothelial 
dy function by inducing cytotoxic peroxide formation and 
inhibiting the va odilator nitric oxide ( 0), which can 
lead to CHD. A commonly found C to T substitution in 
MTHFR, an enzyme that convert homocysteine to 
methionine, has a reduced activity and is more un table 
than the wild-type protein . 
Gene-Gene Interactions 
It is well known that activity for one gene i not 
isolated but is influenced by other genes and their 
products. Since CHD is a very complicated di ea e it i 
likely that there are many gene interactions contributing to 
the di ea e . An example wa found in a well known 
study, ECTM (Etude ca -temoin de l' infactus du mycarde), 
which involved the ACE gene and the angiotensin II type 
1 receptor9• An A to C ub titution in thi receptor i 
as ociated with high blood pre ure and tho e who have 
both this mutation along with the ACE D allele are at an 
even higher risk for heart di ea e9• 
Genetics and Environment 
Heart di ea e has both a genetic and environmental 
component. Both of these factor do not work alone but 
Table 2: Summary of candidate genes linked to heart disease 
Gene product Mutation 
AC~ ACED allele 
Apo Es E4 allele 
PAl-1 7 Mutation in promoter 
MTHFFf C to T substitution at nucleotide 677 
AGTFR1 9 A to C substitution 
a tropomyosin2 15 known missense mutations 
a and~ myosin heavy chain 11 Formation of a/~ hybrid 
(duplication and recombination) 
~-myosin heavy chain 12 Substitution of arginine for glutamine 
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influence one another in determining an individual' 
predispo ition for the illne s. It has been di covered that 
equence within promoter region of genes that help 
determine chole terol levels ( uch a LPL, apo A-1 and 
apo C-ill) bind to fatty acids7. This might imply that diet 
not only acts in a d irect manner toward influencing 
cholesterol level but also indirectly by affecting the 
expre sion of involved protein . Screening for the e 
particular sequences may help to encourage diet 
modifications. 
Genetics and Drug Therapy 
Individuals re pond differently to drugs. Some people 
have more positive re ults than other even if they are 
imilar in age, gender and body ize. Again, genetic 
variation may be the cau e for these differences. Such an 
example exi t with polymorphi ms in the apo E gene and 
the respon e to anti -hyperlipidemic drug . It ha been 
found that men with the apo E4 allele do not respond as 
well to lovastatin, an inhibitor of HMG-CoA reductase, 
than men with the E2 or E3 allele 2• Probucol, another 
chole terol-altering drug, however eem to be much 
more effective for E4 genotype 4 • The mechani m involved 
in genetic-drug interaction is still unclear but the 
implication for this knowledge are very useful. By 
knowing which drug are mo t efficient for a genotype, 
we will be able to de ign drug therapie for each 
individual. 
Conclusion 
We are just beginning to find polymorphism and 
mutations of gene associated with heart disea e and there 
are probably many more to be discovered. As the Human 
Genome Project i coming to an end, the earch for these 
gene may become more successful. Even with the 
knowledge of re pon ible genes, there are everal 
considerations to be made. Heart di ea e is very complex 
and finding ab olute markers is not probable. Interactions 
between lifestyle and environment differ between 
population, which means that a particular genotype will 
not imply equal risk. We will al o have to take the 
genotype of a per on into the context of other known risk 
factors to determine both progno i and treatment . 
Screening individuals at risk ha been expensive and has 
Effect Disease 
Increase in ACE concentration 
affecting blood pressure and 
vascular homeostasis CHD 
Increase of total cholesterol CHD 
Decrease in fibrolytic function CHD 
Hyperhomocystein-emia CHD 
Hypertension CHD 
Abnormal sarcomere Cardiomyopathy 
Unknown Cardiomyopathy 
Increase in frequency of sudden death Cardiomyopathy 
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had limited accessibility but now automated assay kits 
which can identify mutations have been created. They 
have shown to be sensitive, specific, reproducible and fast 
with only a few drops of blood or saliva needed10. A the 
expense drops, it will allow both the patient and doctor to 
treat or change poor habits early in life to improve health 
and to reduce illness. Aside from lifestyle and drug 
treatments, gene therapy, which is only at an experimental 
stage may turn into reality. For example, a transfer of 
vascular endothelial growth factors to sites of aiterial 
damage, is being delivered during angioplasty to 
encourage collateral development4• Although w ide 
screening raises both ethical and legal issues such as 
insurance policies, the overall benefit of identifying p ople 
at risk for diseases where treatments exist to prevent a 
premature death is very significant. 
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CORONARY ARTERY BYPASS 
BASICS GRAFTING: 
Introduction 
Coronary artery disea e (CAD) continue to be the leading cau e of morbidity and mortality in the western world. Every year, 1.5 million people suffer 
a myocardial infarction in the United State . Over one-
third of these patients will die . A the baby-boom 
generation ages, the prevalence, incidence, total mortality, 
and economic co t of CAD will increa e ignificantly_l 
Anatomy, physiology and pathophysiology 
The right and left coronary arteries arise from the 
inu e of va l alva in the ascending aorta. The right 
coronary artery (RCA) pa e in the right atrioventricular 
groove, gives ri e to several acute marginal (AM) 
branches, and in 90% of patient , ends as the po terior 
de cending artery (PDA) in the posterior interventricular 
groove (right coronary dominance). Thu , the main upply 
of the right ide of the heart, including the SA and the A V 
nodes, and the posterior fa cicle of the left bundle branch, 
i the RCA. The left main coronary artery gives rise to the 
left anterior descending artery (LAD) and the left 
circumflex artery. LAD and it diagonal branche upply 
the anterior and apical aspect of the left ventricle. The 
perforating branches supply the interventricular eptum 
including the right bundle branch and the anterior fascicle 
of the left bundle branch. The LAD is a crucial coronary 
artery in that it supplies the major portion of the left 
ventricle. The circumflex artery proceeds laterally and 
po teriorly around the left atrioventricular groove, giving 
ri e to everal obtu e marginal (OM) branche . It supplies 
the po tero-lateral and po terior aspect of the left 
ventricle. In 10% of people, the circumflex artery provides 
the posterior de cending coronary arte:1 (left coronary 
dominance) and thus the AV node a well. 
Coronary blood flow normally approximates 1 mL per 
gram of myocardium per minute and delivers 0.1 mL of 
oxygen per gram per minute to the heart. The extraction of 
oxygen in the average coronary bed is 75% and may 
increase to 100% in periods of stress. Coronary flow occurs 
primarily during dia tole, and i a function of the 
difference between sy temic diastolic pressure (in the 
proximal aorta) and left ventricular end diastolic pre ure. 
Coronary arterie po es ignificant va odilatory reserve, 
allowing a three to six-fold drop in the coronary artery 
re istance in periods of need.3 
Athero clerotic di ea e of the coronary arteries will 
eventually lead to an imbalance of oxygen supply and 
demand that prevents adequate perfusion of the 
myocardial tissue. The re ulting i chemia may progre to 
infarction of the cardiac muscle in the distribution of the 
respective coronary artery. Chronic arterial insufficiency 
re ults in progressive dilatation of the left ventricle 
ub equent to accumulation of minor infarctions leading 
THE 
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to conge tive heart failure (CHF) econdary to y tolic 
dy function. The equelae of acute myocardial infarction 
fall into two categorie : i) CHF due to pump failure or a 
mechanical complication, uch a ventricular epta1 defect, 
mitral regurgitation due to papillary muscle dysfunction, 
left ventricular rupture, and cardiac tamponade; and ii) 
life-threatening ventricular dy rhythmias or heart-blocks.~ 
Management 
The management of coronary artery di ease (CAD) 
may be divided into three progressive stages: i) life-style 
modifications, ii) medical management, and iii) invasive 
management. Life- tyle modifications include exerci e, 
diet, and environmental modifications. Medical 
management of CAD includes anti-angina medications 
uch a beta-blocker , calcium channel blockers, ACE 
inhibitors, and anti-platelet agents particularly aspirin. 
Risk factor management uch as blood pre sure control in 
hyperten ive patient , cholesterol control in 
hyperlipidemic patients, and gluco e control in diabetic 
patients are an integral part of the medical therapy for 
CAD patient . The inva ive management of CAD, in 
patients refractory to medical management, includes two 
different approaches: i) percutaneou transluminal 
coronary angioplasty (PTCA) and I or stenting, and ii) 
direct reva cularization of the coronary arteries using 
venous and arterial conduit : coronary artery bypass 
grafting (CABG)Y 
Patient for whom an invasive intervention is 
indicated fall into three categories. Fir t category includes 
patients in whom angina refractory to medical 
management is pre ent. Second category includes patients 
in whom the extent of CAD, the ventricular function, and 
the degree of inducible ischemia on stress testing are such 
that surgery may improve survival. In this category, 
CABG is indicated for patients with left main stenosis 
greater than 50%, three vessel di ease with ejection 
fraction of le than 50%, three ve el disea e with ejection 
fraction greater than 50% and significant i chemia, and 
one and two ve sel di ea e with extensive myocardial 
involvement with le ions not amenable to PTCA. Third 
category include patients in whom CAD is pre ent 
concomitantly with other conditions for which open-heart 
urgery i indicated, such as evere aortic stenosi . In 
general, PTCA and I or stenting is re erved for patients 
with imple ingle-vessel di ease, or uncomplicated 
multives el di ea e, providing that the lesions are distinct, 
and not diffuse. 5 
Surgical technique of CABG 
Conventional surgical revascularization of the heart 
involves five step : i) median temotomy and appropriate 
di section through pericardium, ii) administration of 
heparin, e tablishment of cardiopulmonary bypass (CPB}, 
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and inducing cardioplegic arrest, iii) anastomosis of 
aphenous vein grafts (SVG), left internal mammary 
(LIMA), inferior epigastric, gastroepiploic, and/ or radial 
artery graft ,6 iv) termination of CPB, and v) wound 
closure . Establishment of CPB involves right-s ided 
cannulation through the right atrium, and left sided 
cannulation through the proximal aorta. Thus, the venous 
retun:'- to the right atrium is drained into the heart-lung 
machine,_ and after membrane oxygenation, is pumped to 
the proxrmal aorta, distal to ite of application of a cro s 
clamp . High-potassium cardioplegic solution, 
administered to achieve arrest of the heart, is infused 
proximal to the cross damp, through a small cannula in 
pa~ents no~ suffering from aortic regurgitation (AR). In 
patients with AR, retrograde cardioplegic infusion is 
establish~d ~hrough cannulation of the coronary sinus. 
The temunation of CPB, after the proximal ana tomo is of 
!he bypass grafts to the proximal aorta is comple ted, 
mvo~ve~ removing the aortic cross clamp, and weaning 
~e eJec~g hea:t from the CPB machine by decreasing the 
nght atrial dramage to the heart-lung machine. Once the 
heart is able to sustain adequate systemic pre sure and 
cardi~c ~utput, the C~B machine is turned off, circulating 
heparm IS reversed W1th protamine, and the cannulae are 
removed.2 
CABG: Outcome, morbidity and mortality 
Coronary by pass grafting has been hown to 
significantly improve anginal symptoms in over 90% of 
patients. Likewise the incidence of myocardial infarction is 
redu~ed . Succe ful ~evascularization improves resting left 
ventricular wall motion and enhances exerd e ventricular 
performance. Most importantly, revascularization of the 
heart is demonstrated to significantly improve survi al in 
patients with CAD. The greatest benefit is evident in 
patients with severe, multivessel CAD? 
Oper~tive mortality ha been steadily decrea ing. 
Even dunng the 1990's operative mortality decrea ed 
~arthe~ from 3.57% ~ 1990 to 2.76% in 1997. Advanced age 
1s an mcremental nsk factor for hospital mortality after 
CABG (Table 1). The mortality rate al o varies with the 
pre-op status of the patient. Mortality for elective CABG 
was 3.6%, whereas mortality for alvage CABG was 30. %. 
(urgent CABG operative mortality i 5.2%, emergent 
CABG operative mortality i 9.9%). 
Age group 
20-50 
51 -60 
61-65 
66-70 
71-80 
81-90 
>90 
Table 1. Mortality rate by age group 
Number of Pts 
18717 
38923 
25879 
21269 
51040 
8872 
106 
Operative mortality rate 
1.24% 
1.42% 
2.12% 
2.60% 
4.07% 
6.71% 
11% 
Table 1. As expected, older revascularization patients tend to have higher 
operative mortality rate . This data is compiled from 1997 U.S. data 
(N-170000) on the Society for Thoracic Surgeons' web site: www.sts.org 
Table 2: Common complications of coronary artery revascularization 
Complication 
Atrial fibrilation 
Transient stroke 
Deep mediastinitis 
Permanent stroke 
Ventilation > 24 hrs 
Dialysis dependant Renal failure 
Incidence 
19.32% 
0.75% 
0.63% 
1.69% 
5.87% 
0.92% 
Relative risk ratio 
1.45 
1.46 
3.58 
10.84 
12.66 
18.57 
Table 2. Post-operative morbidity associated with coronary artery 
revascularization is listed in decreasing rate of incidence. The relative risk 
ratios (RRR) indicate the higher likelihood of operative mortality. The RRR are 
statistically significant (P<0.005). The data was compiled from 1997 U.S. 
data (N-1 70000) as reported on Society of Thoracic Surgeons' web site: 
www.sts.org. 
T_he inci~enc~ of orne of the important morbidi ty 
a soaated W1th thi operation are ummarized in Table 2. 
~espective operative mortality relative risk ratios are 
hste~ ~s ~ell . A major contributor to post-operative 
~orbidity 1s the need for CPB, which induces a systemic 
inflammatory response, and can cau e neurop ychological 
a~d multi-organ d ys function . The advantage a nd 
disadvantages of the CPB machine are discussed below. 
CPB machine wa developed in the 1950 , and was 
design d to facilitate cardiac surgery. It's advantage are 
~um~rou . The heart i arrested and deflated, the urgical 
field 1 blood-less, and the surgeon i able to perform the 
?peration efficie ntly, accurately, and quickly. 2 Mos t 
rmportantly, the surgeon upports the patient' circulation 
usmg the CPB machine while corrective surgery is being 
performed. 
Di advantage of CPB machine are three-fold . First, 
priming of the bypas circuit result in hemodilution and 
po t-operative water retention, both of which can increase 
the pos t-operative length of tay. Second, circulation 
thr?ugh incompletely bio-compatible CPB cannulae, 
tubmg, and membrane oxygenator, results in damage to 
blood elements, a systemic inflammatory response (SIRS), 
and a po t-operati ve hy pocoagulable state . Th ird, 
manipulation ~fa di eased ascending aorta can generate a 
shower of micro and macro-embol i that ma y cause 
cerebrovascular accidents (CV A), and I or 
neurop ychological dy function.2 
The occurrence of CV As in heart-surgery patients 
remain a significant draw-back to this s ucces ful 
operation. To avert embolization of athero clerotic 
plaque , urgeons routinely examine the aorta carefully to 
locate a healthy segment for cannulation.2 Even with this 
p~ecaution~ the rate of a cerebral e ent i approximately 
8 Yo for patients over the age of 70, and 16% for patients 
over the age of 80.9' 10 Recently, aortic filters have been 
manufa~tured to ca pture e mboli shed during the 
cannulation of the aorta. The efficacy of such filters is 
curr~ntly under study. Beating-heart bypass operations, if 
feas1ble, can reduce the risk of CV As by avoiding aortic 
manipulation11 (discus ed below). 
48 
------------------------ U. W.O. Medical Journal 70 (1) 2000 
Evolution of CABG 
I~ ~he h~p~ of decreasing operative mortality and 
morbidity, muumally-invasive techniques of CABG have 
evol~ed during _the past three to four years. These 
techniques have mvolved the use of a smaller incision, 
and / or attempting to bypass ve sels without the support 
of the CPB machine. To summarize, the following 
p~otocols have been developed: i) OPCAB, ii) MIDCAB, 
m) Port-access, iv) ministernotomy CAB, and most 
recently v) closed-chest CAB via endo copic methods. 
~he OPCAB operation12- 16 involves a full-length 
med~an sternotomy, but the bypass is attempted on the 
beating heart using stabilizing instruments. In this 
procedure, the surgeon does not have full access to the 
posterior aspect of the beating heart. As well, 
n:ta~ipulations of the beating heart may result in 
significant hemodynamic instability by interfering with 
venous return to the heart. Early studies indicated that 
OPCAB is as safe as conventional CABG in selected 
patients. Reported OPCAB operative mortality ranges 
from 1.0% to 2.5%.12-16 As a result, the number of OPCABs 
done are dramaticallJ increasing. 
The ~CAB17- operation most commonly involves 
the graftmg of LIMA to LAD through left anterior 
thora~otomy, or RIMA to RCA or PDA through a right 
antenor thoracotomy, on a beating heart. Other arterial 
conduits, such as the inferior epigastric and the 
gastroepiploic artery have also been used. Direct 
anast~osis of ~e SVG and radial artery to the ascending 
aorta IS not possible through a small thoracotomy incision. 
If the use of such grafts is indicated, the SVG and radial 
artery can be anastamosed to the LIMA, and then to a 
coronaqr artery as a "T" graft . Recently a lateral 
MIDCAB24 approach has been attempted to bypass OM 
branches of the circumflex artery. The SVG is proximally 
anastomosed to the de cending aorta in this procedure. 
The lateral MIDCAB operation does not allow the surgeon 
to have ac~ess to the LAD and proximal RCA. Early 
concerns eXIsted that anastomo is carried out on a beating 
heart~ through. a limited-access incision, may not be 
technically preCI e, and may have a high occlusion rate. 
Several studies, however, have shown that graft patency 
after revascularization using the LIMA to LAD 
anastomosis is con;]'arable between conventional CABG25-
30 and MIDCAB17• (graft patency > 90%). Furthermore, 
the risk of CV As has been shown to be decreased in 
MIDCAB as compared to conventional CABG.ll Growth 
in the number of MIDCAB procedures, however, ha been 
relatively flat becau e MIDCAB is mainly re erved for the 
surgical therapy of single ve el disea e. As such, it 
compete more or les directly with PTCA. 
Another approach, the Port-access approach31 · 36 
in~olve establi hment of CPB and arrest of the heart by 
u mg the femoral ve sel for right and left sided 
cannulation . The heart is arre ted with a cold blood 
cardioplegic solution delivered through the central lumen 
of a ~alloon occlu ion catheter in the a cending aorta, and 
cardiOpulmonary by pass is maintained with 
femorofemoral bypass. This is followed by a left anterior 
thoracotomy to access the coronary arteries. With the heart 
arrested, the minithoracotomy affords enough room for 
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Table 3. Pre-operative and intra-operative factors with 
significant contribution to post-operative mortality 
Pre-op factors 
Cardiogenic shock 
Prior Ml < 6 hrs vs no Ml 
Resuscitation 
Renal failure requiring dialysis 
Renal failure 
Prior Ml in 6-24 hrs vs no Ml 
PTCA to OR < 6 hrs 
Pulmonary hypertension 
CHF 
Prior CAGB 
Arrythmia 
Peripheral vascular disease 
Immunosuppressive therapy 
Prior non-cardiac operation 
lntra-op factors 
lntra-op IABP 
Cryoprecipitate transfusion 
FFP transfusion 
Platelet transfusion 
RBC transfusion 
lnotropes leaving OR 
Anti-arrythmics leaving OR 
Ventricular pacing 
Relative risk ratio 
7.89 
6.12 
5.13 
3.47 
3.45 
3.45 
3.32 
2.92 
2.87 
2.66 
2.3 
2.22 
2.13 
2.03 
9.57 
5.19 
4.48 
4.11 
3.7 
2.88 
2.87 
2.32 
Table 3. Pre-operative status and intra-operative factors have predictive value 
in determining the risks of operative mortality. Only statistically significant 
(P<O.OOS) relative risk ratios above 2.0 are compiled in this table. The data is 
obtained from the 1997 U.S. data (N-170000) on the Society for Thoracic 
Surgeons' web site: www.sts.org. 
the surgeon to bypa s multiple vessels on a deflated 
ea ily manipulated heart. Early studies indicate that 
operative mortality and §,raft patency are comparable to 
c~~v_entiona~ CABG .32· 6 However, this approach is 
cn~c~ed . for Its prolonged CPB times, and the small yet 
definite nsk of retrograde aortic dissection, particularly if 
the femoral or iliac arteries are diseased. 
. T~e ministernotomy CAB37 approach is essentially 
I~entical to the conventional CABG procedure with the 
difference that the entry wound is smaller. That is, with a 
smal~er in~ision, the surgeon has access to all coronary 
?rte~es with full CPB upport. The ternotomy is made 
infenor to the attachment of the third rib to the sternum. 
The rninisternotomy CAB is still in its infancy. Dr. Doty 
and c~lleague ·37 in Salt Lake City have reported thi 
operation on_77 patients so far, with an average of 4.1 
gr~s- ~~ pati~nt (comparable to conventional CABG). In 
theu uu~al senes, they reported an operative mortality of 
2 .~~- It IS not clear whether post-operative pain after a 
mm~sternotomy is significantly les than after a full 
median ste~otomy. It remains to be seen if this procedure 
develop Its own niche in patient with a particular 
concern for co metics. 
. The clo ed chest CAB involves in ertion of urgica1 
UIStrument and a robot-controlled video camera through 
small 5 to 10 rnm inci ions in the che t wall. Bypass may 
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Plate 1. Invasive management of CAD. 
The rate of PTCA and CABG over the last two decades. 
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Plate 1. Whereas the number of surgical revascularization of the heart has 
steadily doubled over each decade, the number of angioplastic procedures 
has grown exponentially in the past 20 years . PTCA is becoming 
progressively effective when combined with stent placement and anti-platelet 
drug (Abciximab) therapy. For complex and diffuse coronary artery disease. 
however, the invasive procedure of choice remains surgical bypass grafting. 
be attempted either on an arrested heart, u ing the Port-
access approach, or on a beating heart. The Port-acce s, 
do ed che t CAB operation ha been reported in France 
and Germany in 4 case . ·39 In all four ca es, the post-
operative cour e has been uncomplicated, and LIMA 
graft have been patent. The beating heart, closed che t 
CAB has been successfully performed on one patient o 
far . Dr. Boyd at the University Campu of the London 
Health Sciences Centre, performed the fir t robotically-
assi ted, do ed chest, beating heart CAB on Sept 24 of thi 
year. The post-operative course for thi patient wa 
uncomplicated, and a post-operative angiogram showed a 
perfect LIMA to LAD graft. 
Closing 
As 21st century approache , the future of ca rdiac 
surgery is clearly headed toward minimally inva ive 
procedures. Closed che t CABG is a newly developed 
procedure, and its advantages and disadvantages need to 
be elucidated in multi-centre studie . It, howe ver, 
provide an exciting opportunity for the cardiac urgeon 
to ignificantly reduce the morbidity a sociated with full 
sternotomy, on-pump bypass surgery. Altho ugh 
rninimally-inva ive operations may be technically very 
demanding, they provide the surgeon with the atisfaction 
of having achieved the arne excellent outcome of 
conventional CABG, with onl y lightly more bodil y 
invasion than a PTCA. 
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ararrert alirns1ralion ct t)dosiD'n lin: aod dirlllaiMls. ~ ilaCI1 roan:~. a2!lle rifln;jals a 
i'll!falll1tn!. P& 1tJere IS oo l!lijliiBlCe '> dale Willllhe use r:l LI'ITOR gM!I1 arnmn1ly witlthese it1Jgs, witllle 
l!lD!IliD1 r:l a~ Sl1ltf Wlf1 ~ lhe benefits arll ns1<s r:l SLd1 a:mnd lherapy stoJd Ill 
ca-eiUiy oaiSideied (see Pl£tAIIOONS. Drug l11eraclmsl 
~ has been repmj 11 Ylll'f r.re C2llS Wlf1 l.FITCJI (see PFECAUIUIS, Drug t1eraalrisl 
llJ1III ctjsltn:lo1 searo.y 1D myoglobruia has also been iepa1ed wilh tt.1G-CM ra1Jclase 
Wibilas. 
l.FITCJI ~ stcUl be ~willtl*ltx 1isar1rued 11 ~ palet ...,.., ac3e semiS W'dlm ~ r:l 
a iil)tllllhr a l'elflJ a nsk facU ~ 10 lle deYeqrner1 r:l renal laUe seardry 10 ~ ISt.d1 as 
SMil! ac3e i'B:b1, ~ ll'QP sugery, l31l!'a SMil! i11lllald:, tnb:lre ;nj ~ lisonlers, ;nj 
trCO"'Jaaed semresl 
PRECAUTIONS 
liloml 
The e11ects ol ab-lliHncklced --in lipapullin ...,lnc:lutlng recU:tion olla\lll 
c:holeAerol on canliovllcular liiOitlicity or II'10fWiy or -ll'lOfWiy line not been -
Beb-e riSiiUJli1Q lherapy l.FITCJI (abvasla1l1 cab.mj, .., atll!fTlll stcU!II! made '> W11IOI eleYaled senrn 
~Jqmen liM!Is Wi111WQIJ1ate diet. ~. ;m wei!t1l nwcuon 11 CMliWel!tl pa1ien1s, ;m m 11ea1 Olher 
t.l1dei1jing ii1!dcaiiJOOierns (see ta:ATKlNS MD QJ«:AllJSE). Pate'IIS stcU!II! atMsed 10 i1foon SIJlseqJert 
~ r:llle II'« use r:ll.FITCJI a~~~~ ageRs. 
Qmrt klng-11!m1 dala fnm dhcai1Jials oo ra ideate .., ad¥ine elfecl r:1 aarvastllll on lhe ll.mrllens. 
SI!Ji!i3t decreases 11 crtUalr1g ~ - 11 pabenls 1reated Willl amaslalll..-.:1 Olher teYe been 
<tlserved. Tl'e dhcal SIIJlifi3a r:1 a jXJIIJ11lal b:lg-lem1 SlalllflU:ed defiaelq r:1 ~has ra been 
establshed. l has been iepa1ed 111a1 a decrease i'lll1)'0C3lial ~ leYels cru:llead ID lrpared C3liac 
flJaon , pall!i'IIS bonlerh aJV!Siil'8 hla:1 laUe (see saECT8l B8.llGIW'H'I) . 
Elll!c1 on l..lpopro!!!iJ tal 
in some patients lhe beneficial elfecl r:llowenld m c:holeslerol..-.:1 I.Jl_ .c 1ew!ls may Ill pa1ly -Ill' a 
an:omilant inl:rBase , lll(allew!ls.liili llrther""""'"""' Is olltlined, l is suggesU!d, wt1ere feasillle, 1hatllli!IIS-
ll!l1lel'iiS r:l serum 41(a,) Ill lllowed 141 11 palients placed on aDv.lstltllltoerapy (see saECT8lllllLCGIW'HI'). 
llvpo!•!lilllllb 
MllllPM!II ~ SjiOome has been repaaj Olher tt.1G-CM ra1Jclase ~ wl1ch has il'li1ided 
1 a more r:llhe !tllowing feallJes: ~ <l1giOil(lema, ~ eryl!lernan.s-1<2 syntome, polymyalgia 
i!lelrnatica, vasa.ttis, llJ1Ui. 1lron'tlocylcpe lel.i<llpona.llerrdyli: <l1t!ll1ia. posiliYe NIA. ESR roeas.. 
eosrqto1a, ¥hillS. malgia, il1lClrla. as1hena, ~. few<. ellis, ll!mg, malaise, djs!rea. DOC 
ep&1ermal ~. EI)JheJm ' ill:t.dr9 Slew!ns-.lmol syrOome AlltaJ1t ., daa! ~
syntome has ra been desalled as su:h, LI'ITOR stoJd Ill ilsaJntnJed it ~ IS SlJSili!CII!d. 
UseinPrtcr!ancy 
UPITOR Is c:onliaildic:aled cUing pngnancy (see COfiT1WNDICAJ10 
AlherosderosiS IS a c11onc process arll cisca1truallo1 r:l ~ ciugs cb'l1g ~ stcUl teYe 
I1'!Kt on !he ClJIXI1l! ct klng-lem11herapy r:1 prmry h)lleid..,...ce•oa. OrJies1Billnt ~ palJcls r:1 
- bos)mesiS a-e essenDal W'llQU1IS lor felal ~ fR:ldro Sjl11lleSIS r:l SI800s ..-.:1 eel 
i11i!!iDalesl Since tt.1G-CM ra1Jclase lrtilGas decrease - synlhesis ;nj jXl6Sby lhe S)<llhesis r:l Olher 
txoklgicaly aciM! Slbscn:es derMld fnm - · h!y may caJSe tam 1D lhe !eaJS when U1nstered '> IJI!g-
l&twanen 
There a-e oo data on lhe use r:ll.FITCJI cb'l1g ~· l.FITCJI stoJd be acirnslered m wanen r:l ~ 
age aty when SLd1 pabeniS a-e h9tt ldcely '> an:8i\'e ;nj teYe been lriamed r:llhe jXJIIJ11lalllallrds. ~ lhe 
~ becomes jlri!!J8t wlile lal<r1g l.FITCJI, !he iiDJ stcU!II! ilsaJntnJed ;nj lhe pallert awiSed r:llhe 
jXJIIJ11lal nsk '> lle fellS. 
1'1 iaiS, ll'il< txn:e'1llmms r:latavasta111 a-e SiiTG m 11ose 11 plasma liS ra kriMil-lhiS iiDJ is e>mlild 
11 ll.mr1 Because r:llhe JX)Iel1llal lor ad¥ine reaams 11 iUSII1Q mns. wanen ~a~q l.FITCJI stcUl ra 
lreasl·!eed (see~ 
flllilll:iU!H 
TrealmiJt l!lijliiBlCe 11 a peoialli: ~ IS lmitsd m 006es ct l.FITCJI141 m oo II1!VdaY lor 1 year 11 8 pa!lei1IS 
hoinoz)gcliS trTilial hylbct...,.ce•oa. No cfncal a blx:hei11ical alromaities wee iepa1ed 11 these 
Treamn eoper~erre 11 acUis 70 years a older -221) wntt 006es r:ll.FITCJ1141m !llll'l!)'day has den'li:l1sralad 
1hat lhe safely ;nj elfeaNeness r:l- 11 IJQIUatmw.r; SiiTG '> lhat r:l patienls <70 years r:l age. 
Phal• •a::d<III!IIC ewkJallon ct atavasta111 11 s.qects <Nfif lhe age r:l65 years indicates .., n:reased ALC. P& a 
pracaJIOIBy measue. lhe boesllbse stoJd Ill acirnslered · (see PIWfMCQOGY, ttmr1 
Plana::doietiCS; saECT8l B8.llGIW'H'I). 
f!enallnsuf!!ciency 
Plasma an:8"8aaD1S ;nj I.Jl_ .c lowemg efficacy r:ll.FIT(Jiw.r; sf'own '> Ill srnlar 11 palienls will iT'Cderate 
renalm.tfioercj 00111800 ..., pal1eniS Willl ramal renal flJaon ttMeoe', Sill! 5eleal C2llS r:l ~
teYe been ~ 11 paDei'IIS wit1 a IIsby r:l renal rWfiaercy r:l tno1own seventy, as a pracaJiiliBy rneasue 
;nj pendng lr1te' l!lijliiBlCe 11 renal ilseese, lhe boesllbse {1 0 ~ r:ll.FITCJI stcU!II! U98d in these 
pa!lei1IS. SinD JlecaJDlS <WY 11 paDei'IIS Wi1l1 SMil! llJ1III rWfiaercy peetili'1e dlmn:e <30 rrUnw1 
(<0 5 ntlsec)J, lhe boesl dosage stcU!II! U98d ;nj fl1llemen1ed caJIIOUSiy (see W/liHHiS, '-tJSde Efleds; 
I'AECAliTnlS. Dn.g ~
Refer also k1 DOSAGE MD ADMNST'RAlXlN. 
tMl-CoA i8il.aJse rt1bDs l11i!lfere..., ctaes~era S)<lhesiS ;m as su::11 mil' JhecJell::aly tilt aaera ardl:r 
gaalal 5800 ~ Ch:al Sldes...,-;nj ~ tMl-CoA i8il.aJse rdlibs teYe Slgji!SIBd hll 
Jhese ageniS oo ra nW:e plasina ansa W'IC:IRaon a "1l'* Dena~ reseM! ;m oo ra nW:e basal pas.na 
~warr.on ttJwewr, lhe efteds r:1 tMl-CoA i8il.aJse l'ltilrs on male ter1ily teYe ra been SILded 
11adeiJJ;II! IU'it8sct ~ Tl'e efteds, I qon lhe ~ a>asl1 ~ Mll1ili a-e.........,_ 
Pate'IIS 1Jea1ed ...,_ wile ~ dhcal ewlen:e r:l enltJcme ltjslln:lion stcU!II! eval!a1ed 
_. CUion stcU!II! elii!ICiSed w.., tt.1G-CM ra1Jclase ittiklr a Olher agert U98d m-dDesli!ra 
IIM!Is 1S ~ 1D patB1Is I1DMY,j. cil.gs (e_g keiXlJlme, ~ (J cimllilej 1hat may 
decrease lhe - ct erd:Jgerous SlerOid tmnones. 
Drug ln!I!JctioRs 
~ 11wapy witl1 011.- Lipid Motabollsm RegoUior$: CciTtw1ed iiDJ lherapy stoJd be woacted 
Wlf1 caJlOi1 as ll'llamalion fnm aJ1Iroled Sldes IS lnlllld 
Bile Add Sequoslrlllls: 
Pat!en!s W!!h njd 1> !IJI!era1e I!Mdd:ile!IAe!l ia. lA -t recia01 was !1eale' when l.F!Til'l10 mg .m ~ 
20 g were CXidiMiiS1&ed ~ ~ !han when eilher ctug was oDnnslered a1<11e (·35'!1. klr l.F!Til'l<nl -22'!1. klr 
~ 
Pa1BJ1s W!!h S!!\l!!l!hMdd3:!1Ae!l!i!: lA -t rai.am was 5118 (·53'!1.1 when l.F!Til'l40 mg .m ~ 20 g 
were COil01nslered when CXIIl1Bed 10 1lal wilh l.F!Til'l Ill mg al<lle. Plasrrl! cxn:ers-alll1 rt abVa!tllin was kMer 
(aWocrnalely 26'!1.1 when l.FITil'l 40 mg 1*JS <Deslfpll20 g were COil01nslered CXIIl1Bed wilh l.FITil'l 40 mg 
alrre 
tbwo!Yer, Ule ~ ctug ~was less effecUye 11 kMerl1g Ule 1fW;8ndes !han l.F!Til'l ~ 11 
belli~ rt hjjoed.-aeua: palitllS (see PHAAI.IACQOGY, Clncal SU~esj. 
'Mltn l.F!Til'l is used OOilCllltfllly with ~ or 2n1 Oltler re5l\ "' in1av.ll rt at 1eas1 2 tor.; stn.tt be 
marlal1ed - Ule t'Ml ciugs. sn::e Ule absupli(J1 rt l.F!Til'l may be impared by Ule resit 
Abric Add ~ (Gemfibrozl, Ftnaflnle, lleullntt) and Nlldn 1-.!c Acid): Alltruj11here is 
oo experin:e with Ule use rt l.F!Til'l !r'llll cxrorrenlly With lin: aad denvaiM!s .m niacin. Ule benelils .m rislcs 
rt su:h CXll1tJI1ed ~ stn.t! be ca-eftjy <mSidered. The risl< rt ll1)qlal!1y li.M;l veatrnert with Oltler ctug6 11 
ltls class is roeased With cxrnrrert ilininislration (see W/JifHiS, lotJsde Effects). 
Caumlrin Antic:olgullnts l.F!Til'lllad II) cD:aly Sl}'lli:art e!fed"' pratrorrbin line when aoTrrisU!red 10 
pa!Jti11S rea!IW'9 chrora: wafam ~ (see SlllCliD l!llllGW'H't'). 
Digom CadiMiQialUI rt nUtiple OOses rt lJ'ITil'!<n! cigoltr1 roeased slead'f-slale IR;ma digaian 
an:enllaiiOnS by awaxmateiY 20'!1.. Palienls 1al<i1g cigoa1 stn.t! be fi10fiUed cb;ely lW1d --
Oral Coull acepiMs: Coaannsratm rt l.F!Til'l With "' cra1 ~ arlaiWY,l 1mg romome .m 35jJg 
...,. esnfrt, roeased IR;ma IDU!I*"'ins 4'0C levels) rt I'Ol!CtwOor'e lW1d ...,. tsr.dd by ~
:m. <nl 20'!1.. ~.These roeases stn.tt be amdered when seledrg"' cra1 ~
Antacids: Alinnslraliorl rt akJnnJTi .m ~ based ll1laals. su:h as MaD" TC SUspension, Wilh l.F!Til'l 
decreased J*Gna aJI1C8'1ra1UlS rt l.FITil'l by~ 35'!1. IA-t reclJai<l1 was no1 aAered t:u Ule 
~ e!fecl rt l.F!Til'l may be atfected 
Cimelidne: Adrnnsralm rt anmn with l.F!Til'l dd no1 al1er J*Gna aJI1C8'1ra1UlS or lA -t kMerl1g ellicacy 
rt l.F!Til'l. r-. Ule ~bM!rllg e!fed rt l.F!Til'l was nW:edlrorn 34'!1.10 26'!1.. 
~ P-450-medllled .....,..,.,Ab>astalls mettxiled by Ule c,utmre P~ l!lOII12)'I1l!, CYP 
3A4 ~ a CYP 3A4 i'liliklr, n:reased atJVaS1311liR;ma levels by 40'!1.. Coaani1sD1IIi<l rt CYP 3A4 
i:tiim,su:has~;i:e. rnacrtile~(IQd'l,)~<nl~.
~-.me riln,lal agents ~-e. Uaarelcle, l<iiiDanl2Die), or Ule ~ re1az1xme may 1'11\e u-e 
pc81iall0 i"aease IR;ma an:erC3Iions rt tt.«i-0>'\ nn.aase i:tbDs. i"dd'g l.F!Til'l (see SlllCliD 
llllllGW'HY). ca.cm stn.tt tus be e>erased..., aro:JiliUt use rt f1ese agents (see WAit.N3S. 
Pia 11iiiCilkil!lit ~ lotJsde Elleds; P!RAIJlllNS. Renall'1sul!i:lln:y .m Ercb:me FtrdD1; oosra Nil 
AIMtSTRA1l)t SH£ClHJIH.OOW'Ifl1. 
In a sl1rly heal1t1y SLqeas. cudiMGalia I rt ma>Of1U11 cb;es rt belli aDYaslali11fll nQ lW1d lerfEJladi"e 
(1 20 mg), a CYP 3A4 SLClsrale. was stow110 pnxluce a modest n:rtBSB 111erfEJladi"e AOC. The Ole I'11I!MII 
remared iJ"da1ged. tbwo!Yer, SliD! llll'll!l1ldicn - f1ese t'Ml ctug61311l1 be edlled 11 palitllS With 
~ facb's klr <Wl!rjltma. (e.g.llet>IJSiing pOOnged OT irlleMI, seo.ee cortJBY nry dsease, 
l'ijprt<alemia), caJ1i<11 stn.ti be e>i8ased when these agents are cud I M i61I!J ed (see WAif.N3S. P1 Q I liiiCilki itOC 
ln1eractOls; oosra Nil ADMHSTPAfOOl. 
Antipyrine: ArqJj!h! was used as a non-Sil"Ciiic model klr ctug6 .-by Ule na:roscmal hepanc tl1lj!lle 
system~ P~ system) l.F!Til'lllad oo e!fed <11 Ule JJaniiiCilkiil!liCS rt llllipjrile, lhJs l1li!I3CIDlS With 
Oltler ctug6 .-"" Ule Sll1le cyiOdltme isozyrres are no1 expected 
&ylhiornydo< In heal1t1y i"dwbbls. J*Gna an:enllaiiOnS rt aDvaslalll n:reased awocrnate1v 40'!1. Wllh 
aainnslratm rt l.F!Til'l <nl et)'1t'rllm)a1. a looNn i-nbiDr rt CYP 3A4 (see w~ lotJsde Effects) 
Other Concomitant Therapy: In ch:al Slides. l.F!Til'l was used anxmtnly with ri1yper1ensNe agents .m 
esvogen repacenerw ~ wnu ewler1:e 10 dale rt c0:a1y sopbt a<Mrse intiJadions. lnleradiln slides 
Wllh speck agents 1'11\e 1'101 beer1 ccrO.cted. 
Pationll with 5Mrt ttm ct ....., MuM: Hljler ctug <bsages (Ill ~ r8(Jftd klr m~e palien1s With 
seo.ee hjjoeddesten*'mia [niding famlal hjjoet:holes1er are assoc:ialed wilh ioeased J*Gna iiNels rt 
- Caution should lie exer<:llod In sucll ..---...... .-ely IIOIIIy impaired,~. 
01' .. CO-iitalilly ..... - digaxln 01' CYP 3M inliliilon (-W~ ~
lntorlctions, - Elllicts; PRECAIIT10IIS, Onlg 1nlencllons; DOSAGE AND .-.-sTIIATlOII). 
!lrvg/lMiorJIDr TR!In!!nctions 
l.F!Til'l may- senrn b'll15l11l1aSe ..-d aeali1e ~ levels (from sl<llietll rrusde). In Ule <llfennlal 
liagDils rt d1est par111 a palieit oo ~ wilhl.F!Til'l. C3dac .m l'llfC3diac fractms rt these lll2)'lntS stn.t! 
bedel!mnd. 
AIW9ISE REACTIONS 
l.F!Til'lls generaly wel-l:iraled. ~ iea:li<l1s 1'11\e usualy beer1 njd lW1d trnet.ln arotrrtled ch:al slides 
~ lW1d actille-aJ1Irol ~slides Wllh Oltler ~ age'iiS) irrodWig 2S02 palitllS, 
<2'!1. rt pa!Jti11S were discainJed !lie 10 a<Mrse e>ptliences at1l'b.Cal*' 10 l.FIT<R Of these 2S02 patieRs, 
1721 were treated klr at leasl6nmths .m 1253 klr 1 Yf!i11 or more. 
~ Oill)tllOI1Q!S CXCiflilg at ll1 incilerl:e ~1'!1. 11 patlti1IS piWiiC:ipa1l1g 11 placeOxtriC'ole cfl1ical s:Ldes rt 
l.F!Til'l<nl leJ01I!d 10 be ~. prdJaltt or defi'ilely ctug related are stow1 in Tallie 1 below: 
TABLE 1. Associltod-.. Ewlntsl!!!par1!!!! in ~1% ol Pllionls In Pllcebo ~Clinical Tillis 
GASTliOirnST1NA 
COnslipation 
Dm1lea 
Oyspepsla 
Rall*nce 
Nausea 
NEJMlUS SYSTEM 
Headache 
lliiSCal.AN£OUS 
Pain 
Myalgia 
AsU1enia 
- .. (11=270) lJ'ITOR '!lo (II= 1122 ) 
<1 
1 
<1 
The ieamnerded cD;e rt l.F!Til'l6 10 mg ooce a day The mapty rt palitllS ad'le-.e .m marta11 age~ 
chJeilerrt levels Wilh l.F!Til'l10 ~A sqib'l ~response is Mlert within 2 weel<s,<nl Ule 
ma>Of1U11 response 6 usualy aclliMd ..... 2-4 weel<s. The response is main1al1ed clm,j chrora: ~ 
raes Cll1 be !r'llll at 2n1 lire rt u-e day, with or wnu food. <nl stn.tt ~be !r'llll in u-e IMiiRJ. raes 
stn.t! be RMiJall2ed accordrtJ 10 bi!seh lA -t ..-G'or TG levels, Ule desied lA -t ..-G'or TG twge1 (see Ule 
OelearJn .m Mngemert rt Hnoed.-rtalra, V«r1ong ~ oo H,p:JcJlAIQ!ittile<n! rtlier ll'jslprjemias 
~ ..-G'or Ule L6-~ f:O..r:alm 1'\'o(Jan (lm'l. Ule g;a rt ~.mUle pa!ielt's R!$IDISI!-
rt cDsage, lll!!aiSSaY. stn.t! be made at lileivals rt 4 -or more. The reamnetided cD;e m;JO klr 
llllSI palien1s IS 10 10 40 ll9'dar-The""""""' 0051! is Ill~. v.hd1 may be r8IJftd in a iilllli1Y rt palitllS 
(see seCiiOil betlwi-
Upid - sllould lie rnonitor1ld periodically and, H .-y, llit - ol UPITil'l ~ baled oo 
tarvet lipid- lecalll•ided by~ 
The "*"'"'"'ll!Cil:licns In IDtalltdesterrt lW1d lA-{; levels 1'11\e beer1 obseMld 11 2 OOse-response Slides. lW1d 
may serve as a !JJide 10 b'ea1merl rt palien1s With njd 10 rroderale hjjoeciU!s1eirta 1 e . 
TABLE 2. ~ in Pllionls With Mild 1D Moderate ltypeicllolestli olemia 
(Me!! Percent Omqe from Base!i!el' 
Tolai-C: 7.1 mmolot' 
(273 mglttl 
10 
!N-22) 
-29 
lA-C: 4.9 mmolot' -39 
(1 90 mglttl 
Seyn py• ..... 
UP1Til'l Dose (mg!day! 
20 
!N-20) 
-33 
40 
!N- 21) 
-37 
·50 
Ill 
!N-23) 
In pal8iiS With seo.ee ~ rcUiing tonozygor.s .m he1iJilz)<pJS famlal hypelchoiestettile<n! 
~1Aeie1e (Type 1), hirjier <bsages MJ 10 Ill~ may be~ (see WNH¥35, Ptmnacrt<reli:: 
ln1eradois, lotJsde Effects; PI£CAIIOONS. Drug ln1eraclin;j. 
Concomil3nt ~ 
See PI£CAIIT10NS, Drug lntelactions. 
Doslge In Pllionls With Renal lnsulllciency 
See PI£CAIIT10NS. 
PHAIIMACBITICAL /NFOIIMATION 
Plq)er t&ne: Alnaslalllcatun 
Chemi:aiN<wne:(R-fl".R/)·2-(4-~~5-(1~~~~-
1li-P'Imlle-1~ aad,- sal (2 1) 1rllychte 
~ FanUa. ~·:JI,O 
MolecUar We9t: 1209 42 
Slll:llal FanUa. 
0 
o-1Ca·· 
•311,0 
~ Alnaslall1 calciJn 6 a 10 olf-wlite aystaline powdil' ltlll is~ f1SClWe l1liJiiiOUS 
scimls rt pH 4<nl beloiw. AIDMstalilcatunls Y«y sl!tidr scLille in--· pH 7.4 ~buffer lW1d 
at8lllrOte. sl!tidr scLille in ell8d, lW1d fieely scLille In i1lttta'O. 
Tll!let Conl!o!jtian; 
Ea::ll tate a:nlai1S 8ilher 1 0 mg, 20 mg or 40 mg aiOIVaSialin as Ule ac1M! ir,J8Iierl. Ea::ll tate also a:nlai1S Ule 
"*"'"'"'IOHilldcrial f9eci!nls: calciJn cartJonate, cnlella -. aosawmellose m.m. ~ cebJse, 
li!ctlse ~- fii3!1IOSi.m star.lle, mo:roc:ryslalin cebJse. ~ ll'll!lhyk:ebls, pct,eltrfene 
gl)<:d. 1ak:. btarLm - · polysatJa1e !ll<nl Sl1li!CI"«:cne enUsion. 
Slai!Wty and 5acnqo l!ecoiiiiDKialions; 
SIDre at alfiROIIed room 1i!l11lti3ILf8 15 10 25'C. 
AVAJLA/JIUTY OF DOSAGE FORMS 
l.F!Til'l (amas1a1l1 calciJn) Is aYailallle in oosage snengdls rt 10 mg, 20 mg lW1d 40 mg aDvasla1in per --
10 mg: wtite, elillOcal. filnH:oa1ed-- cxxled "10""'""' Side lW1d "1'0 155""' Ule Oltler Availallle 11 boGies rt 90 
Wets. 
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Feature Articles 
CHLAMYDIA PNEUMONIAE: 
A POSSIBLE CAUSE OF 
ATHEROSCLEROSIS 
INTRODUCTION 
Chlamydia pneumoniae is a Gram negative obligate intracellular bacterium. The organism has a biphasic life cycle consi ting of a mall, den e elementary 
body and a larger, metabolically active cell called the 
reticulate body. The elementary body i the infectious 
form of the agent and is u ually tran mitted between 
human via aero ol drop . The reticulate body i the 
vegeta ti ve fo rm and divide via binary fi ion to form 
inclu ion bodies in the ho t cell. ' C. pn eu moniae is 
re pon ible for a variety of re piratory yndrome , uch 
as: pneumonia, pharyngiti , bronchiti , a thma and 
chronic ob tructive pulmonary di ea e. 2 C. pneumoniae 
infections are common and it i e timated that 50- 70% of 
adult are eropositive. 1 In recent year , thi bacterium ha 
been identified a a po ible cau e of athero clero i . 
Athero clero i i the principal underlying cau e of 
coronary artery disea e. The athero clero i develop a a 
re ponse to injury to the endothelium and mooth mu cle 
of the arterial wal1.3•4 
Endothelial injury lead to the adherence of platelet 
and acti vation of macrophage which migrate t the 
subendothelium.3•4 The macrophage inge t low d n ity 
lipoprotein and become foam cells.H 5 Relea e of growth 
factor , by the macrophage and platelet , lead to the 
proliferation of smooth mu cle cell and ecretion of 
extracellular matrix.3•4 The earlie t le ions are fatty treaks 
which in turn develop into fibrou plaque (a fibrou cap 
surrounding a lipid rich core), and eventually become 
calcifiedY The e athero clerotic plaque decrease arterial 
lumen diameter and may lead to total ob truction. If there 
i ulceration or rupturing of the plaque, a thrombu may 
form a a re ult of platelet adherenc and aggregati n . If 
the thrombu continue to increa e in ize, the already 
narrowed lumen may become partially or fully blocked, 
thu precipi tating i chemia.3.4 It ha been ugge ted that C. 
pneumoniae infection of endotholelial or smooth mu de 
cell of ve el wall re ult in local inflammation and 
fibro i and ubsequent atheroma formation. 6 Chronic 
infection with C. pneumoniae may also timulate the 
production of pro-inflammatory cytokine , thu increa ing 
the ri k of cardiova cular di a e. 
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INFECTION WITH C. PNEUMO IAE AND 
ATHEROSCLEROSIS 
C. pneumoniae fir t became associated with 
athero clerotic di ea e when tudies demonstra ted 
increa ed titres of immunoglobulin G (IgG ) and IgA 
antibodie in the erum of male who had coronary artery 
di ea e or who uffered acute m yocardial infarction , 
compared to control . 
Saikku et al., demonstrated that tho e individual who 
po e ed elevated titre of antibodie had twice the ri k 
of coronary ar tery di a e .9 In addition to 
eroepidemiological tudie , oth r experiment have 
found C. pneumoniae within atheromatou le ion via 
irnmunohi tochemi try and polymera e chain reaction 10, 
electron micro copy", and culturing technique .12 
The pre ence of C. pneumoniae in a thero cle roti c 
le ion , however, doe not produc enough evidence to 
indicat a di tinct role, and there i debate a to whether 
the pre nee of C. pneumoniae i cau ative, contributory, or 
merely coincidental. Animal tudie have contributed 
greatly by providing further evidence on the role of C. 
pneumoniae in the d evelopment of athero clero i . 
Laitenen at el. , u ing ew Zealand white rabbit , 
demonstrated that after intra-na al or tracheal inoculation 
of C. pneumoniae, 2 /3 demon trated a thero clerotic-like 
change in the aorta, while no le ions were found in the 
control .13 Additionally, trea tme nt with antibiotic 
following infection of rabbit prevent the development of 
atheromatou le ion . It ha a1 o been demonstrated that 
C. pneumoniae accelerate the athero clerotic process in the 
aortic arche of apolipoprotein-E deficient mice. 14 
CLINICAL TRIALS 
The po ibility of C. pneumoniae producing arterial 
inflammatory change ha Jed to everal clinical tri al 
utili z ing macrolide antibiotic therapy a a mean of 
treating athero clero i . In rabbit , weekly treatment with 
azi thromycin after expo ure to c. rneumoniae, prevent d 
the acceleration of athero clero i .1 There have also b en 
hum an clinical trial which demon trated a fivefold 
reduction in adver e cardiova cular outcome in patient 
receiving azithromycin15, and a reduction in future cardiac 
event from 10% to 1% u ing roxithrom yc in .16 
Unfortunately, the number u ed in the human clinical 
trial were mall, and ther fore the re ult mu t be 
interpreted with orne caution.2 
CO CLUSION 
Although a direct cau a l relation hip ha not b en 
e tabli hed between C. pneumoniae and athero clero i , 
recent cientific evidence ha trengthened the likelihood 
that C. pneumoniae may initiate or wor en athero clerotic 
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di ea e . The re ults of clinical tr ials using macrolide 
antibiotics have been especially encouraging; however, 
further re earch is needed. There have not been any large 
clinical trials corroborating athero clerotic improvement 
w ith antibiotic . In addition, one needs to e tabli h that 
the optimistic re ults are not the consequence of drugs 
ac ting in a non-antimicrobial fashion on other 
inflammatory mechanism .2 
Finally, one must look at the consequences of using 
antibiotics within the community; the wide pread u e of 
antibiotic may electively increa e drug-resistant bacteria. 
Should C. pneumoniae be a n infectiou cau e o f 
a thero clero i , one would be able to identify and trea t 
tho e at ri k. In the future, one might be able to eradicate 
a thero clerosis by means of a simple pill! 
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THERAPEUTIC 
ANGIOGENESIS: 
MYOCARDIAL 
PROSPECTS FOR 
THERAPY GENE 
INTRODUCTION 
I schemic heart disease remains the leading cau e of mortality and morbidity in the Western world . Therapeutic approaches to the management of patients 
with chronic myocardial ischemia are currently aimed at 
reducing disease progression via risk factor modification, 
reducing myocardial oxygen demand and cardiac events 
with medication or increasing blood supply to 
compromised myocardium by percutaneous coronary 
intervention (PCI) or coronary artery bypass surgery 
(CABG). However a significant portion of patients are 
refractory to medical therapy and are not candidates for 
PCI/ CABG . The growth in our understanding of 
molecular signaling pathways in blood ves el formation 
has led to research aimed at stimulating growth and 
development of new collateral vessels that will form 
endogenous bypass conduits, termed therape utic 
angiogenesis. This review outline the impetus for 
angiogenesis in the myocardium and will describe the 
molecular and cellular events of angiogenesis, including 
the key regulatory angiogenic factors. Finally, a the 
ability to induce myocardial angiogenesis would have 
dramatic impacts in cardiovascular medicine, progres 
into the field of therapeutic angiogenesis will be 
summarized. 
Myocardial Requirements for Angiogenesis 
The three primary stimuli believed to stimulate 
angiogenesis are: 1) mechanical factor 1, 2) hypoxia2, and 
3) inflammation3. Mechanical factors, such as increased 
shear stress associated with increased blood flow, may 
induce angiogenesis by disrupting the endothelial surface, 
resulting in the release of proteases and I or angiogenic 
factors.! The homeostasis of myocardial oxygenation is 
regulated within narrow limits by moment-to-moment 
adjustments in coronary artery tone, which in turn 
controls blood flow in direct proportion to cardiac oxygen 
demand.4 This is true even under conditions of stre s, for 
example during exercise or in early stages of cardiac 
disease. However, the vasodilatory reserve of coronary 
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arteries is limited and, particularly in the face of severe 
atherosclerosis, when oxygen demand exceeds supply, 
hypoxia ensues, impeding m ocardial function. 
Fortunately the heart is equipped with a long-term 
homeostatic mechanism for maintaining myocardial 
oxygenation in the face of hemodynamic or metabolic 
stres es; chronic hypoxia triggers neovascularization.5 
Inflammation al o repre ents an important modulator of 
myocardial angiogenesis. Following infarction, 
myocardial necrosis is accompanied by the influx of 
lymphocytes and macrophages with subsequent release of 
angiogenic factors. 6 The e mechanisms are by no means 
mutually exclusive and the continual interaction of each 
likely occurs in vivo. 
Cellular Components of Angiogenesis 
A number of components of the stable vessel are 
potentially involved in active neovascularization.7 Most 
prominent are the endothelial cells (ECs). Once thought to 
be passive liners of the microvasculature, the e cells are 
now recognized as a composite active endocrine organ. 
Pericytes sit adjacent to the endothelium and contribute to 
the regulation of vessel ize through adjustment in 
muscular tone and may check the proliferation of ECs.7 
Providing structural integrity to the thin walled 
capillary are the basement membrane (BM) and the 
extracellular matrix (ECM). The arrangement and 
composition of the ECM appears to be vital to the 
angiogenic response.7 For example, collagen modulate EC 
proliferation and motility, while heparin sulphate 
proteoglycans (HSPGs) bind various growth factors, 
thereby serving as a repo itory of an~ogenic modulators 
in anticipation of appropriate stimuli. Macrophages and 
platelets may al o contribute to angiogenesis, releasing a 
host of factors capable of modulating the angiogenic 
response. 
Angiogenic Growth Factors 
Early investigative work into the mechanism of 
angiogenesis arose from oncology research, as it was 
observed that tumors could be implanted into an 
avascular region, such as the corn a, and induce the in-
growth of new capillarie . Thus, the impetus became the 
identification of the relea ed diffusible activators capable 
of stimulating the relatively quiescent vasculature to 
proliferate. A number of potent angiogenic factors have 
been discovered, including ba ic and acidic fibroblast 
growth factor (bFGF and aFGF), vascular endothelial 
growth factor (VEGF), transforming growth factor-beta 
(TGF-~)9• 11 , insulin-like growth factor-1 (IGF-1) 12, 
hepatocyte growth factor (HGF)13•14, tumor necrosis factor-
alpha (TNF-a)15, platelet activating factor (PAF)13, nitric 
oxide ( 0)16' 17, adenosine1 20, and angiopoietin21 . 
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An Integrated View of Angiogenic Regulation 
A number of different stages have been proposed for 
the process of angiogenesis7•22; however, in reality 
angiogenesis is a cascade of overlapping events; any 
division therein is mainly didactic. Figure 1 depicts a 
speculative cascade for the molecular control of 
angiogenesis based upon the evidence accumulated to 
date. A step-by-step description of this diagram follows: 
1. An initiating stimulus, such as hypoxia or ischaemia, 
is required to activate the quiescent vasculature. 
2. An upregulation of EC VEGF23.24, bFGF25 and ()26•27 
gene expression ensues. 
BM 
EC 
ECM 
Featur e Articl e s 
5. The angiogenic factors released from the ECM, ECs 
and HSPGs, in addition to co-factors (heparin and 
plasmin) provided by the extravasation of plasma, 
provide the chemotactic impetus for EC migration 
away from the vessel wall and into ischemic 
myocardium. ECs subsequently differentiate, change 
shape and adhere to one another to form the lumen of 
a new capillary.7 
6. VEGF, bFGF and NO are chemotactic for 
macrophages I monocytes and induce these cells to 
release of a host of angiogenic modulators . 
Fibroblasts, too, potentiate EC proliferation and 
POOP 
TNPa 
FGF 
IOF-1 
TOFj! 
Fibtoblut 
7 ~ 
BMIECM:J /-~ 9 ~ 
~pJ)(]F r/ Pon:yte 
Figure 1: Integrative model of myocardial angiogenesis 
3. These factors act via autocrine and paracrine 
pathways to : (a) increase the permeability and 
dilatation of the ve el wall, (b) induce the relea e of 
proteolytic enzymes28•29, including serine proteases, 
urokinase-type and ti ue-type plasminogen 
activators (uP A, tP A), matrix metalloproteinases, and 
collagenases which dissolve the local BM and ECM 
and (c) timulate EC motility. 
4. (a) The degredation of the ECM also releases 
(activate ) sequestered VEGF and bFGF bound to 
HSPGs in the ECM. (b) In the heart, cardiomyocytes 
may release adenosine, VEGF, bFGF, and 0 in 
respon e to injury, while increases in blood flow 
(shear tress) and oxygen consumption in normal or 
border-zone tissue surrounding an infarct may also 
stimulate the relea e of angiogenic factor . 
migration by releasing HGF into the extracellular 
milieu and initiating the in situ biosynthesis of P AF, 
VEGF and HGF itsel£.13 
7. In addition to their structural role, pericytes may 
activate TGF-j331, which subsequently inhibits EC 
proliferationll and promotes differentiation and 
formation of tubules32• The e tubes fuse and coalesce 
into loops and blood circulates through the new 
vascular bed. Only now does de novo BM synthesis 
begin, and as a re ult the immature vessel is initially 
relatively leaky. 
8. IGF-1 also contributes to the differentiation and 
morphogenetic pha es of angiogenesis by shifting the 
p~oteolytic balance back to homeostasis and, along 
With TGF-j3, by stimulating the fibroblast synthesis of 
BM / ECM components. 10 
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9. Fibroblasts and pericytes are attracted to the forming 
vessel, secreting matrix component and providing 
structural and functional support? Given its apparent 
role in vasculogenesi , it has been uggested that 
angiopoietin ma y be involved in the control of 
pericyte proliferation and migration in this stage of 
angiogenesis. 21 
The angiogenic cycle is complete. 
Therapeutic Angiogenesis 
In the heart, the extent of coronary collateral 
vascularization (blood flow) is a determinant of infarct 
size, the amount of surviving viable myocardium and, 
thereby, prognosis in ratients suffering an acute 
myocardial infarction. 3 However, often thrombus 
formation proceeds faster than collateral development, 
which may require days to weeks.34 Therapeutic induction 
of myocardial angiogenesi immediately follow ing a 
myocardial infarct offers the hope of minimizing or 
preventing the re ultant cardiomyocyte cell lo s, fibro i , 
lo s of function, wall thinning and, ultimately, heart 
failure. Even more efficacious would be therape utic 
induction of coronary collateral development in the 
ischaemic myocardium of patients with coronary artery 
disease before progression to infarction. To date, re arch 
ha focused on the most prominent of the identified 
angiogenic growth factors in the development of 
therapeutic angiogenic strategies- VEGF and the FGF . 
Evidence that administration of bFGF35 and VEGF36 
could therapeutically induce angiogenesi s was first 
accomplished in a rabbit model of hind-limb isch mia. 
Extending this work to the myocardium, intracoronary 
administration of bFGF37 of VEGF wa shown to enhance 
collateral perfusion and myocardial vascular density in 
re pan e to myocardial ischaemia in a canine model. 
Similarly, exogenously administered bFGF improve 
coronary flow and reduce infarct ize in compromi ed 
porcine myocardium39• However, de pite the efficacy of 
systemic pharmacological intervention 40•41 , th re i 
concern over ob erved sy temic activity of admini tered 
growth factor peptides. 
Gene therapy may circumvent thi by providing 
continuous, local expre ion of angiogenic agents. 
Potential delivery vectors include plasmid , viral v ctor 
(adenoviru es or herpes implex viru e ), or cells. Again 
utilizing the rabbit model of hind-limb i chemia, I ner' 
group has demonstrated augmented collateral 
development42 following percutaneou application of 
plasmid VEGF165,which had been applied to a hydrogel 
polymer coating of an angioplasty balloon43• Use of an 
adenoviral vector expre sian VEGF ha al o been hown 
to improve mJ'ocardial perfusion and function in a 
porcine model. 
The encouraging re ults in animal models have 
resulted in the initiation of clinical trials of therapeutic 
angiogenesi . Proof of concept for the clinical ben fit of 
angiogenic growth factor was initially documented in 
patients with critical limb i chaemia . 45·~6 Recently, aFGF 
ha been used for the fir t time in patient undergoing 
elective CABG.47 The growth factor was injected into the 
myocardium distal to an internal mammary artery - left 
anterior descending (LAD) ana tomo is and close to the 
LAD in a region containing additional steno es of the LAD 
or one of its diagonal branche . Angiography twelve 
weeks later demonstrated capillary formation around the 
site of injection prouting from the proximal part of the 
coronary artery and rejoining the di tal parts of the ve sel. 
Isner ha also undertaken a pha e I clinical tria] evaluating 
therap utic angiogene i in patients with severe i chaemic 
cardiac di ease who are not candidates for mechanical 
reva cularization, including tho e with occlu ion of 
vessel too mall to be bypassed, those without conduits, 
and tho e who are not surgical candidates becau e of 
concomitant di ease. However, thi tudy evaluates the 
safety and efficacy of direct injection of naked plasma 
VEGF D A as ole therapy for evere (functional class 3 
or 4) exertional angina. Early result from five patient 
reported that all patient experienced marked ymptom 
improvement and I or objective e idence of increa ed 
myocardia] perfu ion, as evaluated by angiographic and 
single photon emis ion computed topography (SPECT)-
se tamibi tudie , between 30 and 60 day following the 
procedure. Similarly, bFGF and VEGF, deli vered by 
intracoronary injection, have entered into a pha e I trial in 
ischaemic myocardium not amenable to CABG.6 
While early results suggest that application of 
angiogenic growth factors to the myocardium i safe and 
ma y lead to decrea ed symp toms and increased 
myocardial perfusion in elected patients, significant 
question remain. Optimizing the anatomic site, number 
and do e of intramyocardial injections will require further 
work. The appropriate formulation or vector al o remains 
to be determined. Recombinant VEGF protein has al o 
shown to be efficacious for the induction of limb and 
myocardial angiogene is in pre-clinical and preliminary 
clinical inve tigation 47 and the adenoviral VEGF vector, 
shown to increa e myocardial perfusion and function in 
porcine myocardi um, is now being tes ted in human 
subject 44 • 
Perhap mo t ignificantly, minimally in va ive 
method of growth factor introduction will need to be 
developed to permit proper scientific tudies that include 
randomization of human subject ver us placebo. Current 
clinical studie involving VEGF require a mini-
thoracotomy. The availability of a catheter ba ed y tern to 
deliver reliable percutaneous myocardial gene deliver~ 
may solve thi i ue and is currently under inve tigation4 . 
Recent work has also inve tigated the pericardia! space as 
a potential site for angiogenic factor delivery and I or 
expre ion.50..s1 Cardiomyocyte transplantation into carred 
myocardium ha already been hown to re tore heart 
function in rats52 and, in combination with gene therapy, 
offer a means of replacing fibrou car with functional 
cardiomyocytes while simultaneously inducing 
angiogene i to alvage surrounding viable myocardium 
and ensure adequate oxygenation to the transplanted cells. 
Summary 
Adequate blood upply is a condi tion for myocardial 
survival and function. Thu , va cular growth is under 
tight r gulation by a multifactorial ca cade balancing the 
initiation and down-regulation of angiogene i . The 
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pre ence of growth factor in the myocardium alone is not 
sufficient to permit angiogenesis; additional stimuli-
chemical, molecular, or mechanical-are required . 
Re earch ha demonstrated that the addition of pecific 
growth factors can initiate coronary collateral 
development in the pre ence of myocardial i chemia. 
However, it remain to be full y elucidated whether 
angiogenesis can be efficaciou ly induced through the 
introduction or up-regulation of a ingle vital growth 
factor or whether the altered expre ion of multiple factor 
i necessary to adueve therapeutic result . Thus, future 
tudies must be aimed at e tabli hing the optimal 
angiogenic factor(s), dose and route of administration for 
extrapolation to the clinical etting. Gene therapy i 
currently the focu of therapeutic angiogenic re earch and 
re ult from early clinical trials offer the promi e of 
minimally invasive myocardial reva cularization for 
patient with evere i chemic heart disea e. 
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A LITERATURE REVIEW 
BILE DUCT 
OF 
CANCER EXTRAHEPATIC 
Introduction 
Extrahepatic bile duct (EHBD) carcinoma is an uncommon malignancy with overall five year survival rates less than 5%1• Le ions are frequently 
mall, making diagnosis difficult, and they are often 
locally invasive at the time of presentation making 
re ection irnpo sible2• Tumour usually spread within the 
bile ducts and, locally, they may invade the hepatic artery, 
portal vein and liver parenchyma3. Surgical resection 
offers the only chance for long-term survival1•11 • Surgical 
cure and prognosis are based primarily on the stage of the 
tumour at the time of diagno is. Anatomical location of 
the lesion, morphological type, and grade of the tumour 
al o affect prognosis4 • Overall, the five year survival with 
urgical re ection is less than 30%. 
These tumours arise from epithelial cells lining the 
major extrahepatic bile ducts. The majority of tumours 
appear histologically and microscopically similar5. 
Generall y, tumours are mucin-producing 
adenocarcinoma . Three anatomic divisions are recognized 
for tumour cia ification: (1) Upper third, involving the 
hilar region and confluence of right and left hepatic ducts -
this type of EHBD tumour is also known as a Klat kin 
tumour; (2) distal to the junction of cystic duct and the 
uperior border of the pancrea (middle third); and (3) the 
lower third at the distal end of common bile duc:f-11 • 
Location of the tumour i responsible for differing 
survival rate 4 11 • Lesions of the distal third are most often 
curable with re ection, whereas Klat kin tumours (upper 
third lesion) are often invasive and uruesectable at the 
time of g_resentation, and have low survival rates with 
re ection 11 • Unfortunately, the confluence of the hepatic 
ducts c_onstitut~ the location of argroximately one-half of 
all malignant bile duct cancer 6-10•1 • • 
Morphologic subtypes include papillary I polypoid, 
a nd clerosing tumours . These lesions can be well, 
moderately, or poorly differetiated2• Papillary lesions have 
a significant long-term survival advantage compared to 
clerosing lesions 11 • In EHBD cancers, local invasion, 
lymph node metastases and the status of the surgical 
margins are primary factors affecting prognosis28• 
The etiology of EHBD cancers is not well defined29.30. 
A link between gallstones, gallbladder di ease and bile 
duct cancers has been observed29 • In addition, biliary 
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enteric anastomosi , inflammatory bowel disease, 
choledocal cysts, and smoking have also been shown to 
increa e the risk of bile duct cancers in both men and 
women. Other factors uch as unsaturated fat intake, bod 
weight, and alcohol show only a weak correlation . 
Associations between cancer of the bile duct and 
ulcerative colitis (UC) have been observed35• A tudy by 
A~"':' ari et a/35 reviewed thirteen patients at the Mayo 
Clinic between 1935-1973 with documented association of 
UC and bile duct cancer. Onset of bile duct cancer was 
insidious in each ca e. Common presentation for these 
patient wa fatigue, anorexia, and weight loss followed 
by dark urine, pruritus, jaundice and acholic stools35. The 
incidence of bile duct cancer in patients with UC been 
reported as between 0.4% -1.4%35. At onset of cancer, mo t 
patients had mild to moderate periodic exacerbations of 
UC with one having no symptoms35• 
Presentation and Diagnosis 
Patient typically pre ent with painless jaundice and 
weight loss. Clinically the e patients present with cleral 
icteru , jaundice, dark, tea-coloured urine, and clay-
coloured stools. As ductal obstruction worsens patients 
develop pruritu , hepatomegaly and are at risk for 
developing a cending cholangitis. If the tumor is confined 
to right or left branche and occluding the lumen, jaundice 
may not be present, delaying symptoms and pre entation 
longer5•31• Early diagnosis is crucial to survival13• Initial 
inve tigations after a complete history and physical 
examination include appropriate blood work which 
should include liver function tests. 
Once a pattern of obstructive jaundice ha been 
identified, abdominal ultrasound is the most effective 
initial radiologic investigation. Ultrasound will 
demonstrate a dilated intrahepatic biliary tree and, 
depending on where the primary tumour is located, 
dilation of the extrahepatic bile ducts to the level of the 
~umour. At this stage, the differential diagnosis may 
mclude: choledocholithiasis, benign bile duct stricture , 
sclerosing cholangitis, and pancreatic neoplasms. Imaging 
of the EHBD can be achieved by perfoming either 
endo copic retrograde cholangiopancreatography (ERCP) 
or by percutaneous tran hepatic cholangiography (PTC). 
At the time of ERCP or PTC, the obstructed bile duct can 
be tented or drained to allow for decompression of the 
obstructed biliary sy tern. A sub equent CT scan should 
be done to help stage the tumour (rule out distant 
metastases, and evaluate the extent of local invasion). In 
some centres, hepatic arterial angiography is used to 
assess local vascular invasion which may preclude 
surgical intervention. If the EHBD cancer is not re ectable, 
palliation can be obtained with a PTC drain or an ERCP 
placed drainage stent?2·34 
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Management 
The mean survival for patient for untreated EHBD 
cancer i 3-6 months ·36• Chemotherapy alone has had 
little role in the treatment of EHBD tumours for curative 
or palliative management!. These tumours unfortunately 
do not respond to any great degree to currently available 
chemotherapeutic agents. Radiotherapy can increase 
length of survival, quality of life, and shows benefit in 
patients with previous curative or palliative surgery 1. It 
may al o benefit patients with local recurrences 1. The use 
of high dose radiotherapy is a feasible therapeutic option 
for the management of EHBD cancer. Radiation therapy 
can be delivered by external beam or intraca itary 
radiotherapy via a PTC drain37.51_ 
Indications for use of radiation treatment include: (1) 
adjuvant therapy following complete resection; (2) 
palliative radiotherapy for patient with positive margins 
or local recurrence following surgery; and (3) palliative 
treatment of nonresectable advanced tumours 1• 
eoadjuvant chemoradiation for EHBD cancer can be 
used preoperatively36•38• Proponents of this approach 
believe some tumours may be decreased in ize to allow 
for re ection and theorize that the neoadjuvant approach 
may improve survival. Few data exist to support this 
approach at present. 
The ide effect of radiation treatment for EHBD 
cancers are variable and most complaints are related to 
irradiation of inte tinal epithelium1• Diarrhea, nau ea and 
vomiting are commonl. 
The principles of su rgical management of HBD 
cancers in~olve~ comp~ete en bloc re ectio~ of the prim~ 
tumour With histologtcally proven negative margins · . 
Management based on anatomical location is as follows: 
(1) upper 1/3 (Klatskin tumour), resection of bifurcation of 
bile duct +I- as ociated hepatic resection; (2) middle 1 I 3, 
may be amenable to local resection or 
pancreaticoduodenectomy (Whipple procedure); (3) distal 
1/3 of biled duct, pancreaticoduodenectomy. The aim of 
surgical palliation is to relieve biliary obstruction, thereby 
decompre ing the biliary tree39• This i accompli hed by 
performing a biliary enteric bypass. 
Surgically placed U-tubes have been used in the pa t 
to palliate patients, but are used much le s frequently than 
PTC drain or ERCP-placed stents3•39 . Percutaneou 
techniques have associated problems. Mortali~ may reach 
up to 25-31% and infection is also a concern 1• External 
catheters lead to the loss of fluid and electrolyte a well a 
bile constituents3• They also provide a portal of entry for 
bacteria leading to cholangitis, epticaemia, and liver 
ab ces e 3. Catheters require daily care, dressing and 
irrigation. If obstructed they can be changed with ea e and 
may be u ed as a portal for intracavitary radiotherap . 
Mortality rates for percutaneous and endoscopic palliative 
procedure have been estimated at 15-33% for 30 day po t 
procedure6•22•23• 42 • This is imilar to the perioperative 
mortality rate for surgical palliative bypa s. 
Palliative surgical decompre ion of biliary 
ob truction in patients with unre ectable EHBD cancer 
involve Roux-en-Y biliary-enteric ana tomose . The 
location of the bypa depend upon the origin of the 
primary tumour. The bypass can be performed both intra-
and extra-hepatically. The intra-hepatic approach 
commonly employed i the "round ligament" approach 
(segment ill approach) to the ducts of the left lobe lateral 
to the ligamentum teres39• 
Guidelines for the choice of a decompression 
procedure include: (1) general condition or health of the 
patient; (2) effectiveness of the procedure with re pect to 
quality I duration of survival; (3) associated 
complications17. Regardle s of the procedure employed, 
the goal of palliation i the relief of ;ymptom of 
ob truction -jaundice, pruritu , malai e, etc1 . 
Surgical re ection can be accompli hed with 
acceptable operative mortality and morbidity with respect 
to length and quality of life6•12-17• The key to ucce ful 
surgical management of EHBD cancers is early and 
accurate preoperative diagno i 13• Invasion of the hepatic 
artery, portal vein and di tal metasta e are the u ual 
reasons makin§ the e tumous nonresectable at 
diagno i 3' 13' 1731.38.3 • Contraindications to re ection include: 
(1) regional/ distant meta ta e ; (2) bilateral intrahepatic 
spread beyond econd order ducts; (3) inva ion of the 
main trunk of the hepatic artery; (4) inva ion of the main 
trunk of the portal vein9•13•17•43• 44•45. 
A tumour is considered re ectable if it is localized to 
the bile duct. Procedure for radical urgery are 
individualized and preoperative mapping with PTC and 
ERCP are crucial to plannirlg. If resection is performed a 
margin of 1.5 em from the edge of the tumour e pecially 
on the hepatic side i recommended46. 
Postoperative complication include ana tomotic 
leaks, wound infection, bleeding, intra-abdominal ab ce s 
formation, sep is, pancreatitis, and portal vein 
thrombo is13• As a result of improved surgical technique 
and po toperative management of patients, the 
po toperative mortality rate has decrea ed . The 
perioperative mortality rate depends upon the extent of 
the surgical resection, but range from 2-5%47. 
Liver transplantation as a form of management i not 
an effective treatment for the management of EHBD 
cancer. It has been e timated that up to 0% of transplant 
patient died or manife t di ea e recurrence within one 
ye~·2+27 • In the literature, there have been a few report of 
curative surgery with liver transplantation for hilar 
carcioma with adequate long-term urvival, if margins 
are clear and lymph node are negative .49. At pre ent, thi 
i still not an accepted therapeutic option and is 
considered experimental. 
Conclusion 
Extrahepatic bile duct cancer are rare neopla m with 
overall five year urvival rate less than 5%. En bloc 
surgical re ection with negative hi tologic margins offer 
the only chance for cure. Even with surgical re ection, 70-
7~% of patient~ develop tumour recurrence and ultimately 
die from the di ease. onre ectable patients can be treated 
palliatively with PTC drainage of the obstructed bile duct 
or via ERCP placed tent . Adjuvant radiotherapy via 
external beam or intracavitary radiotherapy may improve 
urvival. Palliative radiotherapy may slow progre ion of 
the tumour and minimize a ociated ymptom . Although 
extra-hepatic bile duct carcinoma are rare, they should be 
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con idered in the differential diagno is of patient who 
pre ent with ob tructive jaunctice. 
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CURRENT OPTIONS IN LOCAL 
TREATMENT BREAST CANCER 
INTRODUCTION 
Breast cancer is the most common malignancy in women1, and the mortality from this disease is second only to that of lung cancer as a cause of death 
among women2• In the general population, an individual 
woman's lifetime risk for developing breast cancer is one 
in nine1• These numbers are staggering to many women, 
for whom breast cancer often carries powerful emotional 
connotations aside from its medical consequences. This 
disease is particularly frightening because it runs an 
insidious course. The preclinical, prediagnosis stage of a 
breast tumour's history and the clinical phases after initial 
treatment are often measured in decades3. Breast cancer 
has an essentially fixed rate of recurrence for 15-20 years 
after initial treatment. This is in marked contrast to most 
other cancers, for which a 5-year survival can be 
considered a cure4• 
Patients diagnosed with breast cancer and their 
clinicians are faced with multiple treatment decisions5. 
These include combinations of surgery, chemotherapy, 
radiation therapy and hormonal therapy. The choice of 
treatment decisions in breast cancer is largely guided by 
tumour stage at the time of diagnosis, and patient 
preference. Breast tumours are staged according to 
tumour size, presence of nodes or distant metastases, and 
whether the tumour is inflammatory or ulcerates the skin 
(see Table 1). In patients with less advanced disease, 
surgery is still the mainstay of treatment. However, 
surgery in patients with advanced systemic disease is 
limited. Radiotherapy and hormonal manipulation are of 
considerable importance to treat or palliate si tes of 
Stage 
stage 0 
stage 1 
stage 2A 
stage 28 
stage 3A 
stage 38 
stage4 
TABLE 1- Staging and Prognosis of Breast Cance~ 
Description 
in situ carcinoma 
primary tumour <2cm, 
negative axillary lymph nodes, 
no distant mtastases 
primary tumour <2cm 
and positive axillary lymph nodes, 
or primary tumour 2-5cm 
with negative nodes 
tumour 2-5cm and positive 
nodes, or tumour >5cm 
and negative nodes 
tumour >5cm with ipsilateral 
axillary nodes or 
fixed lymph nodes 
internal mammary lymph nodes, 
or tumour extending to chest wall 
and ulcerating the skin 
distant metastases 
5-year survival 
95% 
85% 
75% 
65% 
50% 
41% 
10% 
By Helen Lewandowski 
metastases 1• This article focuses on current issues in the 
local treatment of breast cancer, and how it should be 
timed in relation to systemic treatments. 
LOCAL TREATMENT OF BREAST CANCER 
Historically, the evolution of local treatment has 
mirrored the prevailing theories on the spread of breast 
cancer. At the turn of the century, Halsted popularized the 
radical mastectomy, which involves en bloc resection of 
the breast, overlying skin, underlying pectoral muscles 
and axillary contents6. This was based on the belief that 
tumour spread occurs in an orderly fashion by direct 
invasion and through lymphatic channels. The goal of 
breast cancer surgery was to remove the maximum 
amount of breast tissue and axillary lymph nodes in order 
to fully eradicate the tumour. This policy remained 
unquestioned dogma for several decades until patient 
survival analysis in the 1950's and 1960's demonstrated 
that this radical surgery was not improving patient 
survival5. The realization that failure after surgery was 
more often due to systemic dissemination of tumour 
before surgery than to inadequate local sur?ery cau ed a 
shift towards more conservative approaches . 
Currently, there are several surgical options available 
to patients with operable tumour. In patients with ductal 
carcinoma in situ, these include simple mastectomy and 
breast-conserving surgery (BCS) without axillary node 
dissection. Patients with invasive stage 1 and 2 cancer 
have a choice between BCS with axillary lymph node 
dissection, and modified radical mastectomy (MRM). 
Simple mast ctomy involves a resection extending from 
the clavicle to the costal margin and from the midline to 
the latissimus dorsi . The entire axillary tail and the 
pectoral fascia are completely removed . The skin is 
excised and skin flaps are similar in thickness to those in a 
radical mastectomy. However, the axilla is not invaded 
and axillary nodes are not remo ed. Modified radical 
mastectomy consists of removing the breast, nipple-
areolar complex and dissection of axillary lymph nodes. In 
contrast to radical mastectomy, the pectoralis major 
muscle is spared. Rarely, the pectoralis minor muscle may 
be removed to facilitate dissection of the higher level 
lymph nodes. Breast-conserving surgery for invasive 
cancer includes lumpectomy and quadrantectomy, and 
consists of resection limited to removal of the breast 
tumour with a margin of normal breast tissue. Axillary 
dissection is performed and the patient receives post-
operative adjuvant breast irradiation. All these procedures 
can be performed on an outpatient basis with few 
complications, few readmissions, and good patient 
acceptance7• Issues which patients and their clinicians 
must address include the choice of mastectomy versus 
BCS, the role of axillary dissection, and the timing of 
chemotherapy relative to surgery. 
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SURGERY 
Initial treatment for women with stage 1 or 2 breast 
cancer is surgery. The option available are modified 
radical mastectomy and breast-conserving surgery. 
Evidence from six prospective randomized controlled 
trials has shown that removal of the tumour followed bl 
radiotherapy results in similar survival as mastectomy . 
Without particular reasons for electing mastectomy, the 
choice between BCS and MRM is made according to 
patient preference. The goal of BCS is to provide 
atisfactory cosmetic results without compromising local 
tumour control or survival compared to l'vfRM'l. However, 
there are conditions in which mastectomy is favored. It is 
indicated for diffuse-appearing microcalcifications on 
mammography, multiple tumours in different breast 
quadrants, failure to obtain tumour-free margins, and if 
radiotherapy is contraindicated. Contraindications to 
radiotherapy include physical disabilities preventing its 
u e, a history of therapeutic irradiation of the breast or 
chest, treatment during the first or econd trimester of 
pregnancy, scleroderma and SLE . BCS is also not 
recommended in the presence of a large tumour / breast 
ize ratio or a large breast size5• In addition, there are risk 
factors for local recurrence following BCS. These include 
extensive ductal carcinoma in situ, young age, multiple 
tumours and high nuclear grade of tumour. Local 
recu~rence may lead to hi~h patient anxiety and may 
reqwre salvage mastectomy . In the e patient , the risks 
and benefits of mastectomy versus BCS should be 
carefully weighed on an individual basis. 
In addition, the option of breast reconstruction after 
mastectomy should be di cus ed with the patient before 
any definitive surgery. Breast reconstruction techniques 
include silicone gel implantation beneath the pectoralis 
major muscle, and the use of m yocutaneous flaps to 
transfer skin, fat and muscle from distinct parts of the 
body. Currently, the most commonly used flaps are the 
latissimus dorsi and transverse rectus abdominis (TRAM) 
myocutaneous flaps3. Regardless of the technique u ed, 
the goal of breast reconstruction is re-creation of the breast 
mound. The main indication for this procedure is the 
patient's desire to have it performed. The only true 
contraindications to breast reconstruction are significant 
comorbid conditions that would interfere with the 
patient's ability to tolerate a longer operative procedure in 
the ca e of immediate reconstruction, or additional 
procedures in the case of delayed reconstruction3. 
AXILLARY DISSECTION 
The appropriate treatment for the axilla remains 
controversial. Although Halsted' s principles promoted 
extensive axillary dissection, more recent evidence has 
questioned the impact of axillary dissection on survival. A 
trial by the ational Surgical Adjuvant Breast Project 
howed that radical axillary dis ection did not positively 
affect survival in patients with stage 1 and 2 breast 
cancer 10. Axillary dissection is also as ociated with 
ignificant surgical morbidity . Possible complications 
include post-operative infection, pare thesias, alterations 
in houlder mobility and lymphedema. However, the 
M i sce llan eous A rti cle s 
presence o r absence of metastatic involvement of the 
axillary lymph nodes is the strongest prognostic factor for 
patients with primary invasive breast cancer. In addition, 
extensive axillary dis ection is associated with greater 
reduction of recurrence risk in the axilla than sampling 
only a few nodes 11 • Thus, the decision on whether to 
remove axillary nodes and how extensively to do so 
requires balancing expected health benefits versus side 
effects. 
Currently, there exist clinical guidelines for axillary 
dissection 11 • These are that removal and pathological 
examination of axillary lymph nodes should be standard 
procedure for patients with early invasive breast cancer. 
For accurate staging and to reduce the risk of recurrence in 
the axilla, level 1 and level 2 nodes should be removed. 
Level 1 nodes are tho e situated lateral to or below the 
lateral border of the pectoralis minor muscle. These nodes 
receive most of the lymphatic drainage from the breast. 
Level 2 nodes are situated deep to the pectoralis minor 
muscle and receive lymph from Ievell nodes and and also 
some drainage directly from the breast. 
After axillary dissection, irradiation of the axilla 
should be carried out with caution. Omission of axillary 
dissection may be con idered when the risk of axillary 
metastases is very low or when knowledge of nodal status 
will have no influence on therapy. Recently, attention has 
been focused on the technique of sentinel 
lymphadenectomy to identify node positive patients5• 
The e involve the use of markers such as vital blue dye 
and techneti u m-labelled sulfur colloid to identify a 
sentinel node that drains lymph from the tumour area. If 
the entinel node has no evidence of metastatic breast 
cancer, complete axillary dissection can be avoided. If the 
node is positive for metasta es, axillary dissection should 
be performed. In a study of 62 patients, the sentinel node 
was identified successfully in 92% of cases and was 
positive in all patient found to have metastatic disease. 
There were no skip metastase 11 • As this technique is 
refined, a significant amount of axillary dissection and 
surgical morbidity may be avoided in the future. 
TIMING OF SURGERY AND CHEMOTHERAPY 
Traditionally, chemotherapy has been used as an 
adjuvant therapy following surgical resection in breast 
cancer . However, neoadjuvant or preoperative 
chemotherapy has been commonly used in treating 
variou cancers, including breast cancer12• The rationale 
underlying this is that treating metastases at the earliest 
possible time may avoid rapid growth of metastases after 
treatment of the primary site and may prevent emergence 
of resistant clones. Decreasing the size of the primary 
tumour may make unre ectable tumours resectable, may 
make organ /?reservation more likely and may improve 
local control . This approach is mainly used in women 
diagnosed with stage 3 breast cancer. This includes 
patients diagnosed with stage 3A disease, which is 
generally considered operable, and stage 3B disease which 
is inoperable. Patients with inflammatory breast cancer are 
als~ included in stage 3B disease. This subgroup of 
patients has a particularly poor prognosis, and is 
characterized by tumours with a rapid onset of erythema, 
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edema and ridging13• 
Women with stage 3 breast cancer are a complex 
group in terms of treatment. Currently, multidi ciplinary 
therapy is the treatment of choice for the e patients. The 
accepted strategy is primary or neoadjuvant 
chemotherapy followed by either surgery, radiotherapy or 
both. Most patients achieve a respon e to chemotherapy 
that results in downstaging of the tumour. With the 
multidisciplinary approach, 5-year survival rates are 30-
60%, compared to 10-20% for local therapy alone13• In one 
study, patients with stage 3 breast cancer including 
inflammatory disea e were treated with chemotherapy 
followed by surgery and additional chemotherapy. 
Patients with inflammatory brea t cancer or 
supraclavicular nodes also received adjuvant 
radiotherapy. Overall 5-year survival was 56%, and wa 
affected by stage (3A or 3B), presence of inflammator:f 
breast cancer and the number of positive nodes 1 • 
However, it i not clear that the apparent improvement in 
outcomes resulted from the use of neoadjuvant 
chemotherapy as much as the use of chemotherapy itself. 
In another report, the addition of chemotherapy after 
radiotherapy and surgery in patients with stage 3 breast 
cancer improved 3-year survival from 57% to 90%, and 
this difference remained highly significant at 5 years12• 
Therefore, neoadjuvant chemotherapy has not been 
shown to improve survival when compared to adjuvant 
chemotherapy for stage 3 breast cancer. However, the u e 
of neoadjuvant chemotherapy may decrease the tumour 
size and thereby reduce the scope and difficu l ty of 
surgery. In one study, patients with locally advanced 
brea t cancer deemed unre ectable with primary wound 
do ure underwent 8 weeks of infusional 5-fluorouracil 
and radiation therapy. 73% of patient had an objective 
clinical response and all were able to undergo MRM with 
primary wound closure 14 . Additionally, the use of 
neoadjuvant chemotherapy reduces the likelihood that 
skin grafts or complex reconstruction will be required, and 
may decrea e the inten ity and morbidity of irradiation 
needed to treat the brea tor che t wall 12• 
The use of neoadjuvant chemotherapy in stage 3 
breast cancer gave rise to the idea of applying this 
approach to patients with earlier stage, operable brea t 
cancer. This was based on tudies showing 
"micrometa tases" in the blood and bone marrow of a 
significant number of patients undergoing surgery for 
early tage breast cancer15• It was felt that if the e are 
treated earlier, there is the potential for higher cure rate . 
However, the use of neoadjuvant chemotherapy for 
patients with operable breast cancer i controver ial. It 
may achieve significant tumour regression but the 
primary goal of improving survival has not yet been 
clearly demonstrated 15 • At this stage, neoadjuvant 
chemotherapy for operable brea t cancer i still considered 
investigational. 
CONCLUSION 
The current management of brea t cancer require a 
multidi ciplinary approach involving surgical, medical 
and radiation oncologists. This field is constantly 
evolving. Local and systemic treatment mod a lities 
constitute es ential aspect of treatment. Several urgical 
option are available to patients and their clinicians. The 
choice between mastectomy and BCS should be based on 
tumour factors and and patient preference following a 
thourough di cussion of the e options. Following surgical 
treatment, the need for adjuvant chemotherapy and I or 
radiation therapy must be determined based on tumour 
characteristics such as stage, grade, hormonal status and 
patient characteri tics uch as menopausal status and 
previous m dical hi tory. By weighing these factors 
carefully, breast cancer treatment may be optimized for 
patients on an individual basi . 
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RECENT ADVANCES IN 
MELANOMA UNDERSTANDING 
Reducing melanoma mortality i an important public health goal for dermatology, and as a result, has been intensively tudied from an epidemiological 
point of view. 1 The recent literature on melanoma will be 
di cus ed. 
Melanoma i a malignant di ease ansmg from 
melanocytes. Melanocytes produce melanin, which 
generate a brown skin color. Skin cancer is the most 
commonly diagnosed cancer in the United State and 
Canada (more than 63,000 Canadian will develop kin 
cancer each year); anyone born today has a 1 in 7 risk of 
developing skin cancer during his/her lifetime. 17 
Although the incidence of melanoma is lower than other 
type of skin cancer, it i the mo t erious form of skin 
cancer and has the highest death rate. 3 In 1996 in the 
U.S.A, there were an e timated one million ca es of kin 
cancer; 5 percent of tho e were melanoma and caused 75% 
of kin-cancer death _3 In 1999, a 6% increa e in melanoma 
incidence is expected which will mean that 44,200 
American will be diagno ed this year (3200 in Canada), 
with approximately 7,300 deaths attributed to melanoma.3 
In Ontario, there are approximately 1400 people 
diagnosed with melanoma (men > women) each year with 
approximately 300 deaths per year. 16 A disturbing trend is 
that the incidence of melanoma in Canada ha doubled 
during the past 20 year .17 Clearly, more need to be done 
in terms of education and prevention. According to Dr. 
Ja on Rivers from the University of British Columbia, the 
increase in the age-specific incidence for melanoma has 
tabilized for women, especially for more recent birth 
cohorts, but in men the rate i till increasing.26 Table 1 
provides skin cancer statistics and trends in Canada. 
Melanoma occur among all racial and ethnic group . 
It i more frequent in re ident of areas of high ambient 
solar irradiance, more frequent in un ensitive people and 
occur with highe t density on body site expo ed to the 
un. In addition, melanoma ha been hown to be more 
frequent in people with intermittent high sun expo ure.2 
The u eful acronym for identifying a possible melanoma is 
de cribed in Table 2. The incidence among dark skinned 
ethnic groups i 1 per 100,000 per year or les , but among 
light- kinned people has been measured as high as 50 per 
100,000. 1 In common with most cancers, melanoma 
incidence increases with age. However, in Cauca ians, it i 
relatively more common in young adult than most other 
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Canadian Skin Cancer Statistics & Trends 
• Half of all new cancers are skin cancers 
• Approximately 63 ,000 new cases of skin cancer will be 
diagnosed this year in Canada 
• Approximately 3,200 new cases of melanoma will be diagnosed 
this year in Canada 
• In 1998, 7 40 deaths were attributed to malignant melanoma 
• The incidence of melanoma doubled among the white population 
between 1973 and 1991 
Table 1: Skin Cancer in Canadians 
cancers. In fact, in the U.S.A, melanoma is more common 
than any noncutaneous malignancy in the 25 to 29 year 
age group, and it accounts for more years of life lost per 
case among adults than any major site other than 
testicular cancer. 3 As well, a gender difference in 
melanoma location exi ts; that is, women have an exces 
of melanoma on the legs, and men have an exces of 
melanoma on their ear , calp and especially the posterior 
trunk .U5 In 1996, a study in the Journal of Cutaneous 
Medicine and Surgery found that men and women had a 
similar anatomic distribution of painful sunburns, and 
since the anatomic distribution of melanoma differ , "it 
would appear that factors in addition to sunburns in 
adults account for the differences in the anatomic 
distributions of melanomas in men and women." 15 
Unawareness of Melanoma 
A high proportion of U.S. residents are unaware of the 
dangers of melanoma . Forty-two percent of those 
surveyed had no knowledge of the disease, with the level 
of awareness lowest among people ages 18 to 24 year . 
The survey also found the level of melanoma 
awarene s to be directly related to levels of education and 
income. Of those with annual incomes of less than $20,000, 
60 percent reported they did not recognize the term 
The ABCD's of Melanoma 
Asymmetry-<>ne half doesn't match the other half. 
Border irregularity-edges are ragged, notched or blurred (not well 
circumscribed). 
~lor-color is not uniform. Shades of tan, brown and black are 
present; red, white or blue may also be present. 
Diameter-more than six millimeters. 
Other Warning Signs of Melanoma: 
• change in the size, shape, or color of a mole 
• oozing or bleeding from a mole 
• a mole that feels itchy, hard, or tender to the touch 
Table 2: Principles in detecting skin cancer ' 
Source: American Academy of Dermatology 
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melanoma. Only 31 percent of tho e with annual incomes 
of $75,000 or more reported no knowledge of the disea e.3 
It is likely that many Canadians would be similarly 
unaware of melanoma. 
UV and Melanoma 
The two types of ultraviolet radiation that reach the 
earth from the sun are ultraviolet A (UV A) and ultraviolet 
B (UVB). UVB has long been a sociated with sunburn, 
while UV A has been recognized as a deeper penetrating 
radiation. Scientists have long suggested that there may be 
an association between UVA radiation and malignant 
melanoma.3 The wavelen?th of tanning parlors is UV A. 
Both tanning parlors22•23•2 and PUV A (Psoralen & UV A 
rays) 25 increa e the ri k of melanoma. It is only r cently 
that UVB rays have achieved similar tatu in causing 
melanoma. In the recent study in the May 1998 issue of the 
American Journal of Pathology, 158 human newborn 
foreskin grafts on immunodeficient mice were treated 
with a chemical accelerant 7,12-
dimethyl[a]benzanthracene (DMBA) alone or UVB alone, 
or UVB combined with DMBA, or nothing. The grafts had 
had no prior sun exposure. Twenty-three percent of the 
grafts treated with only UVB, and 38% of grafts treated 
with the combination of DMBA and UVB, developed 
abnormal pigmented lesions including one human 
malignant melanoma within 5-10 months of exposure. 
Untreated human skin xenografts were unchanged, and 
those receiving only DMBA had very minor changes in a 
few grafts. 
Sun Awareness 
Efforts to educate people about sun protection have 
resulted in an increased awarene s that sun expo ure is 
dangerous. In a study released in 1997 by the American 
Academy of Dermatology, a decline in the attitude that 
having a tan was healthy and an increa e in the reported 
u e of unscreen by adult (35% in 19 6 to 53% in 1996) 
was noted.3 Unfortunately, during the arne decade, the 
UV exposure of adults, as measured by sunburning (30% 
in 1986 to 36% in 1996) also increased, a did the regular 
use of tanning beds (2% in 1986 to 6% in 1996).3 The risk 
factors for developing skin cancer are listed in Table 3. 
Sunscreens Increase Cancer? 
• blond or red hair 
• blue eyes 
• Caucasian 
• changed/changing mole 
• congenital mole 
• fair complexion 
• freckles 
• immunosupression 
• inability to tan 
• melanoma in first-degree 
relative 
• one or more large or 
irregularly pigmented lesions 
• personal history of melanoma 
• severe sunburns in childhood 
Table 3: Risk factors for skin cancet 
Source: Centers for Disease Control 
Recent controversy over the role of sunscreens in 
preventing melanoma has raised que tions about the u e 
of the e agents. There is concern among some 
dermatologist that unscreens alone do not protect 
against melanoma. Sunscreen might unfortunately lull 
you into a fal e ense of security, making you feel that you 
can stay out much longer than you should. Unfortunately, 
some individuals with the belief that sunscreen provides 
sufficient protection, may ignore other sun safety 
behaviors that could provide additional protection. 
Sub equently, these same individuals may ignore 
suspiciou marks or lesions as potentially dangerous 
becau e the feel that sunscreen alone provide all the 
protection they need.3 Historically, the sunscreens used in 
the pa t offered poor longer wavelength UV A protection 
which may have also played a role in melanoma rate not 
falling with increased sunscreen use . Use of these 
sunscreens may have increased the long UV A exposure if 
sun exposure increased since the suncreen decreased 
burning. There is actually little evidence that protection 
again t the sun protects against melanoma, but this issue 
is difficult to study epidemiologically.2 Clearly more 
research into thi matter is nece ary. 
Self-Examination 
According to a study published in the May, 1998 
Journal of the A merican Academy of Dermatology, people are 
more motivated to examine their kin for skin cancer if 
they have had di cu ions with doctors and if they think 
they are at hi~h risk for developing melanomas and other 
skin cancers. It is estimated that skin self-examination 
(SSE) may reduce mortality from melanoma by 63%. 
Eighty-one percent of tho e surveyed who talked to a 
health care orker were doing SSE compared to 35% who 
were practicing SSE but had not talked about sunning 
with a doctor or nur e. SSE was reportedly performed 1.5 
time more often by women than men, with white persons 
performing SSE 1.7 times more often than other races. 
Some education beyond high school also increa ed the 
practice of regular SSE. Thus, there is clear evidence for 
the n ed for prevention through skin self-examination in 
melanoma. Thi will both ease its economic burden, and 
more importantly save live . 
Relating Melanoma Risk to Nevi 
Recent r search has found that the risk for melanoma 
wa trongl related to the number of small nevi, large 
non-dysplastic nevi, and clinically dysplastic nevi. In the 
absence of d splastic nevi, increased numbers of small nevi 
were a sociated with an approximately 2-fold increased 
risk, and increased numbers of both small and large non-
dysplastic nevi were associated ith a 4-fold increa ed 
risk. One clinically dy plastic nevu was associated with a 
2-fold increased ri k, while 10 or more conferred a 12-fold 
increa ed risk. As well, there is an estimated 81.6%21 to 
100%19 lifetime risk of melanoma in a person with familial 
dysplastic nevi who ha two relatives with melanoma. 19 In 
regard to congenital nevi, they appear to significantly 
increa the risk of malignant melanoma if they are large 
(= 20cm).3.2° The reported risk in patient with large 
congenital nevi varies from 3.8% -18%.20 
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Genetic Testing for Melanoma? 
It has been hown that approximately 8 to 12% of 
melanomas appear to be inherited in an autosomal 
dominant fashion. A French tudy published in the 
October 1995 issue of the Archives of Dermatology 
concluded "a familial investigation should be performed 
for each pat~ent with cutaneous malignant melanoma 
(CMM), particularly when he or he exhibits phenotypic 
ri k factors for CMM such a red hair and atypical 
moles." 13 
Furthermore, th ere is now trong evidence that 
germline mutation of the CDKN2A gene on chromo orne 
9p21 predispo e to melanoma in a sub et of melanoma-
prone familie . A tudy published recently in the Journal 
of Cutaneou Medicine and Surgery concluded "the 
identification and subsequent surveillance of unaffected 
individual who have a genetic predi position to 
melanoma may lead to the detection of early (curable) 
melanomas and to a reduction in mortality." 10 
Cost of Treating Melanoma 
A recent tudy in the U.S. found that the annual direct 
co t of treating newly diagno ed melanoma in 1997 was 
e timated to be $563 million. Dr. Ja on River from the 
University of British Columbia noted tha t the Canadian 
figure i unknown, but estimated it to be 5-10% of the 
American co t.26 The American study broke down the cost 
of treating each stage of the disea e and found that Stage I 
and II disea e each comprised about 5% of the total cost; 
stage Ill and stage IV disease consumed 34% and 55% of 
the total co t, respectively. About 90% of the total annual 
direct cost of treating melanoma in 1997 was attributable 
to less than 20% of patients (those patients with advanced 
di ease, that is, stage III and stage IV). The study 
concluded that "in addition to the potential urvival 
advantages, aggre sive primary prevention through sun 
protection and intensive screening to enhance earlier 
detection shou ld reduce the economic burden of 
melanoma care." 5 
Laboratory Tests And Imaging for Melanoma 
There i an ongoing controversy abo u t the use of 
laboratory and imaging studie for baseline and for 
follow-up evaluation to detect malignant melanoma 
(MM) metastases. Some argue that no laboratory te ts or 
imaging studies hould be routinely ordered for patients 
who exhibit no evidence of metastases on history or 
physical examination. However, CXR screening may be 
sugge ted since it detects about 5% of metastase which 
would have been classified clinically as AJCC (the 
American Joint Committee on Cancer) stage I or II MM. 
LDH levels, which are inexpensive, are routinely ordered 
by orne physicians because metastases have been 
infrequently detected in asymptomatic patients. Some 
physicians also consid er computed tomography (CT) 
scans for patients who have thicker primary MM; CT of 
the c:hest sho~d be considered e recially if the patient has 
cerVIcal or axillary adenopathy.1 The final position from 
the Guidelines for the Management of Cu taneous 
Melanoma i that "extensive investigation for systemic 
metas tases in patien ts with primary melanoma is not 
M i sce ll a n eous Artic l e s 
recommended" and that " inve tigation su ch as CT, 
ma~_etic resonance imaging (MRI) cans, and positron 
enusswn tomography (PET) scans should be utilised only 
where specific symptom suggest the pre ence of 
meta ta es.9 
Advances in Melanoma Therapy 
The improvement of treatment options and urvival 
rates for melanoma patient is an important health care 
concern as melanoma is the tenth mo t common type of 
cancer in Canada.1 
Several advance in the evaluation of regional lymph 
node , adjuvant therapy and genetic immunotherapy for 
the treatment of malignant melanoma have improved the 
treatment options for patients, as well as the five year 
survival rate for many patients according to a study in the 
May 1998 issue of the Journal of the American Academy of 
Dermatology. 
The evaluation of regional lymph nodes has proved to 
be an important predictor of the long-term ou tcome. In 
patients with nodal metastase , the actual number of 
di ea ed node i the mo t important factor for the 
prognosis and overall urvival. Selective node dissection 
(which focu es on the main, or entinel, node) may be 
u ed to determine the condition of the entire group of 
nodes.9 Another evaluation of the regional lymph nodes, 
intraoperative radiolymphatic mapf,ing, increase entinel 
node identification to 99 percent. Both of these options 
are still controver ial, and confirmation is needed. 
The most significant prognostic factor for melanoma is 
di ea e stage at presentation. While AJCC stage I and II 
melanomas (localised disease) have five year survival 
rate of ~ 85%, the rate for tage IV (metastatic) disea e is 
less than 5%, with median survival time of 6-10 months.n 
Becau e of the poor progno i of tage IV disease, clinical 
trials of adjuvant therapy are underway. A promising but 
controversial adjuvant therapy involves interferon alpha 
2b ~hich may improve the long-term survival rates of 
patient . A study publi hed in the January 1996 issue of 
the Journal of Clinical Oncology hawed that "IF alpha 
2b wa the first agent to show a significant benefit in 
relap e-free and overall survival of high-ri k melanoma 
patients in a randomized controlled trial." 14 However, at a 
recent conference addressing the issue, it was noted that 
only high dose interferon therapy (as opposed to low 
do e) may have potential benefit, but that at present, since 
clearly more re earch is needed, there is no standard 
therapy for high-risk melanoma patients. n 
Genetic immunotherapy focuse on application of 
gene therapy as it applies to immunotherapy ba ed upon 
the understanding that melanoma appears to be an 
immunoresponsive di ease. One approach to gene therapy 
involves genetically modifying tumor cells to make them 
more immunogenic. Another approach involve the 
injection of foreign genes directly into the tumor in an 
attempt to impact the immune response to the tumor. 
Due to the inconclusive evid ence tha t adj u vant 
therapy is beneficial for persons with melanoma, the 
Guidelines for the Management of Cutaneous Melanoma 
recommend referral to a melanoma centre for adjuvant 
therapy such as immunotherapy, chemotherapy or gene 
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therapy in patients with melanoma > 4mm in thickne 
and / or wi th involved node , whose progno is is poor.9 
Melanoma is certainly one of the mo t s tu died 
condition in Dermatology, and with reason. Wi th the 
promising research into it treatment and prevention, we 
hope to ee declines in the incidence and improved 
urvival in the near future . 
REFERENCES 
1. Williams HC, Strachan DP (Eds.). (1997). The Challenge of Dermato-
Epidemiology. ew York: CRC Press. 
2. Leig/1 IM, ewton Bishop fA , Kripke ML (Eds.). (1996). Skin Cancer: 
Cancer Surveys Vo/.26. New York: Cold Spring Harbor Laboratory Press. 
3. http://www.aad.org (American Academy of Dermatology) 
4. http://www.wvhealth.wvu.edu/Skinlstat .him (West Virginia Umversity) 
T ao H, Rogers GS, Sober AJ. An estimate of the annual direct cost of 
treating culnneous melanoma. JAm Acad Dermato/1998; 38: 669-6 0. 
5. Atillasoy ES, Seykora JT, Soballe PW, Elenit as R, Nesbit M, Elder DE, 
Montone KT, Sauter E, Herlyn M . UVB induces atypical melanocytic 
lesions and melanoma in human skin. Am J Pathol. 1998 May; 152(5):1179-
1186. 
6. Robinson JK, Rigel OS, Amonette RA . What promotes sk111 self-
examination? JAm Acad Dennato/1998; 38:5. 
7. johnson TM, Yahanda AM, Chang AE, Fader OJ, Sondak VK. Advances in 
melanoma therapy. JAm Acad Dermato/1998; 38:5. 
B. Australian Cancer etwork. (1997). Guidelines for the management of 
cutaneous melanoma. Sydney, Australia. 
9. Hogg D, Brill H, Liu L, Monzon J, Summers A, From L, Lassam ]. Role of 
the eye/in-dependent kinase inhibitor CDKN2A in familial mela noma. 
journal ofCutaneoi/S Medicine and Surgery 1998; 2(3): 172-176. 
10. Kirkwood J, Eggermont A (1998, ovember). Is high-dose interferon the 
standard adjuvant treatment in melanoma. Express Report from data 
Presented at the 23rd European Society for Medical Oncology Congress 
(EMSO), Athens, Greece. 
11. Huan g CL, Provost , Marghoob AA, Kopf AW, Levin L, Bart RS. 
Laboratory tests and imaging studies in patients with cutaneous malignant 
melanoma. JAm Acad Dermato/1998; 39 (3): 451-461 . 
12. Grange F, 01ompret A, Guilloud-Bataille M , Guillaume JC, Margulis A , 
Prade M , Demenais F, Avrilm MF. Comparison Between Familial and 
onfamilial Melanoma in France. Arch Dermato/1995; 131 : 1154-1159. 
13. Kirkwood ]M, Strawderman MH, Emstoff MS, Smith T], Borden EC, Blum 
RH. Interferon alfa-2b adjuvant therapy for l1igh-risk resected cutaneou 
melanoma: the eastern cooperative oncology group trial EST 1684. journal 
ofCiinical Oncology 1996; 14 (1): 7-17. 
14. Wasti QH, Kopf AW, Marghoob AA, Stefanato CM, Romero ]B, Roo BK, 
Bart RS. Anatomic distribution of cutaneous melanoma and painful 
sunburns in adults. Journal of Cutaneous Medicine and Surgery 1996; 1(2): 
81-85. 
16. http://www.cancercare.on.ca/ocr/ m1e Ontario Cancer Registry) 
17. http://wuno.dermatology.orgldivision!cmf!cmfl .htm (Canadian M elanoma 
Fo1mdation) 
18. http://www.hc-sc.gc.ca/ (Health Canada Online) 
19. Bergman W, van Voorst Vader PC, Ruiter OJ. Dy plastic nevi and the risk 
of melanoma: a guideline for patient care. ed Tijdschr Geneeskd 
1997;141 (42):2010-4. 
20. Marghoob AA, Sclwenbach SP, Kopf AW, Or/ow Sf, ossa R, Bart RS. 
Large congenital melanocytic nevi and the risk for the developmeut of 
malignant melanoma. Arcl1 Dermatol. 1996; 132:170-175. 
21. Tucker MA, Fraser MC, Gold tein Am, et a/. Risk of melanoma ar1d other 
cancers in melanoma-prone families. J Invet. Derma to/. 1993;100:350S-5S. 
22. Westerdah/, ], Olsson H, Masback A, Ingvar C, Jonsson , Brandt L, et a/. 
Use of sun beds or sunlamps and malignant melanoma in southern weden. 
Am J Epidemio/1994;140:691-9. 
23. Walter SO, Marrett LD, From L, Hertzman C, Sharwon HS, Roy P. The 
association of cutaneous malignant melanoma with the use of sunbeds and 
sunlamps. Am f Epidemio/1990;131:232-43. 
24. Cascinelli , Krutmann ], MacKie R, Pierotti M , Prota G, Rosso , et a/. 
European School of Oncology advisory report: 1111 exposure, UVA lamps 
and risk of skin cancer. Eur J Cancer 1994;30A:548-60. 
25. Stern RS, icl1ols KT, Vakeva LH. Malignant melanoma in patients treated 
for psoriasis with methoxsalen (p ora/en) and ultraviolet A radiation 
(PUVA): The PUVA Follow-Up Study. N Eng/ J Med 1997;336:1041-5. 
26. Rivers ]. The Un iversity of British Columbia. Personal Communication, 
February 11, 1999. Q 
FAMILY MEDICINE 
W hy 200 Ontario Physicians have 
discovered the benefits of 
MCI's management expertise 
Flexible arrangements • 
Full or part time positions • 
Short or long term • 
Busy walk-in shifts • 
Family practice • 
We have 24 locations in the Toronto area. 
To explore your options with MCI in complete 
confidence, please contact Margaret Gill ies at 
MCI Medical Clinics Inc. 
160 Eglinton Ave. East, Suite 200 
Toronto, Ontario M4P 385 
(416) 440-4040 ext. 433 
practice@mcimed.com www.mcimed.com 
70 
------------------------- U. W.O. Medical Journal 70 (1) 2000 
Miscellaneou s Articl e s 
CARDIOVASCULAR MANIFESTATIONS 
OF RHEUMATOLOGIC DISEASES: 
A REVIEW 
Agreat variety of sy temic di ea e and yndrome di play cardiova cular manife tations, and among these, the rheumatologic di eases figure 
prominently. Such effect range from the trivial and the 
benign, such as most pericardia! effusion occurring in the 
context of collagen vascular diseases, to the severe and 
life-threatening, eg myocardial fibrosis occurring in 
cleroderma. 1 This review erves to briefly highlight the 
cardiac con equences of orne of the more common 
rheumatoid conditions. 
Sy temic lupu erythemato us (SLE) is a multisy tern 
di order in which tis ue are damaged by autoantibodie 
and immune complexes2 The va t majority of case occur 
in women in their child-bearing years. The disorder has a 
prevalence of 20-50 cases per 100,000, and is more frequent 
in blacks than in white . 
Pericarditi i the mo t common cardiac manife tation 
of SLE, and occur in two thirds of patient . It is generally 
benign, sometime associated with pericardia} effusion , 
and rarely lead to tamponade or constrictive pericarditis. 
If not evident from the clinical background of SLE, the 
diagnosis can be made by the pre ence of lupu 
erythematosu cells or a titre of antinuclear antibodie . 
Valvular insufficiency is a rare consequence of SLE and i 
a result of Libman Sachs endocarditis, which may lead to 
sy temic emboli. Myocarditis may result in conduction 
abnormalitie , heart failure, or udden death. 
The antipho pholipid yndrome is a well-known ub t 
of lupus and is associated with valvular dysfunction, a 
tendency towards thrombo i , myocardial infarction (MI), 
pulmonary hypertension. and cardiomyopathy. MI occurring 
in a lupus patient may be due to this prothrombotic tendency, 
or may be the result of lupu vasculiti , chronic steroid 
treatment, or coronary athero clerosis. Anticoagulation i 
recommended with high dose coumadin treatment, aiming 
for an INR between 2.5 and 3.0. 
Rheumatoid arthriti (RA) i another multisy tern 
di ea e with diverse multiorgan effect , the sine qua non 
being an inflammatory synoviti that chiefly affect the 
peripheral joints.3 The prevalence of thi disorder is 
approximately 0.8%, with a female:male preponderance of 
3:1. RA may affect any part of the heart, with pericarditi 
again being the mo t common cardiac complication (10-
50% of RA patients); it is particularly prevalent in tho e 
patient with ubcutaneous nodules. Coronary arteriti , 
occurring in up to 20% of patients (ba ed on autop y 
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tudie ), may infrequently result in the occurrence of MI 
or angina pectori . Myocarditi and valvular insufficiency 
are further, rare complications. 
Raynaud's phenomenon can be defined as episodic 
ischemia of the finger or toes occurring in the context of 
expo ure to cold weather or objects.~ It may be primary 
and idiopathic, in which ca e it is known as Raynaud's 
disea e, or may be econdary to an underlying disease, 
medication, or other process. Raynaud's disease has a 
female :male preponderance of 5:1, with a peak onset 
between the age of 20 and 40. The disorder is associated 
with primary pulmonary hyperten ion and coronary 
va o pasm (also known as variant angina). 
Scleroderma is a multiorgan disease typified by fibrosis 
of the kin, blood ve els, and viscera. 5 Cardiovascular 
complications are frequent in the diffuse cutaneous 
systemic dero i ubset, and rare in the more limited form 
of scleroderma. The e manife tations include pericarditis, 
heart failure secondary to hypertension or cor pulmonale, 
and arrhythmias. Left- ided heart failure occurs in up to 
30% of patients with diffuse cutaneous scleroderma. 
Ankylosing spondyliti (AS) is an inflammatory 
di order that characteristically affects the axial skeleton, 
starting in the 2nd or 3rd decade of life.6 The male:female 
preponderance is 3:1. The two cardiovascular effects of AS 
are aortic regurgitation and conduction defects. In a small 
percentage of patient , all three layers of the aortic valve 
and proximal thoracic aorta are thickened and scarred, 
re ult:ing in aortic insufficiency. The frequency of both the 
valvular abnormality and the conduction defect increase 
with the duration of the di ease. 
In do ing, the e cardiovascular manifestations are by 
no means the commonest effects of rheumatological 
disorder , but when they occur, they may be devastating 
to the patient. It is therefore important that the non-
cardiologi t have a good grasp of these complications, in 
term of natural history, diagno i , and management. 
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AOMINISTRAnON). 
B ... · blockor Wttlldrowol 
NORVASC gives no protection against the dangers of abrupt beta-blocker withdrawal and such withdrawal should 
be done by the gradual reduction of the dose of be •-blocker. 
PRECAUTIONS 
Use: ia PMints willl Cotttestiw H .. rt Fail•re 
Although generllty caldum channel blockers should onty be used with caution in patients with heart failure, it has 
been observed that NORVASC had no overall deleterious effect on survival and cardiovascular morbidRy tn both 
short-term and long-term clinical trials in these patients. While a significant proportion of the patients in these 
studies had a history of ischemic hean disease, ang•na or hypenension. the studies were not designed to 
evaluate e treatment of angina or hypenension in patients with concomitant hean faiure. 
HypototosiH 
NORVASC famlodipine besylate) may occasionally precipitate symptomatic hypotension. Careful monitormg of 
blood pressure 1s recommended, especiatty in patients with a history of cerebrovascular insufficiency, .,,d those 
taking medications known to lower blood pressure. 
Peripllorol Edot111 
Mild·to·moderate peripheral edema was the most common adverse evant in the clinical trials (see ADVERSE 
REACTIONS). The incidence of peripheral edema was dose-dependent and ranged in frequency from 3.0 to 10.11% 
in 5 to 10 mg dose range. Care shoutd be taken to dffferentiate this peripheral edema from the effects of Jncrusing 
left ventricular dysfunction. 
Uso io f'rotNocy 
Although arNod1pine was not teratogenic in the rat and rabbn. some dihydropyridine compounds have been found 
to be teratogenic in animals. In rats, amlodipine has been shown to prolong both the gestation period and the 
duration of labor. There is no clinical experience with NORVASC in pregnant women. NORVASC should be used 
during pregnancy ontv if the potential benefit outweighs the potential risk to the mother and fetus. 
N•rsi .. Modters 
It is not known whether amlodipine is excreted in human m;lk. Since amlodipine safety in newborns has not been 
established, NORVASC should not be given to nursing mothers. 
Use: in Ctlildqn 
The use ol NORVASC is not reconwnended in children since safety ond efficacy have not been established in that popula1ion. 
Usoio EJclorty 
In elderty patients (265 years) clearance of amlodipine is decreased with a resulting increase in AUC. In dnical 
trials the incidence of adverse reactions in elderly patients was approxunatety 6" higher than that of younger 
population 1<65 years). Adverse reactions include edema, muscle cramps and dizziness. NORVASC should bo used 
cautiously in elderly patients. Dosage adjustment is advisable I see DOSAGE AND AOMINISTRAnON). 
lnlorlctioo wid! Gropofno~ Juice 
Published data indicate that through inhibition of the cytDchrome P450 system, gropefru~ juice can increase plasma 
levels and augmem pharmacodynamic effects of some dihydropyridine calcium channel blockers. followmg oral 
ad · ·stration of 10 mg amlodipine to 20 male volunteers, pharmacokinetics of amlodipine were sirrular when 
amlodipine was admirvstered with and without grapefruit juice. 
D ... lotoroc:ti-
As 'Nith al drugs, care shoukl be exercised when treating patients wRh rootbple medications. Dihydropyridine calcium 
channel bk)ckers undergo biotransformation by the cytochrome P450 system, mainty via CYP 3A4 isoenzyme. Coad· 
ministration of amlodipine with other drugs which follow the same route of biotransformation may resutt 1n altered 
btoavailabiiRy of amlodipine or these drugs. Dosages of similarly metabolized drugs, particularty those of low thera-
peutic ratio, and especia in patients with renal and/or hepatic impairment. may raquire adjustment whan starting 
or stopping concomitlntty administered amlodipina to maintain optimum therapeutic blood levels. 
Drugs known to be inhibitors of tho cytochrome P450 system include: azote antifungals. cimetidine, cyclosporine, 
arythromycin. quinidine, terfenadine. warfarin. 
Drugs known to be inducers of the cytochrome P450 system include: phenobarbital, phenytOin, rifampin. 
Drugs known to be l>iotansformed via P450 include: bonzodiazepines. ftecainide, imipramine, propofenone, theophylline. 
Amlodipine has a low Irate of first-pass) hepatic clearonce and consequent high bioava~ability, and thus. may be 
expected to have a low potential for clinicalty relevant effects associated with elevation of amlodipine plasma 
levels when used concomitantly with drugs that compete for or inhibit the cytochrome P450 system. 
Ci..tidiH, Warfarin. C,Ciosporia. Digoxia; Pharmacokinetic interaction studies with amlodipine in heatthy 
volunteers haw indicated: 
• ciiMtidina did not alter the pharmacokinetics of amlodipine. 
• amlodipine did not change warfari•·induced prothrombin response time. 
• amlodipine does not significandy alter the pharmacokinetics of ~losporiL 
• amlodipine did not change serum digoxi• levels or digoxi• renal clearance. 
Alotacids 
Concomitant administration of Maatox- (magnesium hydroxide and aluminum hydroxide I had no effect on the dis· 
position of a single 5 mg dose of amlodip10e in 24 subjects. 
Bota-bloekers: When beta-adrenergic receptor blocking drugs are administered concomitantly with NORVASC, 
patients should be carefully monitored since blood pressure lowering effect of beta-blockers may be augmented by 
amlodipine's reduction in peripheral vascular resistance. 
ADVERSE REACTIONS 
ORVASC famlodipine bosylatel has been administered to 1,714 patients (1105 hypertensive and 909 angona 
patients) in controled clinical trials fvs placebo alone and with active cornparatiivo agents). Most adverso 
reactions reponed during therapy were of mild·to·moderate severity. 
ltyportoosioa 
In the 805 hypertensive patients treated with NDRVASC in comoled clinic II trials, adverse effects were reported in 
29.9ll ol patients and requirod discontinuation ol therapy due to side effects in I A ol patients. The most common 
adverse rwac:tions in comoled clinicll trials were: edema f8.9'Jf.land headache fti.J'JI~ The folowing adverse reactJOns 
wore reported With an incidence of~" in the comoled clinical trials program fn=Ui~ 
Conliovosuler. edema I8.9'Jf.), palp~ations l2.0ll), tachycardia 10.7"1. poSilJral dizziness 10.5"1-Skio and 
~pruritus fD.n.). Mncolosltel ... l: muscle cramps (0.5"1-Cootraleod Poripllorol Nervoa 
SystoM: headache (8.3"1. diuiness IJ.Oll), paresthesia (0.5"1--ic N.,.... SysteM: flushing (3.1"1. 
increased sweating f0.9'Jf.), dry mouth fo.7"1-Psyc~iotric: somnolence (1.4"1-Gomoiotntioal: nausea 12.4"1. 
abdominal pein 11.1"1. dys>epsia ID.6"1. constipation IO.S"I- GOMrlll: fa ·gue (4.1"1. pain 10.5"1-
AIIfioa 
In the cootroled clinical trials in 909 angina patients treated with NORVASC. adverso effects were reported in :ns" of patients and required discontinuation of therapy due to side effects in 0.6" of patients. The most common 
adverse reactions reported in controlled clinical trials were: edema f9.9'Jf.land headache 0 .11%). 
The following adve,.e reactions occurred at an incidence of~" in tho cootrolled cirical trials program fn=909): 
Conliowasc:uler. edema I9.9'Jf.), palpitations I2.Dll). postural diuiness 10.6"1- Skio 1od Appoodegos: rash fi.Oll), 
pruritus 10.11%~ Mncolosltelotat muscle cramps (l .!Jll). Cootralood Poripllofal No.- S,.U. headache 
0 .11%), dizziness 14.5"1. partsthesll(l.Oll). hypoestheSio IDA~- Nonooo SystoK ftushing (1.9'Jf.). Psy-
c~iotric: somnolanco(1.3 , insomrna I0.9'Jf.), nervousness ID.7"1-Gomoiotntioat nausea 14.3), 
obdominal pein 12.2"1. dys:>epsi1 fU"I. diarrhea 11.1"1. flatulence II .alii, constipation I0.9'Jf.). Rospirotory Sys-
t- dyspnea 11 . 1"~ Spoc:iel Senses: abnormal vision 11~1. tinnitus (0.6"1-G-rot fatigue (4.11%). 
poin (l.Oll), asthenia fl .!Jll). 
NORVASC has been evalueted for safety in about 11,000 patients with hypertension and angina. 
The follow;ng events occurred in <1% but >0.1% of panents in comparative clinical trials (double· blind 
comparative vs placebo or active agents; n = 2.,615) or under conditions of open trials or marketing experience 
where a causal relationshi:l is uncertain. 
Conliowasc:olar. arrhythmia (including ventricular tachycardia and atrial fibrilation), bradycardia, hypotansion, 
peripheral ischemia, sync ape, tachycardia, poSilJral dizziness, poSilJral hypotension. Cootralood Poripllofal 
NOfVOft Systotn: hypoesthesia, tremor, vertigo. Gulroiotntioal: anorexia, constipation, dysphagia, vomiting, 
gingival hyperplasia. Gnenl: asthenia'. back pain. hot flushes, malaise, rigors, weight gain. Mac•loskei.UI 
Syst:eta: arthnlgia. arthros s. myalgiL Psycli•imic: sexual dysfunction (male' and fematat insomnia, nervous· 
ness, depression. abnormal dreams. anxiety. depersoMiilltion. Respir-.tory Systeta: epistaxis. Skin aH 
Appondogos: pruritus', rash erythematous, rash maculopapular, erythema mulliforme. Spoc:ial Sotosos: canjunctivilis. 
diplopia, eye pa10. tinnitus. Urinary System: micturition frequency, micturition disorder, nocturia. Autnomic Ner-
, .... Systonl: dry mouth, increased sweating. M ... bolic ond Nutritioo 1: thirst. H-iotic: purpura. 
These events occurred in less than 1" in placebo-controlled trials, but the incidence of these side effects was 
between 1" and 2% in aU muttiple dose studies. 
The foUowing events occurred in sO. I" of patients: cardiac failure, skin discoloration. urticaria, skin dryness, 
Stevens,.Johnson S'(Odrome,afopecie, twitching. ataxia, hypertonia, m.graina, apathy, amnesia. gastritis, 
pancreatitis, increased appetite, coughing. rhinitis, parosmia, taste perversion, and xerophthalmia. 
Isolated cases of angioedema have been reported. Angioedema may be accompanied by breathing difficulty. In 
postrnarketing experience, jaundice and hepatic enzyme elevations (mostJy consistent with cholestasisl in some 
cases severe enough to require hospitalization have been reported in association with use of amlodipine. 
SYMPTOMS AND TREATMENT OF OVERDOSAGE s,..,._ 
Overdosage can cause ucessive peripheral vasodilabOn with marted and probably prolonged hypotension end 
possibly a reflex tachycardia. In humans. experience with overdosage ol NORVASC famlodipine bosylate) is · ed. 
When amlod1pine was ing sted at doses of 1()5..250 mg some patients remained normotensive with or without 
gastric lavage while anothor patient experienced hypotansion 190150 mmHg) which normalized following plasma 
expansion. A patiem who took 10 mg of amlodipine with banzodiazepine developed shock which was refractory 
to treatment and died. In a 19 month-old child who ingested 3D mg of amlodipine Ia boot 2 mglkg) there was no 
evtdance of hypotension but tachycerdia (180 bpm) was observed. Ipecac was administered 3.5 hrs after ingestJon 
1nd on subsequent observation (overnight} no sequelae were noted. 
TreltMIIt 
Clinicalty significant hypotension due to overdosage requires active cardiovascular suppon including frequent 
monn.oring of cardiac and respiratory function, elevation of extremities, and attention to circulating nuid volume 
and urine output A vasoconstrictor (such as norepinephrine) may be elpful in restoring vascular tone and 
bfood pressure. provided that there is no contraindica on to its use. As NORVASC is highty protein bound, 
hemodialysis is not likety to be of benefit. Intravenous calcium gluconate may be beneficial in reversing the 
effects of calcium channeJ blockade. Clearance of amlodipine is prolonged in eklerty patients and in pa ents 
with impaired liver function. Sinceamlodipine absorption is stow. gastric lavage may be worthwhile in some cases. 
DOSAGE AND ADMINISTRAnON 
Dosage should be individu>fized depending on patien(s tolerance and responsiveness. For both hypertension 
and angina, the recommended initial dose of NORVASC famlodipine besylate) is 5 mg once daily. ~necessary, 
dose can be increased ah.er 1·2 weeks to a maximum dose of 10 mg once daity. 
Uso iotloo Elclortya<io PotiHCswido hlopairociRooalfwctiH 
The recommended initial dose in patients over 65 years of age or patie1'1tS with impaired renal function is 5 mg 
once daily. ~ required, increasing in the dose should bo done gradually and with caution (see PRECAUTIONS). 
Uso io Potieots widlhlopairocl Hepotic Ftooction 
Dosage requirements have not been established in patients with impaired hepatic function. When NORVASC is 
used in these patients, the dosage should be carefuttv and gradualty adjusted depending on patient's tolerance 
and response. A lower starting dose of 2.5 mg once deity should be considered (see WARNINGSI. 
DOSAGE FORMS 
Availability 
NORVASC is available as Ylhhe octagonal tablets contavnng amlodipine besytate equivalent to 2.5, Sand 10 mg 
amlodipine per tablet The respective tablet strengths are debossed on one tablet face as ·NRV z.s·. ·NRV 5'" 
and "NRV 10" with "Pfaer· on the opposita face. The 5 mg tablet is scored. Supplied in wh~e plastic (high density 
~'7:ne) bottles of I DO tablets for each strength. Also the 5 mg and 10 mg are supplied in bottles of250tablets. 
Store at 15-JO"C. Protect from 6ght 
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